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Alzheimer’s disease (AD) is a devastating neurodegenerative disease characterised by 
cognitive deficit and memory loss. The pathological hallmarks of the disease are the 
deposition of extracellular amyloid plaques containing high levels of amyloid β 42/40 and 
intracellular neurofibrillary tangles containing hyperphosphorylated tau together with brain 
atrophy. AD can be divided into two types: Familial AD, also known as early-onset AD, 
accounts for less than 5% of all AD cases and it is caused by known mutations in APP, 
PSEN1 and PSEN2 genes, involved in the processing of the amyloid precursor protein. 
Sporadic AD, also known as late-onset AD, is the most common form of AD and likely 
caused by genetic variations in many genes. The presence of the ɛ4 allele of the APOE gene 
is the major genetic risk factor of AD. The APOE gene codes for apolipoprotein E (apoE), a 
35-kDa glycoprotein highly expressed in the brain with a major role in lipid transport. There 
are three different isoforms of apoE in humans: apoE3 is the most common isoform in the 
population, apoE2 reduces the risk of AD and apoE4 increases the risk of AD. These 
isoforms differ in just two amino acids, which alters protein stability and leads to differences 
in the fragmentation of apoE. 
An extensive review of the literature of the neuropathology of AD and apoE is described in 
Chapter 1. Moreover, I also describe the various models that have been used in the last 
century to study the underlying mechanisms of the disease. From post mortem human brains 
from AD patients to transgenic models have been used to understand the pathology of the 
disease. However, despite the significant efforts to find the cause and how to stop the 
progression of AD, there are lots of questions that remain unanswered. Therefore, in this 






The general methodology used in this thesis is described in Chapter 2, whereas specific 
materials and methods of each study are shown within each chapter.  
The work described in Chapter 3 shows the use of the established SK-N-SH neuroblastoma 
cell line to understand the fragmentation of apoE. As the reports on the function of the apoE 
fragments and how they are generated are inconsistent in the literature, we studied the role of 
the serine protease HtrA1 in apoE fragmentation. I showed that HtrA1 is responsible 
specifically for the generation of the 25-kDa N-terminal fragment of apoE. Moreover, I also 
showed that the 25-kDa fragment of apoE3 has a neuritogenic function. 
In Chapter 4 I aimed to study the differences in the fragmentation process of apoE isoforms 
as fragments of apoE4 isoform have been reported to increase neurotoxicity in the brain. The 
use of CRISPR/Cas9 technology to generate an APOE isogenic line by changing the 
genotype of the SK-N-SH cells from APOE ɛ3/3 to APOE ɛ4/4 was attempted. Optimization 
of specific gRNAs designed to target the APOE gene generated a double strand break in the 
DNA but, unfortunately, none of the clones analysed underwent a change in APOE 
genotype. However, the generation of a knock-down in apoE expression in some of the 
selected clones can be used as a model to further study apoE fragmentation and the link 
between apoE and HtrA1 by exogenous addition of the different apoE isoforms in culture. 
The generation and characterization of a new model to study AD is shown in Chapter 5. 
Induced pluripotent stem cells (iPSCs) are stem cells that have been reprogrammed from 
somatic cells. iPSCs have become a highly used model to study neurodegenerative diseases 
due to their potential to generate living cells in vitro that contain all the genetic background 
of the patient. I reprogrammed iPSC lines from fibroblasts derived from an AD patient 






In Chapter 6 I have generated and characterised a new protocol to generate iPSC-derived 
basal forebrain cholinergic neurons (BFCNs) that can be used as a model to understand the 
neuropathology of AD. One of the hallmarks of AD is brain atrophy, and the cholinergic 
system is the first region to degenerate in the disease, with BFCNs being the most vulnerable 
neuronal subtype in AD. To generate BFCNs in vitro we followed the developmental 
signalling that occurs in vivo and characterisation of the BFCNs was performed by gene 
expression and functional analysis. This model will be useful to understand the 
neuropathology of AD and to detect underlying mechanisms that occur in the BFCNs at 
early stages before the death of the neurons. 
Overall, the work presented in this thesis opens up new ways to study the neurobiology of 
AD. Here I have generated new cell models that can be used to further understand the link 
between apoE and HtrA1 and the specific function of the apoE fragment; and the generation 
of iPSCs and iPSC-derived BFCNs provides the potential to further understand the 
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1.1. Alzheimer’s disease 
AD is the most common form of dementia. It is a progressive and irreversible 
neurodegenerative disease characterised by cognitive decline and impaired memory and 
thinking. More than 50 million people worldwide were affected by dementia in 2015, with 
expectations that this number will triple by 2050 (World Health Organization, 2017). The 
total global cost associated with dementia was US$818 in 2015 and predicted to be US$2 
trillion by 2030 (World Health Organization, 2017). This devastating neurodegenerative 
disease was first described by Alois Alzheimer in 1907 as a peculiar severe disease process 
of the cerebral cortex (Alzheimer, 1907). The main risk factor of AD is aging and an average 
life expectancy after diagnosis is three to nine years. AD is characterised by cognitive 
impairment and memory loss and, unfortunately, only symptomatic therapies are available 
(Yiannopoulou and Papageorgiou, 2013). 
The autopsy of AD patients has revealed the presence of protein aggregates both 
extracellularly as amyloid plaques formed by amyloid beta (Aβ) peptides (Glenner and 
Wong, 1984), and intracellularly as neurofibrillary tangles (NFT) composed of 
hyperphosphorylated tau protein (Grundke-Iqbal et al., 1986; Ihara et al., 1986; Kosik et al., 
1986). It is still unclear if the pathological features are the cause or the consequence of AD, 
but it has been shown that their deposition starts years before visible symptoms of the 
disease appear (Braak and Braak, 1997). The deposition of these misfolded proteins leads to 
oxidative (Markesbery, 1997) and inflammatory (McGeer et al., 2006) damage, causing 
progressive neuronal degeneration and death. Cholinergic neurons in the basal forebrain are 
the first population of neurons to be affected (Baker-Nigh et al., 2015; Whitehouse et al., 
1982) but, with disease progression, other brain regions such as the hippocampus, entorhinal 







AD can be divided into two forms: Familial AD (FAD), also known as early-onset AD, and 
sporadic AD (SAD), also known as late-onset AD. FAD makes up less than 5% of all cases, 
and it is characterised by mutations in amyloid precursor protein (APP) and/or presenilin 
(PSEN) genes, both of which are involved in Aβ processing (St George-Hyslop and Petit, 
2005), often resulting in the development of the disease at ages between 50 and 65. The 
PSEN1 and PSEN2 genes code for presenilin 1 and 2, proteins that form the catalytic 
subunits of the γ-secretase complex, responsible for the fragmentation of APP into Aβ 
peptides. In contrast, SAD is the most common form, where the possession of the ε4 allele of 
APOE is the major genetic risk factor (Corder et al., 1993; Saunders et al., 1993; Strittmatter 
et al., 1993a), but aging, environmental and lifestyle factors may also influence risk. 
1.1.1. Pathological hallmarks of AD 
1.1.1.1. Amyloid plaques  
The extracellular deposition of Aβ peptides that aggregate to form amyloid plaques, also 
known as senile plaques, is one of the pathological hallmarks of AD (Glenner and Wong, 
1984). The fragmentation of APP is mediated by γ-secretase, a complex formed by subunits 
including presenilin 1 and 2, coded by the genes PSEN1 and PSEN2, with mutations within 
those genes being linked to FAD. As shown in Figure 1.1, APP can undergo fragmentation 
mainly via the amyloidogenic or the non-amyloidogenic pathways. Under physiological 
conditions, APP is cleaved by α- and γ-secretase in the non-amyloidogenic pathway, 
generating the non-pathological fragments soluble APPα (sAPPα), p3 and amyloid 
intracellular domain (AICD). However, under pathological circumstances, the 
amyloidogenic pathway is increased. APP becomes the substrate of β-secretase (β-site APP-
cleaving enzyme 1, BACE-1), releasing soluble APPβ (sAPPβ), whereas a 99 amino acid 
(C99) fragment remains attached to the plasma membrane. C99 fragment is further cleaved 
by γ-secretase, generating AICD fragment and Aβ peptides, predominantly of 40 or 42 





AD patients than in healthy individuals and, as the Aβ42 peptide tends to aggregate into 
oligomers more than Aβ40, they are the thought to be seeds that generate bigger aggregates 
such as oligomers, that are the toxic form of Aβ, and finally the deposition into characteristic 
amyloid plaques (Sengupta et al., 2016; Thal et al., 2006). Amyloid plaques do not only 
include Aβ peptides but other proteins involved in inflammation such as glial fibrillary acidic 
protein (GFAP) or vimentin, proteases such as antitrypsin or cathepsin D, cell adhesion such 
as collagen I or fibrinogen, or other proteins as apolipoprotein E (apoE) or tau (Liao et al., 
2004; Namba et al., 1991). The deposition of the amyloid plaques promotes neuronal and 
synaptic dysfunction, leading to neurodegeneration. More recently, a new protease, η-
secretase, has been shown to cleave APP generating a higher molecular mass carboxy-
terminal fragment (CTF) (Willem et al., 2015). The CTFs have been also found to inhibit 
neuronal activity in the hippocampus and to be enriched in dystrophic neurites of AD brains 
(Willem et al., 2015) which might show a new mechanism of action in the pathology of AD. 
 
Figure 1.1. Fragmentation of APP through non-amyloidogenic and amyloidogenic pathways. 
Amyloid precursor protein (APP) is fragmented under physiological conditions through the non-
amyloidogenic pathway. α-secretase cleaves APP into soluble APP α (sAPPα) and C83, that is 
fragmented further by γ-secretase into the non-pathological fragments p3 and amyloid intracellular 
domain (AICD). In the amyloidogenic pathway APP is cleaved by β-secretase, generating soluble 
APP β (sAPPβ) fragment and C99, that it is fragmented further by γ-secretase into the AICD and 
amyloid β (Aβ). Aβ tends to aggregate resulting in the formation of amyloid plaques. Adapted from 






1.1.1.2. Hyperphosphorylated tau 
The intracellular deposition of NFT formed by hyperphosphorylated and misfolded tau is 
another pathological hallmark of AD. The microtubule-associated protein tau (MAPT) gene 
codes for tau protein, a microtubule-associated protein that stabilizes microtubules in the 
neuronal axons (Binder et al., 1985; Weingarten et al., 1975), as shown in Figure 1.2. 
Whereas the phosphorylation of tau protein is essential for neurite outgrowth, microtubule 
stability and axonal transport (Johnson and Stoothoff, 2004), tau hyperphosphorylation in 
specific amino acid residues leads to release from the microtubules, inducing microtubule 
destabilization, and contributes to tau polymerization and aggregation, leading to insoluble 
NFTs in the brain (Braak et al., 1994) (Figure 1.2). The intracellular deposition of the NFTs 
contributes to neuronal death and the neuropathology of AD. 
 
Figure 1.2. Hyperphosphorylation of tau protein leads to microtubule instability and formation 
of NFT. The microtubule-associated protein tau binds to microtubules under physiological conditions.  
Hyperphosphorylated tau unbinds to microtubules, destabilizing them, and participates in the 






1.2. Neurobiology and neurodegeneration of AD 
1.2.1. The cholinergic system 
The neurons of the cholinergic system use acetylcholine (ACh) as a neurotransmitter. The 
cholinergic system can be divided into two branches, the tegmental cholinergic system and 
the basal forebrain cholinergic system (Figure 1.3A). The tegmental cholinergic system, 
located in the brain stem, is involved in the sleep/waking cycle (Kodama and Honda, 1999). 
The basal forebrain cholinergic system consists of the nucleus basalis of Meynert and the 
medial septum, that project to the neocortex and the limbic system (including the 
hippocampus), plays an important role in learning, memory and attention (Ballinger et al., 
2016; Blake and Boccia, 2018). The loss of basal forebrain cholinergic neurons (BFCNs) in 
neurodegenerative disorders such as AD leads to cognitive impairments and memory deficits 
(Mufson et al., 2008; Whitehouse et al., 1982). 
Acetylcholine is the most abundant neurotransmitter in the brain (Mesulam, 2013). The 
formation of ACh occurs in the presynaptic terminal of the cholinergic neurons, where the 
combination of acetyl coenzyme A (Ac CoA) and choline is mediated by the enzyme choline 
acetyl transferase (ChAT) to form ACh (Figure 1.3B). ACh is transported inside vesicles 
through the vesicular acetyl choline transporter (VAChT), where it gets stored until release. 
Upon release into the synaptic cleft, ACh activates receptors in the postsynaptic terminal 
thereby transmitting the signal. The excess of ACh in the synaptic cleft gets hydrolysed by 
acetylcholine esterase (AChE) into choline and acetate. Choline is transported back into the 
presynaptic terminal through the choline transporter 1 (CHT1) for recycling into new ACh.  
There are two kinds of acetylcholine receptors, ionotropic nicotinic receptors (nAChRs) and 
metabotropic muscarinic receptors (mAChRs). They are located in both pre- and post-
synaptic terminals. The nAChRs have an excitatory function (Changeux et al., 1998), 





located in the postsynaptic terminal can be excitatory or inhibitory (Wess, 2003). During 
development of the CNS, ACh promotes cell survival, neurite outgrowth, cell proliferation or 
differentiation (Abreu-Villaça et al., 2011). Some of these functions are maintained after 
development, and the role  of ACh as a neuromodulator in the CNS has been reviewed by 
Picciotto et al., (2012). Despite the fast-acting role that ACh plays in the neuromuscular 
junction, in the CNS cholinergic neurotransmission works by coordinating the firing of 
groups of neurons, changes neuronal excitability and alters presynaptic release of 
neurotransmitters  (Kawai et al., 2007; Rice and Cragg, 2004; Wonnacott, 1997; Zhang and 
Sulzer, 2004). Moreover, ACh seems to play an important role inducing synaptic plasticity 
and neuronal development (Picciotto et al., 2012), highly important for memory and 
learning. 
 
Figure 1.3. Connectivity and physiology of the cholinergic system. A. Orange arrows show the 
connectivity of the cholinergic system in the human brain. The tegmental cholinergic system and the 
basal forebrain cholinergic system connect with various regions of the brain including brain stem, 
hippocampus and neocortex. B. Physiology of the cholinergic synapse. Acetylcholine (ACh) is formed 
from Acetyl Coenzyme A (Ac CoA) and choline mediated through Choline acetyltransferase (ChAT). 
Vesicular Ach transporter (VAChT) mediates the transport of ACh into vesicles that get released in 
the synaptic cleft. ACh neurotransmission signals through nicotinic and muscarinic ACh receptors 
(nAChR and mAChR) in the postsynaptic terminal. ACh gets hydrolysed by ACh esterase (AChE) 
into choline and acetate. Choline is recaptured inside the presynaptic terminal through choline 





1.2.1.1. Development of cholinergic neurons 
The development of the mammalian BFCNs, as reviewed in Allaway and Machold, (2017) 
and Engel et al., (2016), starts in the ectoderm germ layer with the formation of the neural 
tube. Initial patterning of the neural tube occurs with different gradients of two main 
morphogens: sonic hedgehog (SHH), responsible for inducing ventralization (differentiation 
towards the anterior) of the neural tube, and Wnt, responsible for inducing caudalization 
(differentiation towards the posterior). High concentrations of SHH and low concentrations 
of Wnt are required for the formation of the cholinergic system (Li et al., 2009). The most 
anterior region of the brain is the telencephalon, and its development involves other 
morphogens as retinoic acid (RA), bone morphogenic proteins (BMPs) and fibroblast growth 
factors (FGFs) (Takahashi and Liu, 2006). Studies in mice have shown that the 
anterior/posterior patterning of the telencephalon begins at embryonic day 8.5 (E8.5) when 
the telencephalic neuroepithelia induces the expression of the transcription factors forkhead 
box G1 (FOXG1) and paired box 6 (PAX6) (Haubst et al., 2004; Holm et al., 2007; Tao and 
Lai, 1992). SHH and FOXG1 induce the expression of FGFs, which activate downstream 
transcription factors characteristic of the ventral patterning. The formation of the medial 
ganglion eminence (MGE), a ventral region of the telencephalon from where BFCNs 
projects to the hippocampus and the frontal cortex (Woolf, 1991) is defined by the 
expression of NK2 homeobox 1 (NKX2.1) starting at E9.5. The cholinergic fate of the 
neurons is induced by the expression of insulin enhancer protein 1 (ISL1) at E10.5 (Zhuang 
et al., 2013) and the LIM homeobox 8 (LHX8) at E12.5. The expression of ChAT in neural 
precursor cells arises at postnatal day 7 (P7), with ChAT-positive cells increasing in number 
after P8 and remaining stable during adulthood (Consonni et al., 2009). 
While the full range of molecular drivers for BFCN development remains to be mapped, 
several external signalling factors are necessary for the differentiation, growth and survival 





by BMP9 (Lopez-Coviella et al., 2005), whilst FGF2 and brain-derived neurotrophic factor 
(BDNF) stimulate cholinergic differentiation, promote survival and increase ChAT activity 
(Alderson et al., 1990; Knüsel et al., 1991; Knusel et al., 1990). Nerve growth factor (NGF) 
regulates the expression of ChAT and induces neurite outgrowth and arborization. 
Cholinergic neurons receive the nerve growth factor (NGF) signalling through two receptors: 
TrkA, the high affinity neurotrophin receptor, and the low affinity receptor p75NTR, both of 
which are involved in the maturation and maintenance of the cholinergic identity (Auld et 
al., 2001; Mobley et al., 1985; Sofroniew et al., 2001). 
BFCNs are characterised by their neuroanatomical location and the expression of ACh 
related genes. The key markers to identify mature cholinergic neurons are involved in ACh 
synthesis, transport and hydrolysis, as described in Figure 1.3B. However, the 
characterization of the complete morphology has been difficult due to their extraordinary 
complexity. In vitro studies from primary cultures showed that BFCNs have large cell bodies 
with two to four primary neurites (Ha et al., 1996). However, another study in mice 
demonstrated that individual cholinergic neurons from the basal forebrain region have axons 
that develop up to 50 cm in length, with approximately 1000 branches (Wu et al., 2014). The 
electrophysiological profile of BFCNs has been characterised in rats, where BFCNs show 
regular spontaneous patterns with the mean spontaneous activity of 20 impulses/s (Lamour et 
al., 1986). Other characteristics of the BFCNs are a slow spiking activity (4 - 10 Hz) and 
slow after potentials (400 – 700 ms) when compared with non-cholinergic neurons (3 - 60 
ms) (Markram and Segal, 1990). Moreover, the addition of NGF can increase slow 






1.2.2. Neurodegeneration in AD 
The specific neurodegeneration of the cholinergic system in AD patients was first detected 
when initial studies showed a reduction in pre and postsynaptic markers in the cortex of AD 
patients (Reisine et al., 1978), and a reduction in ACh in the hippocampus (Perry et al., 
1977). Moreover, the loss of neurons from the cholinergic system was shown to be selective 
for the nucleus basalis of Meynert (Davies and Maloney, 1976; Whitehouse et al., 1982). 
The cholinergic deficits occur in preclinical stages on AD (as reviewed in Hampel et al., 
(2018)), and specific loss of these neurons leads to severe cognitive decline and memory 
deficits (Mufson et al., 2008).  
Magnetic resonance imaging studies have shown significant brain atrophy in AD patients 
when compared to healthy patients (reviewed in Pini et al., (2016)) (Figure 1.4A). The 
significant loss of brain weight is a consequence of massive neuronal loss at the end stage of 
the disease, especially in the hippocampus (Padurariu et al., 2012). New neuroimaging 
studies have demonstrated that the basal forebrain volume precedes and predicts the cortical 
pathology and memory impairment (Schmitz et al., 2016). The two major pathological 
hallmarks of AD have slightly different patterns of spread through the different stages of the 
disease. As shown in Figure 1.4B, the deposition of amyloid plaques starts in the basal 
neocortex, further spreading to the adjacent neocortical areas and the hippocampus, and 
finally to all areas of the cortex (Braak and Braak, 1997). The evolution of NFTs in the brain 
differs slightly from the amyloid distribution. NFTs are found initially in the entorhinal 
region, spreading towards hippocampus and neocortex (Braak and Braak, 1997) (Figure 
1.4C). The neuronal loss in AD correlates better with NFTs than amyloid plaques but, within 
the same region, exceeds the number of NFTs (Gómez-Isla et al., 1997). However, BFCNs 
are the most vulnerable neurons to NFT formation, which might play a significant role in the 
neurodegeneration (Mesulam, 2013), as other areas of the cholinergic system do not seem to 







Figure 1.4. Brain atrophy in AD and the development of amyloid plaques and NFTs in the 
brain. A. Healthy brain compared to an AD brain. B. Amyloid plaque development through the brain 
from stage A (mild pathology) to stage C (severe pathology). C. Neurofibrillary tangles (NFTs) 
development through the brain from stage I-II (mild pathology) to stage V-VI (severe pathology). 





1.3. Apolipoprotein E 
1.3.1. Structure and function of apoE 
Apolipoprotein E (apoE) was first described in the 1970’s as a protein constituent of plasma 
lipoproteins (Shore and Shore, 1973). The apolipoprotein E gene (APOE) is located on 
chromosome 19 and is a member of the apolipoprotein multigene family (Li et al., 1988). Its 
sequence has four exons and three introns, encoding a 299 amino acid protein with a 
molecular weight of 37 kDa. ApoE is expressed in a wide range of tissues, predominantly in 
the liver, but also in the brain, kidney, lungs, adrenal glands, ovaries, spleen, muscle and skin 
(Lin et al., 1986). Its expression in the brain is primarily in astrocytes and other glial cells, 
such as oligodendrocytes or microglia and, under certain physiological conditions, in 
neurons (Elshourbagy et al., 1985; Lin et al., 1986). It plays an essential role in the transport 
of cholesterol and other lipids, participating in their redistribution to cells and facilitating 
their cellular uptake (Mahley, 1988). 
The domain structure of apoE is composed of two main domains, with the N- and C-
terminus, linked by a hinge region (Aggerbeck et al., 1988; Wetterau et al., 1988), as shown 
in Figure 1.5. The N-terminal domain (residues 1-167) consists of a four alpha-helix bundle 
with a region enriched in arginine and lysine residues (135-150), that forms the low density 
lipoprotein (LDL) receptor binding domain. The C-terminal domain (residues 206-299) 
consists of amphipathic alpha-helices characteristic of the apolipoprotein family (Li et al., 
1988) and includes the lipid binding region (residues 244-272).  
The three alleles of APOE found in the population give rise to six different genotypes: the 
homozygotes ε2/2, ε3/3 and ε4/4, and the heterozygotes ε2/3, ε2/4 and ε3/4. The difference 
between the three alleles is only two nucleotides, resulting in a protein change of two amino 
acids located in positions 112 and 158. As shown in Figure 1.5, apoE2 contains  Cys112 and 






Figure 1.5. Structure of apolipoprotein E. The N-terminal domain (1-167 aa) is connected by a 
hinge region with the C-terminal domain (206-299 aa). The LDL-receptor binding (135-150 aa) and 
the lipid binding (244-272) regions are shown. Positions 112 and 158 show the different amino acids 
that give rise to each of the apoE isoforms (ɛ2, ɛ3 and ɛ4). 
 
The amino acid change within isoforms in both positions 112 and 158 leads to differences in 
protein stability and interactions: by changing Cys112 into Arg112 in apoE4, the protein loses 
the ionic association between Glu109 and Arg61, leaving Arg61 free to interact with Glu255, and 
therefore creating an inter-domain interaction that reduces the lipid binding capacity of 
apoE4. In apoE3 and apoE4 there is a salt-bridge between Arg158 and Asparagine (Asp)154 
that is lost in apoE2 with Cys158. In this case, there is a salt-bridge between Asp154 and Arg150 
that removes the positive side chain of Arg150 away from the LDL receptor binding region, 
affecting its binding capacity (Hatters et al., 2005). Due to these amino acid interactions, the 
protein stability differs, with the apoE4 isoform the least stable, followed by apoE3, while 
apoE2 is the most stable (Morrow et al., 2000).  
The difference in stability of the three apoE isoforms affects the binding capacity of the LDL 
receptor binding region with receptors, which interferes in its main function as lipid 
transporter. ApoE binds preferentially to the low density lipoprotein receptor (LDLR) family 
(Beffert et al., 2004) and heparan sulfate proteoglycans (Mahley and Ji, 1999). ApoE binds 
the LDLR family members LDLR, very low density lipoprotein receptor (VLDLR), multiple 
epidermal growth factor (EGF) repeat-containing protein 7, LDLR-related protein 1 (LRP1), 
LRP1B, LRP2 (also known as megalin) and apoE receptor 2 (apoER2, also known as LRP8).  





binding domain, EGF-like repeats and β-propeller domains, with a cytoplasmic tail 
containing an NPxY motif. The binding capacity of apoE with its receptors varies within 
isoforms, affecting the intracellular signalling pathways. ApoE2 binding capacity with 
LDLR is weaker than the other isoforms, but it binds more tightly with VLDLR (Takahashi 
et al., 1996). ApoE3 and 4 have similar affinity to LDL, but apoE3 tends to bind to high 
density lipoproteins (HDL), while ε4 binds to LDLs (Weisgraber, 1990). Lipid-free forms of 
apoE are preferentially bound by LRPs (Narita et al., 2002). 
1.3.2. ApoE is the main genetic risk factor of Alzheimer’s disease 
The allele ε4 of apoE is associated with hyperlipidaemia and hypercholesterolemia, both 
related to cardiovascular diseases and stroke (Lahoz et al., 2001; Mahley and Rall, 2000), but 
it is also the major genetic risk factor for AD (Corder et al., 1993).  Even if the allele 
frequency of apoE varies within populations worldwide, the tendency shows that ε3 is the 
most common, followed by ε4, and ε2 is the least common. However, within the AD 
population, the ε4 allele is increased at least three-fold when compared with the general 
population, and ε2 is reduced (Corder et al., 1993; Mahley and Rall, 2000). Moreover, the 
possession of the ε4 allele increases the risk of AD and reduces the age of onset in a gene-
dose response manner as shown in Table 1.1 (Corder et al., 1993; Liu et al., 2013a).  








AD frequency (%) 20 47 91 
Mean age of clinical onset (years) 84 76 68 
 
Although the main function of apoE is in cholesterol and lipid transport, it is important in 
other functions related with apoptosis (Quinn et al., 2004), immunomodulation and oxidative 





neurite outgrowth, synaptic plasticity, destabilization of microtubules, amyloid clearance and 
promotion of neuronal survival. However, these functions are impaired in the presence of the 
apoE4 isoform, as shown in Figure 1.6.   
 
Figure 1.6. Roles of apoE4 in the brain. Adapted from Liu et al., (2013a). 
 
ApoE is predominantly produced by astrocytes in the brain whereas neurons express the 
apoE receptors. However, under stress conditions, neurons also express apoE as a repair 
response (Boschert et al., 1999; Xu et al., 2006), but the presence of the apoE4 isoform can 
have the opposite effect. The mechanism responsible for apoE4 increasing the risk of AD 
remains unknown. It has been shown that apoE4 tends to aggregate more than other isoforms 
of apoE and, as these aggregates are toxic, they can affect neurodegeneration (Hatters et al., 
2006). ApoE4 is also structurally less stable (Morrow et al., 2000), it has reduced lipid 
binding capacity (Xu et al., 2004), less antioxidant activity (Miyata and Smith, 1996) and 
less efficiency stabilizing microtubules (Strittmatter et al., 1994). However, the exact 
mechanism by which apoE influences AD remains unclear. Two of the major hallmarks of 
AD are the presence of extracellular deposition of Aβ, forming amyloid plaques, and the 
intracellular presence of NFT, composed of aggregations of hyperphosphorylated tau protein 





One hypothesis linking apoE and AD involves a direct interaction between apoE and Aβ 
peptides. ApoE has been identified within Aβ plaques found in AD brains (Namba et al., 
1991; Richey et al., 1995), and other studies in vitro have shown that the binding between 
apoE and Aβ occurs between residues 13-17 of the Aβ peptide with residues 144-148 of the 
N-terminal region and residues 244-248 of the C-terminal region of apoE (Strittmatter et al., 
1993b; Winkler et al., 1999). However, another in vitro study detected minimal levels of 
interaction between apoE and Aβ using the physiological levels found in cerebrospinal fluid 
(Aβ:apoE molar ratio of 1:50-75), and proposed instead that apoE influences Aβ metabolism 
via interaction with other transporters and receptors in cells (Verghese et al., 2013).  
ApoE knock-out mice studies have shown that apoE is necessary to initiate and maintain Aβ 
plaques (Bales et al., 1997; Irizarry et al., 2000), while another study reported that apoE 
decreases the initiation of Aβ fibril formation (Wood et al., 1996). Moreover, apoE4 has 
been shown to be less effective in the inhibition of Aβ fibril formation than apoE3 
(Hashimoto et al., 2012; Wood et al., 1996). Even if the exact mechanism by which apoE 
interacts with Aβ remains to be clarified, microglia could be a central player in mediating 
this interaction. Microglia upregulate apoE under certain stress conditions, and they have 
been found surrounding Aβ plaques (Uchihara et al., 1995). A recent study showed that apoE 
deficiency in mice reduced microglial activation around Aβ plaques (Ulrich et al., 2018), 
which could result in a reduced ability to clear Aβ plaques from the brain. 
Another hypothesis linking apoE with AD is the direct interaction between apoE and tau 
protein. ApoE has been located in NFT mediated by tau (Richey et al., 1995). Stable 
complexes between the microtubule-binding domain of tau and the LDL-receptor binding 
domain of apoE3, but not apoE4, have been shown in vitro (Strittmatter et al., 1994). 
Overexpression of human apoE4 in neurons of transgenic mice caused an increase in tau 
hyperphosphorylation mediated by Erk activation (Harris et al., 2004a; Tesseur et al., 2000). 





mice (Genis et al., 1995), which might indicate that apoE3 protects tau from 
hyperphosphorylation. A more recent study using P301S tau mutant transgenic mice on an 
apoE knock-out or knock-in background showed that apoE4 expression caused more brain 
atrophy and neurodegeneration than apoE2 or apoE3, while apoE knock-out mice were 
protected from these changes (Shi et al., 2017). This paper also identified a role for microglia 
in relation to tau, finding that the presence of the apoE4 background promoted microglial 
reactivity after lipopolysaccharide treatment (Shi et al., 2017).  
1.3.3. ApoE is proteolytically cleaved in the human brain 
Apolipoprotein E has been shown to be proteolytically cleaved in the human brain 
generating truncated fragments (as reviewed in Muñoz et al., (2018a)). Unfortunately, not 
much is known regarding fragmentation of apoE2, and reports on the mechanism of 
generation and the function of the fragments are inconsistent in the literature. However, as 
the apoE fragmentation pattern differs between the apoE3 and apoE4 isoforms (Elliott et al., 
2011), understanding the function of the apoE fragments may be critical to understanding the 
role of apoE in AD. There is a 50% reduction of the 25 kDa N-terminal fragment in apoE4 
compared to apoE3 brains (Elliott et al., 2011). When apoE3 or apoE4 was overexpressed 
specifically in either neurons or astrocytes, there was no fragmentation of apoE when 
overexpressed in astrocytes and in neurons there were fewer fragments of apoE4 than apoE3 
(Brecht et al., 2004). This paper also identified that fragmentation was specific to brain 
regions highly affected in AD, such as the neocortex or hippocampus (Brecht et al., 2004). 
Although astrocytes are responsible for high levels of apoE expression, together this data 
suggests that the enzyme responsible for fragmentation is specifically expressed by neurons 
and that the fragments may have a role in regulating disease onset or progression.  
A number of enzymes have been proposed to be responsible for apoE fragmentation in 
different studies (Table 1.2). Enzymes belonging to either the aspartic or the serine protease 





serine protease thrombin, generated a 22 kDa N-terminal apoE fragment that was neurotoxic 
to primary neurons (Marques et al., 1996). Moreover, the 22 kDa fragment from the apoE4 
isoform showed higher toxicity than the apoE3 fragment (Tolar et al., 1997, 1999). However, 
the apoE fragmentation pattern generated in vitro by thrombin digestion is different from the 
pattern observed in the human brain (Elliott et al., 2011). Cathepsin D, an aspartic protease, 
was proposed by Zhou et al. to generate a 24 kDa apoE fragment that does correspond to the 
fragmentation observed in the brain (Zhou et al., 2006). The apoE fragments and cathepsin D 
also colocalize with the amyloid plaques and NFTs in post mortem human tissue (Zhou et 
al., 2006). A chymotrypsin-like serine protease was proposed by Harris et al., supported by 
studies using the specific enzyme inhibitor α1-antichymotrypsin (Harris et al., 2003; 
Tamboli et al., 2014). It was also shown that the C-terminal fragment of apoE4 formed with 
the chymotrypsin-like protease, comprising amino acids 272-299, induces neuropathology 
and behavioural deficits in transgenic mice overexpressing the fragment (Harris et al., 2003). 
Most recently, high-temperature requirement serine protease A1 (HtrA1) was shown to 
induce fragmentation of apoE in vitro, generating a fragment of 25 kDa, encompassing 
amino acids 1-195. HtrA1 was able to cleave apoE4 faster and to a greater extent than apoE3 
(Chu et al., 2016). Of particular interest, recombinant HtrA1 generated apoE3 fragments, 
particularly a stable 25 kDa fragment (Chu et al., 2016), that is very similar to the major 
apoE fragment detected in the human brain (Elliott et al., 2011). 
Table 1.2. Enzymes proposed to cleave apoE. 
 Enzyme proposed Fragment generated 
Marques et al., (1996) Thrombin ApoE 22 kDa N-terminal 
Zhou et al., (2006) Cathepsin D ApoE 24 kDa N-terminal 
Harris et al., (2003) 
Tamboli et al., (2014) 
Chymotrypsin-like protease ApoE 272-299 C-terminal 





Some studies have shown a brain homogenate pattern composed of one fragment detected at 
~23-25 kDa and a smaller fragment detected at ~10 kDa (Cho et al., 2001). The hinge region 
of apoE (that connects the N-terminal and C-terminal regions) is highly exposed in both 
lipid-free and non-lipid free conformations, thus it is a likely potential target of enzyme 
cleavage. Previous studies have shown that apoE4 is degraded more rapidly than apoE3 and 
this may be due to the inherently unstable structure of the protein, i.e. previous data indicates 
that apoE4 forms a molten globule-like state in which the four-helix bundle is partially 
opened and elongated thereby exposing the hydrophobic core of the protein (Wernette-
Hammond et al., 1989). This may result in increased proteolytic enzyme access to the hinge 
region and to hydrophobic regions of the apoE4 isoform of the protein. Predicted cleavage 
sites for cathepsin D, chymotrypsin-like protease and HtrA1 are located throughout the 
amino acid sequence of the protein, and specifically in the hinge region. Interestingly, 
recombinant Htra1, which cleaves apoE after Val195 degrades apoE4 more rapidly than 
apoE3 (Chu et al., 2016). Binding of substrate internal hydrophobic stretches of amino acids 
to HtrA1 may modulate its protease activity, and this could contribute to the apoE isoform 
specific degradation of apoE by HtrA1. Overall this is consistent with the pattern seen in the 
human brain, where apoE4 is present at lower levels than apoE3 and at least the initial 
cleavage occurs in the hinge region (as the predicted molecular weight of the N-terminal 
domain is ~24 kDa and the C-terminal domain is ~10 kDa). It is worth noting that variations 
in apoE molecular weight in different studies could be due to O-linked glycosylation at 
Thr194 (Wernette-Hammond et al., 1989). 
1.3.4. Understanding the function of apoE fragments 
The difference in the apoE fragmentation pattern observed in apoE3 and apoE4 brains lead 
us to question the biological roles of the different apoE fragments and whether they have a 
relationship with AD pathogenesis (Table 1.3). Specific apoE fragments have been directly 





the initiation of neurodegeneration (Aizawa et al., 1997; Brecht et al., 2004; Harris et al., 
2003; Huang et al., 2001; Love et al., 2017).  An 18 kDa N-terminal fragment (1-172 aa) of 
apoE4 was found within NFT of AD patients (Rohn et al., 2012), however the presence of 
this fragment in cerebrospinal fluid or plasma did not correlate with AD or APOE genotype 
(Gause et al., 2017). Huang et al. found a different fragment, 1-271 aa of apoE4, to be part of 
NFT-like inclusions in neuronal cells (Huang et al., 2001). Moreover, there was reduced 
truncation of apoE3 compared to apoE4 and the inclusions did not occur in non-neuronal 
cells (Huang et al., 2001). The same group generated a transgenic mouse overexpressing the 
fragment 1-271 of apoE4. The mice that expressed high levels of the fragment died at 2-4 
months of age, showing AD-like neurodegeneration including tau pathology in the cortex 
and hippocampus. Meanwhile, the mice that expressed lower levels of the fragment showed 
impaired learning and memory at 6-7 months of age (Harris et al., 2003). Transgenic mice 
hAPPFAD (Mucke et al., 2000) overexpressing apoE3 or apoE4 showed a decrease in Aβ 
deposition and increase of Aβ clearance compared to mice that did not overexpress human 
apoE. However, the overexpression of the apoE4 1-271 fragment resulted in lower binding to 
Aβ peptides than apoE3 or apoE4, suggesting there was a decrease in Aβ clearance and an 
increase in Aβ deposition (Bien-Ly et al., 2011). A similar fragment size was also tested in 
Neuro-2a mouse neuroblastoma cells, showing that the 1-272 apoE4 fragment (including 
both LDL-receptor binding and lipid binding regions) induced neurotoxicity and 
mitochondrial dysfunction, whereas the 1-240 fragment of apoE4 (containing only the LDL-
receptor binding region) or full-length apoE4 did not (Chang et al., 2005). However, the 214-
272 fragment of apoE4 (containing only the lipid-binding region) did not induce 
neurotoxicity; therefore, this data suggests a requirement for both regions of apoE4 to cause 
mitochondrial dysfunction and neurotoxicity (Chang et al., 2005). 
Other research groups have used mimetic peptides to address the function of specific 
fragments. The apoE fragment 141-155 was shown to cause specific degeneration of neurites 





apoE 141-149, showed inhibition in proliferation and cytotoxicity in IL2-dependent T 
lymphocytes (Clay et al., 1995). Another peptide, apoE 133-149, corresponding to the LDL-
receptor binding region, was shown to be responsible for reducing inflammation after injury. 
The peptide was able to mimic the effects of the full-length protein, suppressing microglial 
activation and release of tumor necrosis factor-α and nitric oxide after lipopolysaccharide 
administration in BV2 mouse microglial cells (Laskowitz et al., 2001; Lynch et al., 2003). 
The same 133-149 apoE peptide showed a neuroprotective function after exposure to N-
methyl-D-aspartate, suppressing cell death and calcium influx in primary neuronal-glia 
mixed cultures from brain cortices of foetal rats (Aono et al., 2003). From the same group, 
the peptide was studied in mouse models of other disease models, including multiple 
sclerosis and post-ischemia necrosis and also led to an improvement after administration of 
the 133-149 apoE peptide (Li et al., 2006; McAdoo et al., 2005). Another group used the 
same peptide apoE 133-149 to understand its interaction with neuronal nicotinic 
acetylcholine receptors (nAChRs) (Gay et al., 2006, 2007; Klein and Yakel, 2004). There 
was a complete inhibition of acetylcholine-evoked responses in rat hippocampal slices when 
the peptide was added. Furthermore, the same effect was seen when using the shorter peptide 
apoE 141-148, but not with 133-140, demonstrating that the interaction with nAChR is 
mediated by the arginine-rich domain (Klein and Yakel, 2004). Further studies in Xenopus 
laevis oocytes showed that the interaction of the apoE 133-149 peptide, or the shorter 141-
148, disrupted nAChR signalling by blocking the α7 nAChRs (Gay et al., 2006, 2007). 
Isoform-specific proteolysis has been identified in a number of different studies, showing 
higher levels of fragmentation of apoE4 compared to apoE3. A study in Neuro2a mouse 
neuroblastoma cells identified an intracellular apoE C-terminal 13 kDa fragment following 
transfection with the human apoE3 or apoE4. This fragment, that was highly expressed in 
apoE4-transfected cells, inhibited the formation of Aβ fibrils and stabilized the formation of 
Aβ hexamers in vitro (Wellnitz et al., 2005).  Other studies have focused on the role of 





extracellular proteases collagenase and matrix metalloprotease-9 (MMP-9) produce a 17 kDa 
apoE 1-151 fragment and in the apoE4 background the fragment traffics to the nucleus of 
BV2 mouse microglial cells increasing cell death (Love et al., 2017). Dafnis et al. showed in 
the SK-N-SH human neuroblastoma cell line that the 19 kDa N-terminal fragment of apoE4 
(apoE 1-165) stimulated the intracellular accumulation of Aβ42, generating ROS, but this 
effect was absent with apoE3 or with the 21 kDa fragment (apoE 1-185) (Dafnis et al., 2010, 
2016). However, the 1-185 fragment of apoE4 promotes MMP-9/tissue inhibitor of 
metalloprotease 1 (TIMP1), induced by expression of IL-1β in human neuroblastoma SK-N-
SH cells and astrocytoma cells SW-1783 cells (Dafnis et al., 2012). The 22 kDa fragment 
proposed to be generated by thrombin cleavage exhibited neurotoxicity from apoE4 but not 
when generated from apoE3 in primary neurons (Marques et al., 1996). The same fragment 
was studied in embryonic chick sympathetic ganglia and embryonic rat hippocampus tissue 
showing that the fragment generated an increase in intracellular calcium and the neurotoxic 
function of the apoE4 fragment was mediated through the heparan sulfate proteoglycan-LDL 
receptor-related protein complex (Tolar et al., 1997, 1999). Overall, most of the studies have 
been focused on the toxicity generated by the apoE4 fragments (Table 1.3 and Figure 1.7), 
and little is known regarding the potential neuroprotective effect of the apoE3 major 
fragments observed in the human brain. 
Table 1.3. Proposed functions of apoE fragments in cell and animal models related to AD and 
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1.4. Modelling AD 
Since AD was first described by Alois Alzheimer in 1907 (Alzheimer, 1907), different 
models have been used to study the disease. Initially, Alois Alzheimer described the 
symptoms of his patient, Auguste Deter, and post mortem analysis of her brain indicated 
alterations in the NFTs that were dyed with silver stain (Alzheimer, 1907). Post mortem 
brain tissue was first used to study AD and it was used to describe the neuropathology of the 
disease, including the two main pathological hallmarks (Braak and Braak, 1997). However, 
as post mortem brains show only the end point of the disease, other models are required to 
understand the mechanisms underlying earlier stages of the disease. 
1.4.1. In vivo models 
Since the discovery of the genes involved in FAD, transgenic animal models have been used 
to understand their specific role in the pathology of the disease. Transgenic animals are 
generated by insertion of a gene of interest in the animal genome or by deleting a specific 
gene from the animal genome. Invertebrate animal models such as Caenorhabditis elegans, 
Drosophila melanogaster or Danio rerio have been used due to their short lifespan, well-
characterised development and behaviour (as reviewed by Saraceno et al., (2013)). However, 
mammalian models, especially mice, have been broadly used in the study of AD. 
The transgenic mice generated to develop the pathology characteristic of AD have been 
extensively reviewed in the literature (Elder et al., 2010; Hall and Roberson, 2012; LaFerla 
and Green, 2012; Saraceno et al., 2013). Since 1993, transgenic mice overexpressing the 
human APP gene (hAPP mice) (Buxbaum et al., 1993), deficient for the APP gene (Takei et 
al., 2000; Zheng et al., 1996) or with specific tau mutations (Lewis et al., 2001; Oddo et al., 
2003a) have been generated, helping understand the physiological role of the proteins. To 
model AD, transgenic mice generated overexpressing APP with the mutations known from 





all the pathological features of AD, they are useful to understand different aspects of the 
neurobiology of AD. In 1995, the first transgenic mouse overexpressing mutant APP was 
able to reproduce an AD phenotypes was published (Games et al., 1995) and, since then, 
transgenic lines with various mutations in the APP gene are available (Chishti et al., 2001; 
Hsiao et al., 1996; Sturchler-Pierrat et al., 1997). Furthermore, transgenic mice with 
mutations in more than one gene have generated the 3xFAD mouse, harbouring mutated 
APP, PSEN1 and tau transgenes (Oddo et al., 2003b), and the 5xFAD mouse, with 3 
mutations PSEN1, PSEN2 and 3 mutations in APP (Oakley et al., 2006), that show 
neurodegeneration and synaptic loss in addition to memory and cognitive deficits associated 
with AD. However, there are other factors related to AD that should be considered such as 
apoE. Murine apoE is more similar to the human apoE4 isoform than apoE2 or apoE3 as 
both contain Asp112 and Asp158. However, the structure and the function changes as the ionic 
association between Arg61 and Glu255 that occurs in apoE4 is lost due to the presence of Thr61 
in the murine apoE (Getz and Reardon, 2016). Knock-in mice expressing human apoE4 
show cognitive impairments not seen with apoE3 (Grootendorst et al., 2005) and, when 
crossed with hAPP mice, the apoE4 knock-in mice show higher plaque deposition than the 
apoE3 (Bales et al., 2009; Fryer et al., 2005). Moreover, when crossing apoE4 knock-in  with 
a mouse model for tau, it exacerbates tau neurodegeneration (Shi et al., 2017). 
While trying to bridge the gap that differentiates rodents and humans, new in vivo models 
have appeared recently. A novel nonhuman primate model that expresses AD-like pathology 
has been generated (Forny-Germano et al., 2014). However, the cost associated with these 
studies makes it difficult to be a commonly used model of study. 
1.4.2. In vitro models 
The study of AD in vitro offers some advantages when compared to animal studies. The 





samples than in vivo models and the possibility to test various conditions of study make in 
vitro models a useful tool when modelling AD. 
1.4.2.1. Established cell lines 
Established cell lines are immortalized cells derived from cancer cells. Human 
neuroblastoma cell lines, such as SK-N-SH or SH-SY5Y cells have been used to study 
neurodegenerative diseases due to their potential to differentiate into a neuronal lineage by 
the addition of factors, such as RA (Agholme et al., 2010; Shipley et al., 2016). Most of the 
studies performed with neuroblastoma cells have focused on neuroprotective compounds 
against some of the AD pathological features, including Aβ (Xia et al., 2007; Zhang et al., 
2010), oxidative stress (Forster et al., 2016; Zheng et al., 2006) and apoptosis (Lombet et al., 
2001; Song et al., 2015). Neuroblastoma cell lines have also been used to understand the role 
of apoE in AD in the human SK-N-SH cell lines (Dafnis et al., 2010, 2012, 2016) or the 
mouse Neuro-2a cell line (Chang et al., 2005; Huang et al., 2001; Wellnitz et al., 2005). 
However, whereas the potential of the established cell lines relies on studying the known 
molecular mechanisms related with diseases, they do not recapitulate specific characteristics 
of sporadic pathologies. 
1.4.2.2. Primary cells cultures 
Primary cell cultures, especially from rodents, are generated from brains of embryos, 
newborns or adults. Their utility relies on the easy availability of these cultures and the 
potential to obtain different cell types including specific neuron subtypes. Primary cultures 
have been used to understand the role of Aβ pathology in different cell types such as 
astrocytes (Grolla et al., 2013; Zhao et al., 2011) or microglia (Krabbe et al., 2013; Paresce 
et al., 1996). Primary neurons, especially from the hippocampal region or cortex, have also 
been used to understand the neuroprotection mechanisms (Eves et al., 1992; Nguyen et al., 





neuroprotection, and primary cell cultures can be generated from transgenic mice that model 
the neuropathology of AD, the differential gap between species and the limitation associated 
with unknown pathological mechanisms needs to be solved.   
1.4.2.3. Induced pluripotent stem cells 
The discovery of induced pluripotent stem cells (iPSCs) revolutionized the way to study 
neurodegenerative diseases. In 2006 and 2007, Yamanaka published a method of 
reprogramming adult fibroblasts into iPSC by introducing four factors (Oct3/4, Sox2, c-Myc 
and Klf4) in mice (Takahashi and Yamanaka, 2006) and human cells (Takahashi et al., 
2007). iPSCs resemble embryonic stem cells (ESCs) in terms of morphology, proliferation, 
surface antigens, gene expression, epigenetic status of pluripotent cell-specific genes and 
telomerase activity and capability to differentiate into cell types of the three germ layers in 
vitro (Takahashi and Yamanaka, 2006; Takahashi et al., 2007), but do not face some of the 
ethical issues associated with ESCs. In just over a decade, iPSCs have become a highly used 
model to study neurodegenerative diseases, including AD, as with them we have access to 
living cells from patients that may reproduce some of the disease phenotypes, either because 
of the known mutation in the FAD cases, or the genetic background in the late-onset cases. 
In the last few years, the amount of studies published using iPSC models for AD has 
increased. Some of the studies reported the generation of iPSCs derived from FAD patients 
(Muñoz et al., 2018b; Muratore et al., 2014; Ortiz-Virumbrales, 2017; Sproul et al., 2014; 
Yagi et al., 2011), or FAD and SAD patients (Balez et al., 2016; Duan et al., 2014; Israel et 
al., 2012; Kondo et al., 2013; Ooi et al., 2013). The differentiation of iPSCs into iPSC-
derived neurons from the FAD and SAD patients showed pathological features characteristic 
of AD such as an increase in Aβ peptide levels, mainly the pathogenic Aβ42 (Muratore et al., 
2014; Sproul et al., 2014; Yagi et al., 2011), of Aβ oligomers (Kondo et al., 2013). These 
iPSC-derived neurons show a response to β-secretase inhibitors (Israel et al., 2012), γ-





tau, the other pathological hallmark of AD, was also increased in this model (Israel et al., 
2012; Muratore et al., 2014). 
Other cell types such as astrocytes and microglia have also been differentiated from iPSCs. 
iPSC-derived astrocytes from AD patients show severe pathology and dysfunction (Jones et 
al., 2017; Oksanen et al., 2017). iPSCs have also been used as a model to understand the role 
of apoE4 in different cell types (Lin et al., 2018). The iPSC-derived cells are a suitable 
model for drug screening in the search for new drugs that could potentially be used in 
therapy. In order to achieve this goal, the development of properly characterised neurons that 
represent the AD model is essential. 
1.4.2.3.1. Differentiation strategies of basal forebrain cholinergic 
neurons from iPSCs 
iPSCs have the potential to differentiate into any cell type of the three germ layers, so they 
can be differentiated into relevant cell types to study AD. As discussed before, BFCNs are 
one of the first types of neurons to degenerate in AD, leading to cognitive impairment and 
memory deficits (Mufson et al., 2008; Whitehouse et al., 1982), and therefore, they are a 
suitable cell model to study the early stages of the neuropathology of the disease, but due to 
their complexity, only a few studies have successfully differentiated BFCNs (Table 1.4). 
Most of these studies start the differentiation process with the generation of embryoid bodies 
(EBs), followed by the formation of neural rosettes and neurospheres. These neurospheres 
contain neural precursor cells (NPCs) from which the different protocols will generate 
BFCNs. 
Nilbratt et al. assessed growth factors that could induce forebrain identity (Nilbratt et al., 
2010). BDNF, NGF, ciliary neurotrophic factor (CNTF) and neurotrophin 3 (NT-3) were 
tested as candidates, but only BDNF and NGF reliably induced the expression of both 





comparison of two protocols to generate functional BFCNs from human ESCs (hESCs) 
(Bissonnette et al., 2011). After pre-treatment with RA, SHH and FGF8, one option relied on 
diffusible ligands for differentiation, while the other additionally transfected the transcription 
factors LHX8 and GBX1 together with a fluorescent tag. Transfected cells could be purified 
by fluorescence activated cell sorting, a step that increased the ratio of BFCNs in the final 
culture to 94%. This method also allowed the successful differentiation of BFCNs from 
human iPSCs (hiPSCs), as described by the same group, showing that iPSC-derived BFCNs 
can be used as a model for AD, producing disease-related pathological features (Duan et al., 
2014).  
Using a different strategy, Crompton et al. published a protocol for non-adherent 
differentiation of iPSCs into BFCNs (Crompton et al., 2013). In this procedure, neurospheres 
were treated with Nodal/transforming growth factor β (TGF-β) inhibitor (small molecule 
inhibitor, SMI) to induce the endogenous expression of SHH, instead of direct addition of 
SHH, resulting in a 90% efficiency of β-III-tubulin/ChAT expressing cells after 90 days 
(Crompton et al., 2013). This 90% efficiency obtained by Crompton et al. differs from the 
38% obtained by Liu et al., which protocol generated a mix cell culture population of BFCNs 
and GABA interneurons both in vitro and after NPC-engraftment in mice (Liu et al., 2013b). 
More recently, another three protocols have been published. Whereas Yue et al. showed a 
simple differentiation protocol where by addition of SHH and BMP9 generated functional 
BFCNs that were able to integrate into the nucleus basalis de Meynert (Yue et al., 2015), Hu 
et al. and Ortiz-Virumbrales et al. showed a combination of SMI and growth factors for their 
BFCN differentiation (Table 1.4). Hu et al. showed how they improved from 20 to 40% 
BFCN efficiency when co-culturing with astrocytes (Hu et al., 2016), and Ortiz-Virumbrales 
et al. were able to generate functional BFCNs in both hESCs and hiPSCs (Moreno et al., 





As summarised in Table 1.4, all the published protocols to differentiate BFCNs from stem 
cells (ESCs or iPSCs) have a duration between 33 and 65 days, show expression of general 
neuronal markers such as β-III-tubulin or MAP2 and specific BFCN markers such as ChAT 
or VAChT. Even if most of them show high efficiency based on ChAT+ve cells, the methods 
for analysing the physiological properties of the BFCN vary from study to study. The 
necessity of a robust protocol that contains all the clinically relevant characteristics of 
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1.5.  Overview and aim of the study 
AD is a devastating neurodegenerative disease that has been studied since the beginning of 
the 20th century. More than 100 years later we are still filling the gaps of knowledge, but we 
are missing necessary pieces to fully understand the mechanisms underlying the trigger and 
pathology of AD. From animal models to various in vitro models are widely used to 
understand the role of every important key player. Each model is giving us a different 
perspective, so we can have a wider view of the disease. The four studies presented here aim 
to improve cell-based models to better understand the role of apoE, one of the major key 
players of AD, and to generate and characterise iPSC lines and iPSC-derived BFCNs to be 
used as a new model to study the neurobiology of AD. 
The specific hypothesis and objectives of this PhD thesis are: 
- HtrA1 is an enzyme responsible for the fragmentation of apoE. 
o We aim to use SK-N-SH neuroblastoma cells to study the role of HtrA1 in apoE 
fragmentation and the function of the specific apoE fragments. 
- The apoE fragmentation and the function of the fragments differ between the apoE 
isoforms. 
o We aim to generate an APOE isogenic line of the SK-N-SH neuroblastoma cell 
line to study to study the differences in apoE fragmentation. 
- iPSCs and iPSC-derived BFCNs can be used as a model to study AD. 
o We aim to generate and characterize iPSC lines from AD patients and healthy 
individuals.  
o We aim to generate and characterize an iPSC-derived BFCNs protocol to study 














General methods are outlined in this chapter. Specific methods relevant to Chapters 3-6 are 
outlined in the relevant chapters. 
2.1. Cell culture 
2.1.1.  Fibroblast culture 
Fibroblasts were cultured in Dulbecco's Modified Eagle Medium (DMEM)/F12 (v/v) (1:1) 
(Invitrogen, USA) supplemented with 10% (v/v) Foetal Bovine Serum (FBS) (Interpath 
Services, Australia) and 100 IU/ml Penicillin, and 100 µg/ml Streptomycin (Life 
Technologies, USA) at 37 °C and 5% CO2. The medium was changed every 2-3 days and 
cells were passaged when 80% confluency was reached. Cells were incubated with Trypsin 
(0.05% Trypsin- Ethylenediaminetetraacetic acid (EDTA)) (Life Technologies) for 3-5 min 
at 37 °C and stopped using DMEM/F12 with 10% (v/v) FBS, after which cells were 
centrifuged at 800 x g for 5 min and split 1:3. 
2.1.2.  iPSC culture 
Human feeder-free iPSCs were cultured in MatrigelTM (Corning, USA) coated 60 mm 
diameter tissue culture plates, fed with TeSR-E8 Basal Medium (Stem Cell Technologies, 
Canada) and kept in a humidified incubator at 37 °C, 5% CO2 and 3% O2. After manual 
removal of differentiated cells under the microscope, the medium was changed every day. 
Colonies were passaged every 5-6 days using 1x dispase (Stemcell Technologies) for 5 min 
at 37 °C. Once the border or the colonies started to detach, DMEM/F12 was added and 
colonies were mechanically detached with a cell scraper, transferred into a conical centrifuge 
tube and centrifuged for 5 min at 300 x g. The supernatant was removed, and colonies were 
gently resuspended in 1 ml TeSR-E8 before they were plated down at 1:5 - 1:10 ratio 





2.1.3.  SK-N-SH, SH-SY5Y and U87 cell culture 
Human SK-N-SH and SH-SY5Y neuroblastoma cell lines, and human U87 glioblastoma cell 
line identities were confirmed by short tandem repeat (STR) profiling at Garvan Molecular 
Genetics (Darlinghurst, Australia) with results matching 100% with the American Type 
Culture Collection Cat #HTB-11, #CRL-2266 and #HTB-14, respectively. Cell maintenance 
and passaging were performed as described in Section 1.1, but cells were split at 1:10 ratio. 
2.1.3.1. Neuronal differentiation of the SK-N-SH and SH-SY5Y cells 
SK-N-SH and SH-SY5Y cells were differentiated into a neuronal phenotype with the 
addition of 10 µM all-trans retinoic acid (ATRA). Cells were plated at the density specified 
for each experiment using DMEM/F12 with 5% (v/v) FBS unless otherwise specified. Cells 
were grown for 24 h before ATRA treatment started, and full media changes were performed 
every 3 days until day 6 or 9 as specified in each experiment. 
2.1.4. Incucyte Zoom analysis 
Live cell imaging of the cultures over time was performed using the Incucyte Zoom Imaging 
System (Essen Bioscience, USA). Cell confluence and neurite length were assessed using the 
Incucyte Live Cell Analysis system. The parameters used were manually optimized for each 
cell type and experiment in a selection of pictures from the different conditions before the 
automated measurement was performed. Neurite length data were analysed in units of mm of 
total neurites detected/mm2. 
2.1.5. Viability assay 
Viability assay was performed using Presto Blue assay (Thermo Fisher Scientific, USA). 
Presto Blue reagent was diluted 10% (v/v) in DMEM/F12. After incubation for 2 h at 37 °C 
with the cells, cell medium was transferred into a black 96-well plate for fluorescence 





reader (BMG labtech, Germany). The background was subtracted with the reading from a 
well that had medium but no cells and each value was normalized to the cell confluence 





2.2.  APOE genotyping 
Genomic DNA was extracted using the ISOLATE II Genomic DNA Kit (Bioline, Australia) 
and DNA concentration and purity were measured using Nanodrop 2000C instrument 
(Thermo Fisher Scientific). Amplification of 200 ng of genomic DNA was performed using 
MyTaqTM HS DNA Polymerase (Bioline). The primers from Table 2.1 were mixed targeting 
the 3 APOE genotypes as followed: Primer mix ɛ2 containing APOE 112C and 158C, primer 
mix ɛ3 containing APOE 112C and 158R, and primer mix ɛ4 containing APOE 158R and 
112R, in addition to HLA control primers in all the mixes. The PCR cycling conditions 
started with an initial denaturation at 96°C for 1 min, followed by 5 cycles of 96 °C for 20 s, 
70 °C for 45 s and 72 °C for 25 s; 21 cycles of 96 °C for 25 s, 65 °C for 50 s and 72 °C for 
30 s, and 4 cycles of 96 °C for 30 s, 55 °C for 60 s and 72 °C for 120 s (Pantelidis et al., 
2003). Amplified DNA was mixed with GelRed Nucleic Acid Gel Stain (Biotium, USA) 
before they were run on 1.5% agarose gel for 30 min at 100 V along with Hyperladder 100 
bp (Bioline) as molecular weight marker. DNA bands were visualized using Gel Logic 2200 
Pro Imaging System (Carestream, USA). 
Table 2.1. List of primers used for APOE genotyping. 
Gene Primer name Sequence (5’ - 3’) Amplicon size 
APOE 
APOE-112C F: CGGACATGGAGGACGTGT 
173 bp 
APOE-158R R: CTGGTACACTGCCAGGACG 
APOE-158C R: CTGGTACACTGCCAGGCA 
APOE-112R F: CGGACATGGAGGACGTGC 
HLA 
(Control) 
HLA-DRB1 F: TGCCAAGTGGAGCACCCAA 
785 and 1598 bp 







2.3.  DNA extraction and sequencing 
Genomic DNA was extracted using the ISOLATE II Genomic DNA Kit (Bioline). DNA 
concentration and purity were determined using Nanodrop 2000C instrument. PCR was 
performed by mixing 100-200 ng DNA with 12.5 µl MyTaqTM HS DNA Polymerase, 10 µM 
of each pair of primers stated in Table 2.2 and water up to 25 µl reaction. PCR reaction was 
amplified in MyCyclerTM Thermal Cycler System (Bio-Rad, USA) using the following 
program: Initial denaturation at 95 °C for 1 min followed by 35 cycles of 15 s at 95 °C for 
denaturation, 15 s at specific annealing temperature and 10 s at 72 °C for extension; and final 
extension at 72 °C for 5 min. 
Table 2.2. List of primers used for sequencing. 
 
Electrophoresis was performed using 4 µl of each sample mixed with GelRed Nucleic Acid 
Gel Stain and run on 1.5% agarose gel at 100 V for 30 min run along with Hyperladder 100 
bp and visualized on Gel Logic 2200 Pro Imaging System. After confirming the specific 
DNA amplification, PCR products were purified using a modified protocol of Pure Link 
Quick Gel Extraction kit (Invitrogen): 16 µl PCR product were mixed with 20 µl water and 
120 µl buffer L3, transferred into the columns and centrifuged at 12000 x g for 1 min. Flow 
through was discarded, 600 µl wash buffer were added and centrifuged at 12000 x g for 1 
min. Flow through was discarded and columns were centrifuged at maximum speed for 2 
min to remove any buffer. After transferring the column into a 1.5 ml microcentrifuge tube, 
Target Sequence (5’ - 3’) Tm Amplicon size 
APOE 
F: CTACAAATCGGAACTGGAGGAAC 











20 µl of elution buffer were added and samples were centrifuged at 12000 x g for 1 min to 
collect the purified PCR product. 
Sequencing reaction was performed by mixing 2 µl 5x Sequencing buffer, 1 µl ABI BigDye 
Terminator v3.1 Ready Reaction Mix (Applied Biosystems, USA), 1 µl Primer F or R (2 
µM), 4 µl water and 2 µl of purified PCR product. Samples were run on MyCyclerTM 
Thermal Cycler System following the program: 96 °C for 30 s followed by 35 cycles of 96 
°C for 10 s, 66 °C for 5 s and 60 °C for 4 min. 
Ethanol precipitation was performed by mixing 50 µl 100% ethanol, 10 µl water, 2 µl 125 
mM EDTA pH 8.0, 2 µl 3 M Sodium acetate pH 5.2 and 10 µl sequencing reaction. The 
samples were incubated at 22 °C in the dark for 20 min after mixed adequately before they 
were centrifuged at 16000 x g for 20 min at 22 °C. The supernatant was removed, the pellet 
was rinsed with 180 µl ice-cold 70% ethanol and the samples were centrifuged for 20 min at 
4 °C. The supernatant was removed and the samples were dried in the dark before being 
processed. 
Samples were run in the 3500xL Genetic Analyzer (Applied Biosystems), SeqA6 Software 







2.4.  mRNA quantification 
2.4.1.  mRNA extraction 
Cell samples for mRNA extraction were washed twice with 1x Phosphate Buffer Saline 
(PBS) before they were harvested in TriSURE (Bioline). Samples were kept at -80°C until 
mRNA was extracted following the manufacturer’s instructions. mRNA concentration was 
measured using Nanodrop 2000C instrument and purity was assessed based on the 260/230 
and 260/280 ratios. DNAse I treatment was performed using Turbo DNA-free kit 
(Invitrogen) following the manufacturer’s instructions. mRNA was purified by ethanol 
precipitation: mRNA was diluted up to 200 µl RNAse-free water and mixed with 20 µl 3M 
Na acetate and 220 µl isopropanol. After vortex, samples were stored at -80 °C for 1 h and 
then centrifuged at 16000 x g for 20 min at 4 °C. The supernatant was discarded, and the 
pellet was rinsed with 70% ethanol before being centrifuged again at maximum speed for 2 
min. The supernatant was removed, and the pellet was dried before it was resuspended in 
RNAse-free water to yield a final concentration between 100 and 500 ng/µl. Purity and 
concentration of the isolated mRNA were measured using Nanodrop 2000C instrument. 
2.4.2. Generation of complementary DNA  
Up to 5 µg of mRNA were processed to generate complementary DNA (cDNA) using Tetro 
cDNA Synthesis kit (Bioline). The protocol was followed as per manufacturer’s instructions 
using Oligo (dT)18 and incubating samples for 30 min at 45 °C followed by 30 min at 85 °C 
in MyCycler Thermal Cycler. The samples were stored at -20 °C until use.  
2.4.3. qRT-PCR 
Each cDNA sample was run in duplicates or triplicates using between 25 to 50 ng cDNA per 
reaction. A no Retro Transcriptase RNA control and non-template control were also run as 





RotorGene 3000 (Qiagen, Germany) were used following the program: Denaturation at 95 
°C for 2 min; followed by 35 or 40 cycles of denaturation at 95 °C for 10 s, annealing at 
specific primer Tm for 10 s and extension at 72 °C for 10 s. Melting step started at 95 °C for 
5 s followed by ramp from 65 °C to 97 °C at 0.1 °C/s before cooling. 
Table 2.3. List of primers used for qRT-PCR. 
 
Target Sequence (5’ - 3’) Tm Amplicon size 
APOE 
F: CTACAAATCGGAACTGGAGGAAC 




























58 °C 120 bp 
R: TGGTGGTAGGAAGAGTAAAG 
GAPDH 
F:  GAGCACAAGAGGAAGAGAGAGACCC 
58-62 °C 214 bp 
R: GTTGAGCACAGGGTACTTTATTGATGGTACATG 
HPRT1 
F:  TGACACTGGCAAAACAATGCA 






2.4.4. Data analysis 
Raw data from LightCycler 480 or RotorGene 3000 instruments was extracted and analysed 
using LinRegPCR  (Ruijter et al., 2009) to obtain the individual efficiency of each reaction. 
Data analysis was performed using Excel following ΔΔCt method using the efficiency 
obtained for each set of primers. GraphPad Prism 7 was used to generate graphs and perform 






2.4. Protein quantification 
2.4.1. Extracellular protein harvest 
Conditioned media from cell culture was collected to analyse extracellular proteins released 
into the media. The conditioned media was collected directly from the plate, centrifuged at 
10000 x g for 5 min to remove cell debris and dead cells, transferred into a 1.5 ml 
microcentrifuge tube and stored at -80 °C until use.   
2.4.2.  Intracellular protein harvest 
Intracellular protein was harvested in RIPA buffer (50 mM Tris HCl pH 7.4, 1% Sodium 
deoxycholate, 150 mM NaCl, 1 mM EDTA, 1% Triton-X and 0.1% SDS in Milli-Q water) 
mixed with 1x protease inhibitor cocktail (Sigma-Aldrich, USA) and 0.1 M phosphatase 
inhibitor sodium orthovanadate. Once conditioned media was removed from the cell culture, 
cells were rinsed with 1x PBS and incubated with 100 µl RIPA buffer per well of a 24-well 
plate for 20 min on ice. Cell lysate was vortexed for 10 sec and centrifuged at 10000 x g for 
5 min. Supernatant was transferred into a 1.5 ml microcentrifuge tube avoiding the small 
debris pellet created at the bottom of the tube. The cell lysate was stored at -80 °C until use. 
2.4.3. DC Assay 
Total protein quantification was performed using the DC Protein Assay (Bio-Rad) following 
the manufacturer’s instructions. Absorbance was read at 750 nm using a Spectramax Plus 
Plate Reader (Molecular Devices, USA). The sample concentration was calculated based on 
a standard curve generated using Bovine Serum Albumin (BSA) (Sigma-Aldrich) diluted in 





2.4.4. Western blot 
2.4.4.1. SDS-PAGE gels preparation 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels used were 
hand-casted using the Mini-PROTEAN® Tetra Handcast System (Bio-Rad) using the 10- or 
15-well format with the reagents and volumes stated in Table 2.4.  
Table 2.4. Reagents and volumes used for hand-casted 12% SDS-PAGE gels. 
 Separating gel Stacking gel 
Distilled water 4.95 ml 1.5 ml 
40% Acrylamide 3 ml 0.3125 ml 
Tris 1.875 ml of 2 M 0.625 ml of 0.5 M 
10% SDS 0.1 ml 0.025 ml 
10% APS 0.1 ml 0.025 ml 
TEMED 0.004 ml 0.0025 ml 
Total volume used per gel 8 ml 2 ml 
 
2.4.4.2. Sample preparation and western blot run 
Samples were mixed with 5x Laemmli Sample Buffer (Bio-Rad) and proteins were 
denatured for 5 min at 95 °C. Samples were loaded into SDS-PAGE gels along with the 
Precision Plus Protein Dual Color (Bio-Rad) molecular weight marker and separated by 
electrophoresis at 120V for 80 min. Protein samples were transferred to 0.45 µm 
nitrocellulose membranes at 100V for 35 min using ice-cold 1x western blot transfer buffer. 
Successful transfer and equal sample loading were determined by staining the membranes 
with Ponceau S Solution Bioreagent (Sigma-Aldrich) for 2 min and the excess stain was 
washed off with distilled water. The membranes were scanned on Epson Perfection 3170 





T) followed by incubation for 5 min with boiling 1x PBS and another 5 min with 1x PBS-T. 
Blocking for 1 h with 5% (w/v) milk in 1x PBS was performed before incubation with 
primary antibodies made up in 5% (w/v) milk in 1x PBS and 0.001% (v/v) sodium azide. 
Primary antibodies were incubated at 4°C for 16 h, followed by three washes with 1x PBS-T 
for 10 min each. Secondary antibodies conjugated with HRP were made up in 5% (w/v) milk 
in 1x PBS-T and incubated for 2 h at 22 °C, followed by 3 washes of 1x PBS-T for 10 min 
each. Membranes were incubated for 2 min with Pierce ECL Plus Western Blotting Substrate 
(Thermo Fisher Scientific). Protein expression was detected by chemiluminescence on 
Amersham 6000RGB (GE Healthcare Life Sciences, UK) instrument or after exposing the 
membranes to X-ray film developed using AGFA-CP1000 Film Processor.  
Table 2.5. List of primary antibodies used for western blot. 
 
Table 2.6. List of secondary antibodies used for western blot. 
Antibody Raised in Dilution Company Cat #  
Anti-apoE Goat pAb 1:10000 Millipore Cat #178479 
Anti-HtrA1 Mouse mAb 1:500 R and D Systems Cat #MAB2916 
Anti-GAPDH Rabbit pAb 1:10000 Osenses Cat #OSG00032W 
Anti-tau S214 Rabbit mAb 1:5000 Abcam Cat #ab170892 
Anti-tau S404 Rabbit mAb 1:1500 Abcam Cat #ab92676 
Anti-tau13 Mouse mAb 1:5000 Abcam Cat #ab19030 
Antibody Raised in Dilution Company Cat # 
Anti-Goat HRP Donkey pAb 1:5000 Jackson ImmunoResearch Labs Cat #705-035-147 
Anti-Mouse HRP Donkey pAb 1:5000 Jackson ImmunoResearch Labs Cat #715-035-151 
Anti-Rabbit HRP Donkey pAb 1:5000 Jackson ImmunoResearch Labs Cat #711-035-152 
Anti-Mouse HPR Goat pAb 1:5000 Merck Millipore Cat #AP308P 





Li-cor Image Studio was used for quantification of western blot bands, Excel was used for 
data analysis, and GraphPad Prism 7 was used to generate graphs and perform statistical 






Cells used for immunocytochemistry were plated on glass coverslips with or without coating 
depending on the specific cell type. When cell cultures were at the desired stage, cell media 
was removed, cells were rinsed with 1xPBS and fixed by incubation with 4% (w/v) 
paraformaldehyde (PFA) at 22 °C. After 10 minutes, PFA was removed and cells were 
rinsed 3 times with 1x PBS, permeabilised with 0.5% (v/v) TritonX-100 in 1x PBS for 15 
min and rinsed 3 times with 1x PBS. Blocking was performed with 5% (v/v) goat serum in 
1x PBS and 0.3 M glycine for 1 h at 22 °C. Primary antibodies were used at the specific 
dilution in 5% (v/v) goat serum in 1x PBS and incubated at 4 °C for 16 h. On the following 
day, cells were rinsed 3 to 5 times with 1x PBS and incubated with the appropriate secondary 
antibody made up in 1x PBS for 1 h at 22 °C. Cells were washed 3 to 5 times with 1x PBS 
before incubation with Hoechst 33342 (Thermo Fisher Scientific, 1 µg/ml) or Reddot 2 
(Biotium, 1:200) for 10 or 20 min respectively for nuclear staining. Coverslips were mounted 
on glass slides using ProLong Gold antifade reagent (Life Technologies). Confocal 
microscopy was performed using Leica TCS SP8 (Leica Microsystems, Germany) 
microscope and images were analysed using Leica Application Suite - Advanced 
Fluorescence (LAS-AF) software. 
Table 2.7. List of primary antibodies used for immunocytochemistry. 
Antibody Raised in Dilution Company Cat #  
Anti-Oct4 Mouse mAb 1:500 Stemcell Technologies Cat #01550 
Anti-SSEA-4 Mouse mAb 1:200 Abcam Cat #ab16287 
Anti-Tra-1-60 Mouse 488 1:100 Stemcell Technologies Cat #A11001 
Anti-β-III-tubulin Mouse mAb 1:1000 Abcam Cat #ab78078 
Anti-ChAT Rabbit pAb 1:100 Abcam Cat #ab181023  






Table 2.8. List of secondary antibodies used for immunocytochemistry. 
 
  
Anti-GFAP Rabbit mAb 1:500 Millipore Cat #04-1062 
Anti-SMI32 Mouse mAb 1:50 Abcam Cat #ab7795 
Anti-MAP2 Mouse mAb 1:500 Millipore Cat #MAB3418 
Antibody Raised in Dilution Company Cat # 
Anti-Rabbit IgG (H+L) Alexa 
Fluor 488 
Goat pAb 1:1000 Life Technologies Cat #A11008 
Anti-Mouse IgG (H+L) Alexa 
Fluor 633 
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Apolipoprotein E is proteolytically cleaved in the human brain in an apoE-dependent manner 
(Elliott et al., 2011) and these fragments might play different roles in the brain. Some studies 
have used mimetic peptides to address the function of specific fragments, showing 
physiological functions such as reducing inflammation after injury and neuroprotection 
(Aono et al., 2003; Laskowitz et al., 2001; Li et al., 2006; Lynch et al., 2003), or triggering 
neuronal signalling cascades (Gay et al., 2007; Hoe et al., 2005). However, some of these 
fragments are also toxic and therefore, might trigger neurodegeneration (Chang et al., 2005; 
Clay et al., 1995; Crutcher et al., 1994; Tolar et al., 1997, 1999). To understand the function 
of specific apoE fragments, it is also highly relevant to determine the enzyme responsible for 
the fragmentation of apoE, and the possible difference in selectivity between apoE3 and 
apoE4. 
Some studies have tried to identify the specific enzyme responsible for the apoE 
fragmentation: thrombin (Marques et al., 1996), cathepsin D (Zhou et al., 2006) and 
chymotrypsin-like protease (Harris et al., 2003; Tamboli et al., 2014). However, the 
proposed fragments generated with those enzymes did not correspond to the fragmentation 
observed in the brain (Elliott et al., 2011). Most recently, HtrA1 was shown to induce 
fragmentation of apoE in vitro (Chu et al., 2016). ApoE degradation by HtrA1 in vitro shows 
the same fragmentation pattern seen in the human brain, with a main fragment of 25 kDa, 
encompassing amino acids 1-195 (Chu et al., 2016). Moreover, HtrA1 has preference for 
apoE4 than apoE3 and the apoE 25-kDa fragment of apoE4 is degraded further at a higher 
rate than the 25-kDa fragment of apoE3 (Chu et al., 2016).  
SK-N-SH neuroblastoma cells have been reported to contain two distinct cell types since 
they were established in 1973 (Biedler et al., 1973). The neuroblastic type (N-type) contain 





have flat and larger cell bodies, resembling epithelial cells. Both cell types have been shown 
to undergo transdifferentiation, a conversion from one cell type into the other one that occurs 
bidirectionally (Ross et al., 1983). Moreover, the conversion occurring is not only affecting 
the morphology of the cells, but the biochemical properties: the neuroblastic type expresses 
the neurotransmitter norepinephrine and shows tyrosine- and dopamine-hydroxylase 
activities, whereas the substrate-adherent type expresses fibronectin or vimentin, similar to 
an embryonic glial phenotype (Ciccarone et al., 1989; Ross et al., 1983). 
Our lab has recently used the SK-N-SH neuroblastoma cell line as a new model to study 
apoE fragmentation (Muñoz et al., 2018c). ATRA-differentiated SK-N-SH cells show an 
increase in apoE and apoE fragmentation over time, as shown in Figure 3.1A and B. The two 
main fragments of 28 and 25 kDa correspond to the N-terminal region of apoE (Figure 
3.1C). Moreover, we showed that the fragmentation of apoE is inhibited in ATRA-
differentiated SK-N-SH cells using a broad spectrum protease inhibitor and a specific serine 
protease inhibitor (Muñoz et al., 2018c). Therefore, SK-N-SH cell line can be used as a 







Figure 3.1. ATRA induces the production of apoE and the N-terminal apoE fragments in SK-N-
SH cells. SK-N-SH cells were cultured with 10 µM ATRA for 3, 6 and 9 days, and conditioned media 
was used to analyse apoE fragmentation. A. Western blot for apoE using conditioned media of 
Control (Ctrl) or 3, 6 and 9 days ATRA-treated cells. B. Quantification of apoE full-length and the 28 
and 25 kDa fragments from western blot in A. C. Western blot using antibodies for apoE full-length 
sequence (Pan) or specific for the N-terminal or C-terminal region. Data in B are derived from one 
experiment performed in triplicate that it is representative of three independently performed 
experiments. Individual data points are shown. Histogram bars represent mean values and error bars 
represent S.E.M. Graph shows * p < 0.05, ** p < 0.01, *** p < 0.001, compared with the control (C) 
condition by one-way ANOVA with Tukey’s post-hoc analysis. Figure adapted from Muñoz et al., 
(2018c).  
3.1.1. Aim of the study 
The aim of this study was to identify whether HtrA1 is responsible for the generation of the 
25-kDa apoE fragment using the SK-N-SH neuroblastoma cell line and to investigate the 





3.2. Materials and methods 
3.2.1. Cell culture and neuronal differentiation of neuroblastoma cells 
Cell culture and differentiation of SK-N-SH and SH-SY5Y neuroblastoma cell lines was 
performed as described in Chapter 2. 
3.2.2. siRNA knock-down of HtrA1 
Two HTRA1 short interference RNAs (siRNAs) and a scrambled control were designed and 
obtained from Sigma-Aldrich: HTRA1 siRNA1 (5’-CAGACAUCGCACUCAUCAATT-3’; 
5’-UUGAUGAGUGCGAUGUCUGTT-3’), HTRA1 siRNA2 (5’-
GAAGUGAUUGGAAUUAACATT-3’; 5’-UGUUAAUUCCAAUCACUUCTT-3’) and 
scrambled control (5’-GAAAGUUGGAUCAAUAAGUTT-3’; 5’-
ACUUAUUGAUCCAACUUUCTT-3’). A third HTRA1 siRNA was designed based on a 
previous publication (Chien et al., 2006) and obtained from Sigma-Aldrich: HTRA1 siRNA3 
(5’-GCCGGCUUCAACGGAGAAATT-3’; 5’-ACUUAUUGAUCCAACUUUCTT-3’). 
siRNA transfection was performed using Lipofectamine RNAiMAX (Invitrogen). U87 cells 
were plated at 150,000 cells/well in a 12-well plate before performing transfection 24 h after. 
Per transfection, 100 µl Opti-MEM (Thermo Fisher Scientific) were mixed with 3 µl 
Lipofectamine RNAiMAX and 1 µl siRNA at 10 µM, incubated for 5 min at 22 °C and 
added to fresh 400 µl DMEM/F12 with 5% (v/v) FBS per well. HTRA1 mRNA expression 
was quantified after 24 and 48 h by qRT-PCR. SK-N-SH cells were seeded at 100,000 cells 
per well in a 12-well plate and cultured under the conditions described above for 9 days. 
HTRA1 siRNA or its scrambled control were transfected 24 h after the initial seeding, and 
medium was changed every 3 days. The untransfected control cells received the transfection 
complex without siRNA. Cells were analysed at day 9 for mRNA and protein expression as 







The primers for qRT-PCR used in this chapter were HTRA1, APOE, GAPDH and HPRT1 as 
described in Chapter 2. 
3.2.4. Western blot 
The antibodies for western blot used in this chapter were anti-apoE and anti-HtrA1 as 
described in Chapter 2. 
3.2.5. Assessment of apoE and apoE 25 neurotrophic activities  
Full-length recombinant apoE (r-apoE) and r-apoE 25 (1-195 fragment) were generated by 
Dr. Qian Chu as previously described (Chu et al., 2016; Muñoz et al., 2018c). Fragments 
were collected using size exclusion chromatography followed by affinity-purification, 
obtaining > 95% purity (Chu et al., 2016; Muñoz et al., 2018c). Concentrations of 5 and 20 
µg/ml of r-apoE and r-apoE 25 were added to SH-SH5Y cells 24 h after plating at 10,000 
cells/well in a 96-well plate format. Cells were cultured with 1% (v/v) FBS and treated with 
10 µM ATRA. Full medium change including replenishment of r-apoE and r-apoE 25 was 
performed at day 3. Images were taken with Incucyte Zoom System at day 0 and 3 before the 
media changes to avoid disturbing the neurite extension, and at day 6 before measuring cell 
viability. Analysis of confluency and neurite length was performed with the Incucyte Live 
Cell Analysis as described in Chapter 2. Cell viability was measured at day 6 using the 







The SK-N-SH neuroblastoma cell line is a well-established in vitro model for human 
neurobiology studies. ATRA promotes differentiation of SK-N-SH and other neuroblastoma 
cell lines like SH-SY5Y cells into a neuronal phenotype (Preis et al., 1988). Differentiation 
of SK-N-SH over time with 10 µM ATRA increases the apoE expression and western blots 
show the same apoE fragmentation as seen in the human brain (Muñoz et al., 2018c). 
To examine the role of the HtrA1 enzyme in the fragmentation of apoE, we used the SK-N-
SH cells as a model. We first assessed the expression levels of HTRA1 by qRT-PCR over the 
time course of ATRA differentiation for 9 days. As shown in Figure 3.2, SK-N-SH cells 
expressed HTRA1 under normal culture conditions and expression increased over time in the 
presence of ATRA. When HTRA1 mRNA expression levels were normalised to its relative 
DMSO control, there was a 3.3 ± 0.2 fold (p = 0.0002, t = 12.58) increase by day 3 and 6.8 ± 
0.5 fold (p = 0.0003, t = 11.39) increase by day 9 in the presence of ATRA.  
 
Figure 3.2. SK-N-SH neuroblastoma cell line expressed HTRA1 and its levels were increased 
after neuronal differentiation with ATRA. HTRA1 mRNA expression analysed by qRT-PCR in SK-
N-SH cells over 9 days of 10 µM ATRA treatment and normalised to the housekeeper genes GAPDH 
and HPRT1. HTRA1 mRNA expression measured at days 3, 6 and 9 of the ATRA treatment compared 
to vehicle control (DMSO). Data are derived from one experiment performed in triplicate and each 
sample was run in triplicate by qRT-PCR. Individual data points are shown. Histogram bars represent 
mean values and error bars represent S.E.M. Graph shows * p < 0.01 compared to each DMSO control 





As shown in Figure 3.1, apoE expression levels and apoE fragmentation increased over time 
in the presence of ATRA (Muñoz et al., 2018c). After showing that HTRA1 levels were also 
increased over time in the presence of ATRA, we used a siRNA approach to knock-down 
HTRA1 and therefore understand the role it plays in apoE fragmentation. The U87 
glioblastoma cell line was used to test the 3 siRNAs that were designed due to the high 
expression of the serine protease HtrA1 in these cells. HTRA1 mRNA levels were analysed 
by qRT-PCR 24 and 48 h after transfection. siRNA3 did not show a significant reduction in 
HTRA1 expression when compared to the non-transfected control. However, both siRNA1 
and siRNA2 showed a reduction of 74 ± 4 % (p < 0.0001, F (3,8) = 0.34) and 86 ± 4 %  (p < 
0.001, F (3,8) = 0.34) when compared to the non-transfected control at 24 h, respectively 
(Figure 3.3). The was no significant difference in expression between the 24 and 48 h time 
points. This data identified siRNA2 as the best candidate to knock-down HTRA1, that it will 
be called siRNA from here onwards. 
 
Figure 3.3. U87 glioblastoma cell line showed a reduction in HTRA1 expression after siRNA 
transfection. U87 cells were transfected with 3 different siRNAs designed to knock-down HTRA1. 
HTRA1 mRNA expression analysed after 24 and 48 h by qRT-PCR and normalised to the housekeeper 
genes GAPDH and HPRT1. HTRA1 mRNA expression was measured at 24 and 48 h compared to 
untreated control. Data are derived from one experiment performed in triplicate and each sample was 
run in triplicate by qRT-PCR. Individual data points are shown. Histogram bars represent mean values 
and error bars represent S.E.M. Graph shows *** p < 0.001, compared to the control for each time 






To examine the role of HtrA1 in apoE fragmentation, we needed to confirm first that the 
siRNA was still knocking-down HtrA1 after 9 days of ATRA treatment. HTRA1 mRNA 
levels were measured by qRT-PCR over time in the untransfected control, the scrambled 
siRNA control and the siRNA transfected cells. Both controls showed an increase in HTRA1 
expression, but siRNA transfected cells showed a 90% reduction of HTRA1 mRNA levels at 
day 9 of ATRA treatment when compared to day 0 (Figure 3.4A). APOE mRNA expression 
was different in each culture condition from day 6 of ATRA treatment: Whereas the 
untransfected control showed a 6.1-fold increase at day 9 when compared to day 0, 
scrambled control APOE levels were increased by 4.3-fold and siRNA transfected cells only 
showed a 3.3-fold increase (Figure 3.4B). There was a noticeable difference between 
treatments when observing the morphology of the SK-N-SH cell cultures at day 9. While the 
untransfected control and the scrambled control showed the presence of both N- and S-type 
described in previous studies (Preis et al., 1988), the siRNA transfected cells showed mostly 
the N-type cells with long processes (Figure 3.4E). Analysis of the cell culture confluency 
over time reflected a decrease in cell growth of 37 ± 2 % (p < 0.001, F (2,9) = 13.65) in the 
siRNA transfected cells by day 9 as compared to the controls (Figure 3.4C). Total cell 
protein measured at day 9 of ATRA treatment also indicated a reduction of 38 ± 4 % (p < 







Figure 3.4. Knock-down of HtrA1 by siRNA reduced APOE expression, cell confluence and total 
protein. SK-N-SH cells were transfected with HTRA1 siRNA at day 0 and treated with 10 µM ATRA 
for 9 days. A. HTRA1 and B. APOE mRNA analysed by qRT-PCR over 9 days of ATRA treatment 
and normalised to the housekeeper genes GAPDH and HPRT1. C. Cell confluency over 9 days of 
ATRA treatment analysed using Incucyte Zoom System. D. Cell protein measured at day 9 of ATRA 
treatment. E. Representative images of untransfected control, siRNA treatment and scrambled control 
at day 9 of ATRA treatment. Scale bar = 200 µm. Data are derived from one representative 
experiment performed in duplicate for A and B, or triplicate for C and D. Data points in A, B and C, 
and histogram bars in D represent mean values and error bars represent S.E.M. Individual data points 
are shown in D. Graphs show *** p < 0.001, compared to the controls by one-way ANOVA with 





Further analysis of the siRNA experiments at day 9 not only showed a reduction of HTRA1 
mRNA levels by 90 ± 9 % (p < 0.001, F (2,27) = 69.23) when compared to the untransfected 
control, but unexpectedly it showed a 29 ± 10 % (p = 0.01, F (2,27) = 69.23) increase in the 
scrambled control compared to the untransfected control despite the fact that the siRNA 
sequence did not show any similarity to known genes (Figure 3.5A). Moreover, we found 
that the reduction in mRNA levels also reflected a reduction in protein levels. Western blot 
analysis showed a 91 ± 5 % (p < 0.001, F (2,6) = 0.55) reduction of HtrA1 in the conditioned 
media of the siRNA transfected culture when compare to the untransfected control (Figure 
3.5B and C). As the HtrA1 levels might be affected by the difference in the number of cells 
at day 9, the protein levels were normalised to total cell protein from Figure 3.4D. 
To assess the effect of HtrA1 knock-down in the apoE fragmentation, western blot of 
conditioned media was performed by loading equal amount of apoE full-length in each lane 
to compare the fragmentation (Figure 3.5D). The quantified data showed that HtrA1 siRNA 
selectively reduced the apoE 25-kDa fragment concentration by 41 ± 8 % (p < 0.001, F 
(2,36) = 0.17), whereas the levels of the apoE 28-kDa fragment remained unchanged (Figure 
3.5E). This is the first indication that HtrA1 specifically regulates the apoE 25-kDa fragment 
production under physiologically relevant conditions. Intriguingly, there was a 25 ± 8 % (p = 
0.01, F (2,36) = 0.17) increase in the apoE 25-kDa fragment concentration, which could be 
related to the 29 ± 10 %  (p = 0.01, F (2,27) = 69.23) increase in HTRA1 mRNA expression 







Figure 3.5. Knock-down of HTRA1 by siRNA reduced the level of the apoE 25-kDa fragment. 
SK-N-SH were analysed at day 9 of differentiation with 10 µM ATRA after being transfected with 
HTRA1 siRNA. A. HTRA1 mRNA expression levels at day 9 normalized to the housekeeper gene 
GAPDH. B. HtrA1 protein expression analysed by western blot using conditioned media from day 9 
of ATRA treatment. C. Quantification of the western blot for HtrA1 in B normalized to total protein. 
D. Representative western blot for extracellular apoE protein from conditioned media at day 9 
showing full-length and fragments. E. Quantification of the western blot for apoE fragments 
normalised to apoE full-length expression. Data in A and E are derived from three independent 
experiments performed in either triplicate or quadruplicate. Data in C are derived from one 
experiment (blot shown in B) representative of three independent experiments independently 
performed in either triplicate or quadruplicate. Individual data points are shown. Histogram bars 
represent mean values and error bars represent S.E.M. Graphs show * p < 0.05, *** p < 0.001, 
compared to the control condition by one-way ANOVA with Tukey’s post-hoc analysis. 
 
As the knock-down of HtrA1 over 9 days had an impact on cell growth, we decided to assess 
the role of HtrA1 in the apoE 25-kDa fragment formation using HtrA1 boronic acid inhibitor 





HtrA1 (Chu et al., 2016; Grau et al., 2006; Saghatelian et al., 2004). After SK-N-SH cells 
were differentiated with ATRA for 9 days, they were incubated in the presence of 1 µM 
HBAI for 24 h based on previous studies (Chu et al., 2016). HBAI treatment did show an 
effect on the intracellular apoE levels (Figure 3.6B and D). However, the formation of the 
25-kDa fragment of apoE was reduced by 86 ± 8 % (p = 0.0004, t = 10.86) after HBAI 
treatment, whereas the 28-kDa fragment and the full-length apoE in the conditioned media 
remained unaffected (Figure 3.6C and D). These data demonstrate that HtrA1 contributes to 
the proteolytic formation of the apoE 25-kDa N-terminal fragment under physiologically 
relevant conditions. 
 
Figure 3.6. HtrA1 inhibitor reduced SK-N-SH cellular apoE proteolytic fragmentation. A. 
Structure of HtrA1 boronic acid inhibitor (HBAI). B. Ponceau staining and western blot for apoE in 
the cell lysate of 9-day ATRA differentiated cells and treated for 24h with HBAI. C. Western blot for 
apoE conditioned media of 9-day ATRA differentiated cells and treated for 24h with HBAI. D. 
Quantification of expression of apoE full-length and fragments from supernatant (S/N) or cell lysate 
(Cell) from western blots in B and C. Data in D are derived from one experiment (blot shown in B and 
C) performed in triplicate representative of three independently performed experiments. Individual 
data points are shown. Histogram bars represent mean values and error bars represent S.E.M. Graph 





To analyse the impact of r-apoE and r-apoE 25 fragment in neurite outgrowth, the SH-SY5Y 
neuroblastoma cell line, a well-established subclone of the SK-N-SH cells (Biedler et al., 
1978), was used as a subclone of the SK-N-SH cell line but lacking the production of 
endogenous apoE and it does not produce the high degree of neurite growth observed in SK-
N-SH cells (Preis et al., 1988). Two concentrations of 5 and 20 µg/ml were chosen based on 
pilot experiments (data not shown) and previous studies (Hussain et al., 2013; Nathan et al., 
2002; Puttfarcken et al., 1997). Without apoE supplementation, SH-SY5Y cells developed a 
neuronal phenotype with extended neurites after 6 days of ATRA treatment under low serum 
conditions (Figure 3.7C). Cell confluence was measured over time without apoE 
supplementation and with the addition of either 5 or 20 µg/ml of r-apoE or r-apoE 25. When 
cell confluence was compared to day 0 for each condition, an increase in all the conditions 
was observed ranging from 1.9 - 2.2 fold (p < 0.0001, F (2,27)) at day 6 (Figure 3.7A). 
Whereas neurite length was 1.46 ± 0.009 mm/mm2 after the 6-day period in the control 
condition, the addition of r-apoE promoted neuritogenesis in a dose-dependent manner. 
Neurite length increased by 2.1 ± 0.1 fold (p < 0.0001, F (2,27) = 1.4) and 2.4 ± 0.2 fold (p < 
0.0001, F (2,27) = 22.4) were detected after addition of 5 and 20 µg/ml respectively after 6 
days. The addition of 5 µg/ml of r-apoE 25 showed an increase in neurite length that was not 
significantly different to day 0; however, after the addition of 20 µg/ml, a 2.2 ± 0.3 fold (p = 









Figure 3.7. Recombinant apoE 25 kDa fragment stimulated SH-SY5Y neuritogenesis. SH-SY5Y 
neuroblastoma cells were differentiated with 10 µM ATRA for 6 days with addition of 5 and 20 µg/ml 
r-apoE or r-apoE 25. A. Cell confluence measured over 6 days and normalized to day 0 of each 
treatment. B. Neurite length measure over 6 days and normalized to day 0 of each treatment. C. 
Representative images at day 6 of treatment. Black arrows indicate neurites. Scale bar = 100 µm. Data 
are derived from two independent experiments performed in quintuplicate. Individual data points are 
shown. Histogram bars represent mean values and error bars represent S.E.M. Graphs show ** p < 
0.01, *** p < 0.001, compared with the respective day 0 for each condition by one-way ANOVA with 
Tukey’s post-hoc analysis. 
 
Cell culture viability showed a decrease of 19% (p = 0.007, F (4,45) = 0.9) after 6 days in the 
presence of 20 µg/ml r-apoE, whereas none of the other conditions were affected compared 
to the control (Figure 3.8A). The analysis of the medium supplemented with r-apoE and r-
apoE25 peptides before added to the cells showed a predominant band at the expected 
molecular weight of 37 and 25 kDa respectively as shown in the western blot in Figure 3.8B. 
In the conditioned media collected at day 6 (that had been on the cells for the last 72 h) here 





medium supplemented with r-apoE showed an increase in the expression of the apoE 25-kDa 
fragment and other smaller fragments after 72 h in culture following the same fragmentation 
pattern as endogenous apoE. Importantly, the r-apoE 25 did not show further proteolysis, 
suggesting that it is a relatively stable fragment in culture.   
 
Figure 3.8. Recombinant apoE and r-apoE 25 stability and effect on cell viability. SH-SY5Y 
neuroblastoma cells were differentiated with 10 µM ATRA for 6 days with addition of 5 and 20 µg/ml 
r-apoE or r-apoE 25. A. Cell viability measured at day 6 normalised to cell control conditions.  B. 
Ponceau staining and western blot showing the apoE expression and fragmentation before (-) and after 
72 h in culture (+) of the control and r-apoE and r-apoE 25 addition. Data in A is derived from two 
independent experiments performed in quintuplicate. Individual data points are shown. Histogram 
bars represent mean values and error bars represent S.E.M. Graph shows ** p < 0.01, compared to the 







The results of this study showed that the SK-N-SH neuroblastoma cell line expresses the 
secreted serine protease HtrA1 and that its expression increases when the SK-N-SH cells are 
differentiated into a neuronal phenotype by ATRA treatment. As the SK-N-SH cells have 
been published as a new cell model to study apoE expression and proteolytic processing 
(Muñoz et al., 2018c), and a recent study has shown that recombinant HtrA1 produced apoE 
fragmentation (Chu et al., 2016), we tested if HtrA1 was responsible for the production of 
the 25-kDa apoE fragment under physiologically relevant conditions. Knock-down 
experiments using a siRNA approach and HBAI showed that endogenous HtrA1 selectively 
cleaved the endogenous apoE into the apoE 25-kDa fragment without affecting the 28-kDa 
fragment or the apoE full-length expression.  
The U87 glioblastoma cell line, an established cell line widely used, has been previously 
reported to show high basal expression of HtrA1 (Minchenko et al., 2015), thus we used it as 
a model to identify the best siRNA sequence against HTRA1. However, in our study with 
SK-N-SH cells, the knock-down on HtrA1 by siRNA showed a decrease on the proliferation 
of the SK-N-SH cells, especially on the S-type, when treated with ATRA over a period of 9 
days (Figure 3.4C and D). HtrA1 belongs to a family of serine proteases that plays an 
important role in protein quality control including proliferation and cell migration (Chien et 
al., 2009; Clausen et al., 2002). Moreover, the expression of HtrA1 has been linked with 
neuronal development and differentiation in vitro and in vivo (D’Angelo et al., 2014; Launay 
et al., 2008). Therefore, the reduction of proliferation in the HTRA1 siRNA transfected cell 
culture can be explained by the role that HtrA1 plays in regulating the growth and 
differentiation survival of neurons and other cell types linked to TGF-β proteolysis (Clausen 
et al., 2011; D’Angelo et al., 2014; Launay et al., 2008). 
In the same set of experiments, we also showed a slight but significant increase of HTRA1 





the scrambled siRNA was designed not to have any biological activity. Consistent with this 
small increase in HTRA1 expression, a small but statistically significant increase in the 
expression of the 25-kDa apoE fragment was detected, supporting the function of HtrA1 in 
the apoE 25-kDa fragment formation.  
The use of HBAI was another approach to confirm HtrA1 as the serine protease responsible 
for the generation of the 25-kDa apoE fragment. As in this case HtrA1 was inhibited after 
secretion and only for the last 24 h of ATRA treatment, it did not have an effect on the 
proliferation or differentiation of the SK-N-SH cells, but it was able to inhibit the production 
of the apoE 25-kDa fragment, confirming HtrA1 as the responsible enzyme for the 
generation of this specific fragment. 
The N-terminal region of apoE contains the LDL receptor-binding domain, which is also 
known to promote neurite outgrowth via interaction with the LDL receptor family members 
(Herz and Chen, 2006; Holtzman et al., 2012; Hussain et al., 2013; Nathan et al., 2002; 
Puttfarcken et al., 1997). In this study, the addition of r-apoE promoted neuritogenesis in a 
dose-dependent manner, which was expected from previous experiments (Hussain et al., 
2013; Nathan et al., 2002; Puttfarcken et al., 1997). However, the specific role that the apoE 
25-kDa fragment could play was unknown. As described in previous work, the generation of 
a r-apoE 25 fragment encompassing the amino acids 1-195 was performed (Chu et al., 2016; 
Muñoz et al., 2018c). We detected a neuritogenic effect in the SH-SY5Y model when cells 
were incubated with 20 µg/ml of r-apoE 25, in agreement with the results after incubation 
with r-apoE full-length (Figure 3.7B). For reasons that remain unknown, there was a 19% 
reduction in viability after 6 days of r-apoE in the cultures, whereas cells under the other 
conditions were unaffected. Two concentrations of r-apoE full-length and r-apoE 25 of 5 and 
20 µg/ml were chosen to correspond to physiologically relevant levels. The concentration of 
apoE in human cerebrospinal fluid and plasma is ~10 and 50 µg/ml, respectively; however, it 





are 95, 122 and 48 µg/g protein in the frontal cortex, the temporal cortex and the cerebellum, 
respectively (Pirttilä et al., 1996). However, it is important to mention that the levels of 
apoE, as a soluble protein, might differ from interstitial fluid to tissue. Also, apoE levels vary 
throughout life, where neonatal brain apoE levels are twice the level in adults (Kim et al., 
2009). For that reason, the concentrations used in this study matched with the ones used in 
previous studies (Hussain et al., 2013; Nathan et al., 2002; Puttfarcken et al., 1997).  
While the SK-N-SH neuroblastoma cell line has an APOE ɛ3/3 background, apoE can be 
found in the population in three different isoforms, apoE2, apoE3 and apoE4. Previous 
studies have shown that apoE concentration is allele-dose dependent; there are lower levels 
in plasma and serum when one copy of APOE ɛ4 is present, and even lower levels in APOE 
ɛ4 homozygous individuals (Martínez-Morillo et al., 2014; Rezeli et al., 2015). One of the 
reasons for the lower protein levels of apoE4 compared to apoE3 might be a faster 
degradation or fragmentation, as a preference in cleavage for the apoE4 when compare to the 
apoE3 protein has been previously reported (Chu et al., 2016; Harris et al., 2003; Marques et 
al., 1996; Zhou et al., 2006).  
The serine protease HtrA1 has been shown to degrade further apoE4 than apoE3 in vitro, and 
thus may play a role in AD. HtrA1 is localized in vivo to microtubules, modulating stability 
and cell motility (Chien et al., 2009; Chu et al., 2016). Moreover, HtrA1 has been shown to 
degrade tau aggregates and fibrillar tau (Tennstaedt et al., 2012), a microtubule-associated 
protein which hyperphosphorylated form is one of the major hallmarks of AD. Furthermore, 
HtrA1 is also implicated in APP processing and interacts with Aβ (Grau et al., 2005; Poepsel 
et al., 2015), which might play a role in protection against AD, as HtrA1 levels and activity 
are increased in the development of AD pathology (Tennstaedt et al., 2012). Even if it seems 
that HtrA1 could play a role in AD by regulating Tau and APP processing, further studies 
need to be done to understand how the fragmentation of the apoE isoforms can play a major 





In conclusion, this study shows HtrA1 as the enzyme responsible for the generation of the 
apoE 25-kDa fragment and reveals a new neurotrophic function of apoE 25. This cellular 
model provides a method to model the neurobiology of AD in vitro.  
3.4.1. Future directions 
In order to model AD, it is highly relevant to understand more regarding the differences 
between apoE3 and apoE4 isoforms, including the selectivity of enzymes such as HtrA1 for 
apoE4 over apoE3. The SK-N-SH neuroblastoma cell line has an APOE ɛ3/3 background, 
but the use of new genetic editing tools such as clustered regularly interspaced short 
palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) system has opened the 
possibility of changing the genotype into an APOE ɛ4/4 background, so we can understand 
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The presence of the APOE ε4 allele is the major genetic risk factor for AD (Corder et al., 
1993) and apoE is fragmented in the human brain in an isoform specific manner (Elliott et 
al., 2011). Specifically, the apoE 25-kDa N-terminal fragment, known to promote 
neuritogenesis (Muñoz et al., 2018c), is present at higher levels in apoE3 when compared to 
apoE4 (Elliott et al., 2011). Moreover, previous studies have shown the proteolysis of apoE 
is allele selective when analysed in vitro with the HtrA1 enzyme (Chu et al., 2016). 
The SK-N-SH neuroblastoma cell line has been used as a model to study apoE fragmentation 
as shown in Chapter 3 (Muñoz et al., 2018c). The APOE ε3/3 background of the SK-N-SH 
cell line limits the model when trying to understand the apoE4 isoform and its fragmentation 
process. However, CRISPR/Cas9 system is a genome-editing technique that could be applied 
to mammalian cells to change the genotype of the SK-N-SH cell line into an APOE ε4 
background and therefore be used as an isoform control. Comparison between isogenic lines 
would allow investigation of apoE fragmentation under physiologically relevant conditions. 
The CRISPR/Cas9 system was discovered as an adaptive immune system response in 
bacteria and archaea (Barrangou et al., 2007; Brouns et al., 2008; Garneau et al., 2010) and,  
more recently, has been used as a genome-editing technique in mammalian cells (Mali et al., 
2013). This technique works as molecular scissors that are guided to a specific location of 
the genome. The Cas9 nuclease is driven to a specific part of the genome in association with 
a guide RNA (gRNA), where it induces a double strand break (DSB) in the DNA. The 
gRNA is a selection of 20 specific nucleotides that is specifically designed to target the 
region of interest in the genome, as shown in Figure 4.1 for the APOE gene. The gRNA pairs 
with the targeted region of the DNA, starting from a specific sequence containing a 
protospacer adjacent motif (PAM), a 5’-NGG motif directly upstream. In this region, the 






Figure 4.1. Schematic diagram of the gRNA1 targeting exon 4 of the APOE gene. The 4 exons of 
the APOE gene are shown, with the gRNA1 targeting a specific region of exon 4. The gRNA contains 
the PAM sequence and it is linked to the Cas9 nuclease, that will induce the DSB 3 bp upstream of the 
protospacer adjacent motif (PAM), represented with red triangles. The asterisk indicates the 
nucleotide that determines the APOE ε3/3 background. 
 
A DSB in the cell can lead to apoptosis or cell arrest; therefore, the cell triggers a repair 
mechanism to fix the break induced by Cas9 nuclease by itself or helped by another piece of 
DNA that uses as a guide to insert nucleotides. The two major repair mechanisms are non-
homologous end joining (NHEJ) and homology-directed repair (HDR) (Rothkamm et al., 
2003) (Figure 4.2). The NHEJ pathway occurs when the cell generates insertions or deletions 
of nucleotides randomly when fixing the DSB generated in the DNA. This pathway is 
constitutively active during the cell cycle and leads to the possibility of generating a 
truncated protein or a knock-out. The HDR pathway is an accurate fix based on the 
utilization of the sister chromatid or homologous chromosome; however, this pathway is 
restricted to the S/G2 phases of the cell cycle, when the cell is dividing (Branzei and Foiani, 
2008). This pathway can be modified to generate a knock-in by introducing a donor double-
stranded DNA or a single-stranded oligonucleotide (ssODN) with the desired sequence 
exogenously. In this situation, the cell repairs the DSB by performing homologous 






Figure 4.2. Schematic diagram of the DNA repair pathways after DSB. After a double strand 
break (DSB) occurs in the target DNA, the cell can follow one of two pathways. The non-homologous 
end joining (NHEJ) pathway generates random insertions or deletions, or the homology-directed 
repair (HDR) pathway that performs recombination with a homologous piece of DNA, and it can be 
utilized to incorporate a new sequence using ssODN. 
4.1.1. Aim of the study  
The aim of the study was to generate an SK-N-SH neuroblastoma isogenic APOE ɛ4/4 cell 






4.2. Materials and methods 
4.2.1. Cell culture and neuronal differentiation of neuroblastoma cells 
The cell culture and the neuronal differentiation of the SK-N-SH and SH-SY5Y 
neuroblastoma cell lines and the SK-N-SH CRISPR clones was performed as described in 
Chapter 2. The seeding density for neuronal differentiation was 50,000 cells/cm2.  
4.2.2. CRISPR lentivirus design 
Three CRISPR lentivirus plasmids with specific gRNA sequences (gRNA1, gRNA2 and 
gRNA3) were designed by Sigma-Aldrich to target exon 4 of the APOE gene. The sequence 
and position of the three gRNAs, as shown in Appendix A2.1 and A2.2, targets the 
surroundings of nucleotide of interest 2903 (based on the APOE sequence shown in 
Appendix A1.1). The in silico on- and off-target score screening of gRNA1 was performed 
using the online platform Benchling (Doench et al., 2016; Hsu et al., 2013).   
The plasmid, as shown in Figure 4.3, containing the guide RNA under the U6 promotor 
expression; puromycin resistance cassette, Cas9 protein expression cassette and a GFP 
expression cassette under the expression of the translation elongation factor 1 alpha (tEF1a) 
promoter. It also contained an ampicillin resistance cassette for cloning, enzyme restriction 
cutting sites, flanking long terminal repeats (LTR) to facilitate the integration into the host 
genome and a Woodchuck hepatitis virus (WHP) posttranscriptional regulatory element 






Figure 4.3. Plasmid map of CRISPR/Cas9 lentivirus. The all-in-one lentivirus CRISPR vector 
contains the specific gRNA under the U6 promoter and the puromycin resistance cassette (PuroR), 
Cas9 nuclease and GFP tag under the tEF1a promoter. Modified from Sigma-Aldrich. 
 
4.2.3. Single-Stranded Oligonucleotide donor design 
Two Single-Stranded Oligonucleotide donor DNAs (ssODN) were obtained from Sigma-
Aldrich. ssODN1, a 120 nucleotide DNA strand, was designed by Sigma-Aldrich to induce 
the nucleotide change in the targeted region and generate the APOE ε4 allele. ssODN2 was 
designed based on an asymmetric design of the ssODN (Richardson et al., 2016), containing 
a total of 127 nucleotides, where 36 nucleotides were localized before the PAM region and 
91 nucleotides were located after. The ssODN sequences and the targeted regions within the 
exon 4 of the APOE gene are shown in Appendix A2.3 and A2.4. 
4.2.4. Puromycin killing curve 
SK-N-SH cells were plated at 16000 cells/well on a 96-well plate before treatment with 
puromycin (Sigma-Aldrich). The following puromycin concentrations were added in 
triplicates 24 h after seeding: 10 µg/ml, 5 µg/ml, 2.5 µg/ml, 1.25 µg/ml, 0.625 µg/ml, 0.3125 
µg/ml and 0 µg/ml as control. Cell death was tracked using the Incucyte Zoom System every 
2 h for a period of 6 days. After 5 days all cells from the 2.5 µg/ml or higher concentration 
were dead, and only < 5% of the 1.25 µg/ml had survived. The concentration of 2 µg/ml was 





4.2.5. CRISPR lentiviral transduction and ssODN transfection 
SK-N-SH neuroblastoma cells were plated at 100000 cells/well in a 6-well plate. Base media 
(DMEM/F12 media with 10% (v/v) FBS, 100 IU/ml Penicillin and 100 µg/ml Streptomycin) 
was supplemented with 8 µg/ml of polybrene to enhance the transduction efficiency. Serial 
dilutions of the CRISPR lentivirus over a range of 10-2 to 10-6 dilution were performed as 
recommended by the manufacturer together with a no-lentivirus control well. Full media 
change with base media was performed 24 h after to remove the lentiviral particles from the 
culture. Antibiotic selection using 2 µg/ml puromycin started 48 h after removal of the 
lentiviral particles until all the cells in the control well were dead. Transduced cells were 
kept in culture without antibiotic to allow their expansion and the cells were manually picked 
for monoclonal selection. Clones were cultured in 96-well plate and expanded into 24- and 
12-well plates when they were reaching 80% confluency until there were enough cells to 
extract gDNA, harvest protein and make stocks. 
Lentiviral transduction of gRNA1 using 10-2 dilution was performed prior to ssODN 
transfection using lipofectamine 3000 following the manufacturer’s instructions. ssODN1 
and the control pmax-GFP plasmid were transfected 24 h after lentivirus addition; while 
ssODN2 was transfected 0, 4, 8 and 12 h post transduction in different wells. 
4.2.6. SURVEYOR Mutation detection kit 
The SURVEYOR Mutation detection kit (Integrated DNA Technologies, USA) was used to 
recognize small insertions after a DSB on the DNA. DNA of the CRISPR clones was 
extracted as described in Chapter 2. Initial PCR amplification of the region of interest was 
done by mixing 100 ng genomic DNA with 25 µl Q5 High Fidelity 2x Master Mix (New 
England Biolabs, USA), 2 µM APOE primer F and R, and water to a total volume of 50 µl. 
The PCR program has an initial denaturation at 98°C for 30 s, followed by 35 cycles of 98 





72 °C for 10 min of final extension and hold at 4 °C. Amplification was checked on 1.5% 
agarose gel to visualize the fragment of 489 bp. 
DNA hybridization of the amplified fragment was performed to generate hetero- and 
homoduplexes prior to being treated with the SURVEYOR Nuclease for heteroduplex 
analysis. For each CRISPR clone, 20 µl of the PCR reaction were used for self-annealing (to 
generate homoduplexes), and 10 µl of the PCR reaction mixture were mixed with 10 µl of 
PCR reaction mixture of the SK-N-SH parental control to generate heteroduplexes if there 
has been a DSB in the CRISPR clone. The thermocycler program for hybridization was as 
follows: 10 min at 95°C, ramp from 95 °C to 85 °C at -2 °C/s; 1 min at 85 °C, ramp from 85 
°C to 75 °C at -0.3 °C/s; 1 min at 75 °C, ramp from 75 °C to 65 °C at -0.3 °C/s; 1 min at 65 
°C, ramp from 65 °C to 55 °C at -0/3 °C/s; 1 min at 55 °C, ramp from 55 °C to 45 °C at -0.3 
°C/s; 1 min at 45 °C, ramp from 45 °C to 35 °C at -0.3 °C/s; 1 min at 35 °C, ramp from 35 
°C to 25 °C at -0.3 °C/s; 1 min at 25 °C and hold at 4 °C. 
Nuclease digestion was performed by mixing 6 µl of the hybridized DNA with 1 µl 
SURVEYOR Enhancer S and 1 µl SURVEYOR Nuclease S. Incubation was performed at 42 
°C for 1 h and reaction was stopped by adding 0.8 µl Stop Solution. 
DNA fragments were analysed by 1.5% agarose gel where the negative samples showed only 
the 489 bp band and the positive samples showed the uncut 489 bp band and two extra bands 
at 374 and 116 bp. 
4.2.7. DNA sequencing 
Genomic DNA extraction and APOE sequencing of the SK-N-SH CRISPR clones were 






The primers for qRT-PCR used in this chapter were APOE (1-4), HTRA1, GAPDH and 
HPRT1 as described in Chapter 2. 
4.2.9. Western blot 
The antibodies for western blot used in this chapter were anti-apoE and anti-GAPDH as 







The SK-N-SH neuroblastoma cell line has been described as a model to study apoE 
fragmentation (Muñoz et al., 2018c). In order to study the difference in the fragmentation 
process between apoE3 and apoE4, the CRISPR/Cas9 technique was chosen to generate an 
isogenic APOE ɛ4/4 control to compare with the parental APOE ɛ3/3 SK-N-SH cells. 
An initial experiment was performed using the three gRNA constructs to determine the one 
with the best efficiency producing a DSB on the DNA. The SK-N-SH cells were transduced 
with the three CRISPR lentivirus with the specific gRNA designs, as shown in Appendix 
A2.1 and A2.2, without transfection of ssODN. After puromycin selection, a total of 78 
clones were manually picked up for monoclonal selection: 32 clones from the transduction 
using gRNA1, 27 clones from gRNA2 and 19 from gRNA3; however, only 42 clones 
survived monoclonal expansion. DNA was analysed using the SURVEYOR Mutation kit, 
where the samples with DSB generated were identified. No DSB showed a single band 
located at 489 bp (Figure 4.4A) whereas if a DSB occurred, in addition to the band at 489 bp, 
another two bands at 374 and 116 bp were found (Figure 4.4B). From gRNA1, 9 clones out 
of the 11 analysed were positive for DSB; from gRNA2, none of the 11 clones analysed were 
positive for DSB; and from gRNA3, 4 of the 13 clones analysed were positive for DSB. In 
summary, 81% of the clones analysed from the gRNA1, 30% from gRNA2 and none from 
gRNA3 had undergone a DSB on the area of interest; giving the lentivirus containing the 






Figure 4.4. Representative agarose gel of two SK-N-SH CRISPR clones after SURVEYOR 
Mutation detection kit. Agarose gel of two SK-N-SH CRISPR clones after SURVEYOR Nuclease 
heteroduplex analysis showing no double strand break (DSB) in sample A and a DSB in sample B. 
Self, self-annealing; Hetero, heteroduplex. 
 
To predict the gRNA specificity, an in silico on- and off-target screening of the gRNA1 
sequence was performed. The prediction of the on- and off-target specificity scores range 
from 0 to 100, where higher values indicate a more specific sequence (Doench et al., 2016; 
Hsu et al., 2013). The gRNA1 obtained an on-target score of 69.4 and an off-target score of 
83.2. Within the off-target sites, TMEM175 gene got a score of 1.43 and 4 mismatches in the 
sequence and a non-coding region in chromosome 1 obtained a score of 1.41 and 3 
mismatches, compared to the APOE gene having a score of 100 and no mismatches in the 
sequence. The off-target sites with the highest score can be found in Appendix A2.5. 
To generate a change in the APOE genotype, the lentivirus containing gRNA1 was used 
together with lipofectamine transfection of ssODN1 24 h post-transduction. The pmax-GFP 
vector was used as a control for positive lipofectamine transfection, giving a 21% 
transfection efficiency measured with the Incucyte Zoom System after 24 h, and puromycin 
selection was performed until 100% of the cells in the control condition were dead. A total of 
51 clones were manually picked up for monoclonal selection and 34 of them survived 
monoclonal expansion. The 34 clones were sequenced for the region of interest of the APOE 
gene, but none of them changed the APOE genotype. However, when compared the 





peak in the electropherogram (Figure 4.5B) starting from the nucleotide were the DSB was 
predicted (Figure 4.3) and others remained with the normal APOE sequence (Figure 4.5C).  
 
Figure 4.5. Representative APOE gene electropherograms of SK-N-SH cells and SK-N-SH 
CRISPR clones. Sequencing electropherograms targeting the region of interest of the APOE gene 
showing A. SK-N-SH cells, B. a double peak electropherogram from the predicted DSB region after 
CRISPR and C. a normal sequence in the APOE region after CRISPR. Asterisk indicates the 
nucleotide that determines the APOE ε3/3 background and red triangle indicates the predicted cut site 
of the Cas9 nuclease. 
 
The lentivirus containing gRNA1 was used in combination with ssODN2 transfection to 
generate the change in APOE genotype. In this case, ssODN2 was based on an asymmetric 
design specific for the gRNA1 to improve the efficiency of the HDR pathway (Richardson et 
al., 2016). Moreover, transfection of ssODN2 at time point 0, 4, 8 and 12 h post-transduction 
were chosen, and puromycin selection was performed again until 100% of the untransfected 
control cells were dead. A total of 20 clones survived the monoclonal selection and 





The sequencing for the region of interest of the APOE gene showed that none of the clones 
tested had changed the APOE genotype. 
Although none of the clones analysed underwent a change in APOE genotype, some of the 
clones showed a double peak in the sequence from the nucleotide of the predicted, as shown 
by the electropherogram in Figure 4.5B. Four of those clones (clones 1, 2, 3 and 4) were 
further characterised to confirm an APOE knock-down (KD) after the DSB. After neuronal 
differentiation with 10 µM ATRA, the parental SK-N-SH cells upregulate apoE expression 
(Muñoz et al., 2018c). To characterise the levels of apoE expression, the parental SK-N-SH 
cells and the four selected clones with potential APOE KD were analysed via qPCR after 
ATRA treatment and DMSO control for 6 days (Figure 4.6). As the gRNA1 was directed to 
induce a break in the exon 4 of the APOE gene (black arrow in Figure 4.6A), the sets of 
primers APOE 1 and 2 were designed to target the gene region before the DSB and APOE 3 
and 4 after the DSB (Figure 4.6A). The SK-N-SH cells and the 4 selected clones showed an 
increase in APOE expression after ATRA treatment when compared to each DMSO control 
(Figure 4.6B-E). However, the APOE expression of the 4 clones was significantly lower 
when compared to the respective condition of the parental SK-N-SH cells (Figure 4.6B-E). 
All the selected clones showed a reduction of more than 70% when compared to the parental 
SK-N-SH cells under the respective conditions. Clone 2 reached a reduction of 94% after 
ATRA treatment when compared to the SK-N-SH parental cell lines. The expression pattern 
of the selected clones followed the same trend in the primers targeting the sequence before 






Figure 4.6. Selected clones show lower APOE expression than parental SK-N-SH cells. SK-N-SH 
cells and selected clones 1 - 4 were cultured with 10 µM ATRA or DMSO control for 6 days. A. 
Schematic representation of the APOE gene showing the 4 exons. Black arrow shows the targeted 
DSB region with the lentivirus containing gRNA1. B-E. mRNA expression of APOE using 4 sets of 
primers targeting the regions showed with grey arrows in A and normalised to the housekeeper genes 
GAPDH and HPRT1. Data in B-E are derived from one representative experiment performed in 
triplicate. Individual data points are shown. Histogram bars represent mean values and error bars 
represent S.E.M. Graphs show ** p < 0.01 and *** p < 0.001, compared to each DMSO condition by 
two-tailed t-test; ### p < 0.001 compared to the SK-N-SH DMSO condition and ††† p < 0.001 
compared to the SK-N-SH ATRA condition by One-way ANOVA with Dunnett’s post-hoc analysis. 
 
Western blots were performed to confirm the reduction in apoE expression in the cell lysate 
(intracellular apoE) and in the conditioned medium (extracellular apoE) in the selected 
clones (Figure 4.7). The parental SK-N-SH cells showed the 35-kDa full-length apoE, with 
higher expression after ATRA treatment than in the DMSO control condition. No expression 
was detected in DMSO conditions in any of the selected clones; however, whereas clone 2 





fragment and clones 3 and 4 showed low expression of both 35 and 28 kDa apoE (Figure 
4.7A). ApoE fragmentation in SK-N-SH cells has been found only extracellularly and is 
secreted into the cell medium (Muñoz et al., 2018c). However, this indicates the possibility 
of synthesis of a truncated protein that remains intracellular. When analysing the conditioned 
medium after 6 days, the parental SK-N-SH cells showed full-length apoE in the DMSO 
control condition and full-length and 28 and 25 kDa fragments after ATRA treatment, 
consistent with previous experiments, whereas none of the selected clones showed apoE 
expression in any condition (Figure 4.7B).  
 
Figure 4.7. Selected clones show lower apoE expression than SK-N-SH cells. SK-N-SH cells and 
selected clones 1 - 4 were cultured with 10 µM ATRA or DMSO control for 6 days. A. Western blot 
for cell lysate showing intracellular apoE expression, and GAPDH expression used as loading control. 
B. Western blot showing extracellular apoE expression in the conditioned medium of the cells and 
Ponceau staining used as a loading control. SK-N-SH conditioned media after 6 days of ATRA 
treatment was used as positive control (+ Ctrl) in A and B. A and B are representative blots derived 
from one representative experiment performed in triplicate.  
 
Before differentiation, the SK-N-SH cells and the selected clones 1 - 4 showed a similar 
morphology as seen in Figure 4.8. After 6 days of ATRA treatment, the parental SK-N-SH 
cells showed the two subpopulations of cells, N-type and S-type (indicated by arrows in 





showed predominantly N-type cells based on the neuroblastic morphology, with only some 






Figure 4.8. SK-N-SH and selected clones 1-4 show a change in morphology from day 0 to day 6 
of ATRA treatment. Representative brightfield images of SK-N-SH and CRISPR clones at day 0 
(before ATRA) and 6 days of ATRA differentiation. Black arrows indicate substrate-adherent cells. 





HTRA1 levels were also analysed in parental SK-N-SH cells and the selected CRISPR clones 
after 6 days of ATRA treatment or DMSO control (Figure 4.9). Whereas the parental SK-N-
SH cells and the CRISPR clones showed an increase in HTRA1 expression when ATRA 
treatment was compared to DMSO control, there was a significative reduction of HTRA1 
expression in the CRISPR clones when compared to the parental SK-N-SH cells (Figure 
4.9). Moreover, the HTRA1 expression levels followed the same pattern like the one shown 
in APOE levels (Figure 4.6). 
 
Figure 4.9. Selected clones show lower HTRA1 expression than parental SK-N-SH cells. SK-N-
SH cells and selected clones 1 - 4 were cultured with 10 µM ATRA or DMSO control for 6 days. 
mRNA expression of HTRA1 and normalised to the housekeeper genes GAPDH and HPRT1. Data are 
derived from one representative experiment performed in triplicate. Individual data points are shown. 
Histogram bars represent mean values and error bars represent S.E.M. Graphs show ** p < 0.01 and 
*** p < 0.001, compared to each DMSO condition by two-tailed t-test; ### p < 0.001 compared to the 
SK-N-SH DMSO condition and ††† p < 0.001 compared to the SK-N-SH ATRA condition by One-
way ANOVA with Dunnett’s post-hoc analysis. 
 
To assess if the reduction in apoE expression in the CRISPR clones was due to a knock-
down in the APOE gene or to the difference in cell phenotype, a new ATRA differentiation 
was performed. The parental SK-N-SH cells, clone 2 and another 3 clones with the double 
peak in the sequence (clones 5, 6 and 7) were differentiated along with 4 CRISPR control 
clones (CRISPR control 1, 2, 3 and 4) that had undergone the CRISPR process and the 





SY5Y neuroblastoma cells, a neuroblastic subclone of the SK-N-SH cells. The sequences of 
all the clones analysed are found in Appendix A2.6. After 6 days of ATRA differentiation, 
clone 2 and SH-SY5Y cells showed only neuroblastic morphology, whereas SK-N-SH and 
CRISPR control clone 1 showed a combination of neuroblastic and substrate-adherent cells 
(Figure 4.10A). ApoE expression was analysed by western blot in the cell lysate 
(intracellular apoE) and conditioned media (extracellular apoE) (Figure 4.10B - E). As 
shown in the representative western blot, both SK-N-SH and CRISPR control clone 1 
showed full-length apoE expression in the lysate and full-length and 28 and 25 kDa fragment 
expression in the conditioned media after ATRA treatment (Figure 4.10B and C). However, 
clone 2 and SH-SY5Y showed a reduction in apoE expression in both cell lysate and 
conditioned medium after ATRA treatment (Figure 4.10B and C). Western blot 
quantification of 4 APOE KD clones (Clone 2, 5, 6 and 7) and 4 CRISPR control clones was 
performed as shown in Figure 4.10D and E. The APOE KD clones showed a significant 
reduction in intracellular apoE when compared to the parental SK-N-SH cells; however, the 
CRISPR control clones or the SH-SY5Y cells did not show a significant reduction (Figure 
4.10D). Moreover, in the conditioned media after ATRA treatment, there was a significant 
apoE reduction in the APOE KD clones, the CRISPR control clones and the SH-SY5Y cells 
when compared to the SK-N-SH cells (Figure 4.10E). Cell confluence and neurite length 
were also analysed and compared to each clone at day 0. Significant differences in the 
increase in confluency were not detected over the 6 days of ATRA treatment (Figure 4.10F). 
Similarly, when neurite length was analysed at day 3, there was not a significant difference 
between SK-N-SH cells, SH-SY5Y cells, APOE KD clones and CRISPR control clones 
(Figure 4.10G). Neurite length could not be analysed at day 6 as the confluence of the 






Figure 4.10. Clone 2 and SH-SY5Y cells show lower apoE expression than SK-N-SH cells and 
CRISPR control clone 1. SK-N-SH, SH-SY5Y, four APOE KD clones and four CRISPR control 
clones were cultured with 10 µM ATRA for 6 days. A. Representative brightfield images at 6 days of 
ATRA differentiation. Scale bars = 50 µm. B. Representative western blot showing intracellular apoE 
expression and GAPDH expression as loading control. C. Western blot showing extracellular apoE 





Quantification of intracellular apoE expression in SK-N-SH cells, four APOE KD clones, four 
CRISPR control clones and SH-SY5Y cells. E. Quantification of extracellular apoE expression in SK-
N-SH cells, four APOE KD clones, four CRISPR control clones and SH-SY5Y cells. F. Cell 
confluence measured over 6 days of ATRA treatment. G. Neurite length measure at day 0 and 3 of 
ATRA treatment and normalised to day 0 of each experiment. Data in D and E are normalised to SK-
N-SH. Data in D - G are derived from one experiment performed in triplicate. Individual data points 
are shown in D - G. Histogram bars in D - G represent mean values and error bars represent S.E.M. 
Graph shows * p < 0.05, *** p < 0.001, compared to SK-N-SH cells by One-way ANOVA with 







The results in this chapter showed a series of experiments that aimed to generate the SK-N-
SH cell line with an APOE ɛ4 background. As the SK-N-SH neuroblastoma cell line (APOE 
ɛ3/3) has been published as a model to study the fragmentation of apoE (Muñoz et al., 
2018c), the generation of an APOE ɛ4 isogenic control would help to understand the 
difference in the fragmentation process between isoforms and the function of the specific 
fragments. Here we aimed to use CRISPR in SK-N-SH cells using the lentiviral transduction 
in combination with ssODN transfection to generate knock-in clones. The generation of a 
DSB in the APOE sequence in 81% of the selected CRISPR clones indicated that the 
lentivirus containing gRNA1 was the best candidate for the experiments. Unfortunately, 
none of the clones analysed showed a changed in the APOE genotype. 
The CRISPR technology has revolutionised the genome-editing world in the last decade. 
Compared to previous genome-editing techniques such as zinc finger nucleases or 
transcription activator-like effector nucleases (TALENs), CRISPR is considered to be a 
simpler and more flexible method with a high editing efficiency (Adli, 2018). The delivery 
of the gRNA and the Cas9 nuclease into the cells can be performed using different 
approaches. Initially, a DNA plasmid containing the gRNA, the Cas9 nuclease and a GFP tag 
was chosen; however, the nucleofection of a > 8 kbp plasmid generated a high rate of cell 
death and the selection via GFP was difficult without a cell sorter (data not shown). As 
shown in Figure 4.3, the transduction of the all-in-one lentivirus CRISPR designed by Sigma 
Aldrich was the final chosen method, as it contained the gRNA and the Cas9 nuclease in 
addition to a GFP tag and a puromycin resistant cassette for antibiotic selection. 
The use of a specific gRNA to perform the editing in the CRISPR/Cas9 system was chosen 
to promote a high specificity of the target region. However, off-target effects have been 
described previously in the system as reviewed in (Mahfouz et al., 2014). The predicted off-





mismatches in the sequence, that compared to APOE gene having a score of 100 and no 
mismatches indicates high specificity to bind the APOE gene over other sequences of the 
genome (Hsu et al., 2013). 
To generate a knock-in using CRISPR/Cas9 technology is a challenge: Firstly, the gRNA 
must target the desired sequence, followed by the Cas9 nuclease inducing the DSB in the 
specific place and, finally, the ssODN needs to be inserted through HDR. In our study, the 
high efficiency on generating a DSB using the lentivirus containing gRNA1 did not lead to 
repair via HDR pathway. All the clones with a DSB in the DNA generated after ssODN1 
transfection underwent the NHEJ pathway, as sequencing of the region of interest showed a 
double peak from the predicted cut site (Figure 4.5B). ssODN transfections instead of a 
double-strand DNA was used to avoid off-target effects by random insertion in the genome. 
Some studies, as Richardson et al. (2016) have generated specific ways to improve the 
efficiency of the HDR pathway. They have shown that, after the DSB occurs, the Cas9 
nuclease releases first the 3’ end of the cleaved DNA strand that is not complementary to the 
gRNA (Richardson et al., 2016). Moreover, they optimised an asymmetric ssODN to 
increase the HDR efficiency by overlapping the Cas9 cut site with 36 bp on the PAM-distal 
side and an extension of 91 bp on the PAM-proximal side of the DSB (Richardson et al., 
2016). To improve the HDR efficiency the ssODN2 used in this study was based on the 
asymmetric design specific for the gRNA1 sequence, as shown in Appendix A2.3 and A2.4. 
Moreover, another challenge to face is the exact time to deliver the ssODN, so it is in the 
nucleus exactly when the Cas9 produces the DSB. As our method to deliver the gRNA and 
Cas9 was plasmid based through lentiviral transduction, the cell needed time to translate the 
Cas9 protein, and then to induce the DSB. Initially, we transfected the cells with ssODN1 24 
h after the lentiviral transduction; however, we decided to expand the time frame with the 
asymmetric ssODN2 by transfecting at time points of 0, 4, 6, 8 and 12 h post-transduction. 





the clones that had undergone DSB took the HDR repair pathway when ssODN2 was 
transfected at any of the chosen time points. 
In this study, more than 50 clones survived the monoclonal expansion after antibiotic 
selection and were analysed; however, due to the intrinsic low efficiency of the HDR 
pathway, there is a possibility that more clones would have been needed to obtain some that 
underwent the HDR pathway. A high-throughput and automated system to select clones and 
sequence the clones might need to be considered to generate and sequence high numbers of 
clones. In addition to the asymmetric ssODN design (Richardson et al., 2016), there has been 
more recent published methods that aim to achieve higher HDR efficiency after DSB, as 
performing a “cold shock” of the cells after transfection (Guo et al., 2018) or generating a 
covalent tethering between the ssODN and the Cas9 nuclease to co-localize them spatially 
and temporally (Aird et al., 2018). Moreover, DSB can lead to apoptosis or cell cycle arrest; 
and whereas the NHEJ pathway is constitutively active, the HDR pathway is restricted to 
phases S/G2 (Branzei and Foiani, 2008; Rothkamm et al., 2003). Other studies have focused 
on inhibition of the NHEJ pathway chemically or genetically (Chu et al., 2015; Maruyama et 
al., 2015) to ensure higher HDR efficiency. To generate a change in the APOE background 
using CRISPR/Cas9, a new way to increase the HDR efficiency in combination with a higher 
throughput technology needs to be considered. 
The NHEJ repair pathway is characterised for introducing or deleting nucleotides in the 
sequence to fix the DSB generated in the DNA, resulting in a possible loss-of-function of the 
protein of interest. Four of the CRISPR clones that showed double peaks in the 
electropherogram (Figure 4.5B) were further analysed for a knock-down in APOE 
expression. The 4 selected clones showed a reduction in APOE expression levels after 
ATRA differentiation (Figure 4.6), and the expression was confirmed in apoE protein level 
(Figure 4.7). However, there were morphological differences between the parental SK-N-SH 





did not contain substrate-adherent cells showed the lowest APOE and HTRA1 expression 
(Figure 4.6 and Figure 4.9). Moreover, the control clone that was manually selected after 
CRISPR but did not generate a DSB showed higher apoE levels than clone 2 but lower than 
the parental SK-N-SH cells (Figure 4.10B and C). This CRISPR control clone showed both 
S- and N-type cells, but not as many S-type cells as many S-as the parental SK-N-SH cells 
(Figure 4.10A). However, the SH-SY5Y cells, characterised as neuroblastic, showed apoE 
expression levels as low as the CRISPR clone 2 (Figure 4.10B and C). Based on our results, 
it therefore appears that apoE could be expressed by the substrate-adherent cell type that 
shows a more glial phenotype. To confirm if the lack of expression in the CRISPR clones is 
due to and APOE KD after NHEJ pathway repair or related to the neuroblastic morphology 
of the cell type, further studies need to be performed. Moreover, to confirm that the double 
peak shown in the electropherograms does not come from a mixed population of cells, single 
cell sequencing would need to be performed in order to identify the exact mutation induced 
after CRISPR in every clone. Whereas neurons do not express apoE under normal 
circumstances, some studies have shown its upregulation upon excitotoxic stress induced by 
kainic acid (Boschert et al., 1999; Xu et al., 2006). Further monoclonal selection of the 
selected CRISPR clones and the CRISPR control clones to ensure a pure neuroblastic culture 
similar to the SH-SY5Y cells followed by kainic acid treatment can be used to confirm the 
APOE KD of the CRISPR clones. 
Similar to APOE expression, there was also a reduction in HTRA1 expression levels in the 4 
selected clones (Figure 4.9). There is the possibility that HtrA1 might be expressed by the 
substrate-adherent cells that exist in the SK-N-SH parental cell line instead of the 
neuroblastic cells that are predominant in the CRISPR clones. However, we have shown that 
when r-apoE is added into the SH-SY5Y cells, the neuroblastic subclone of the SK-N-SH 
cells that it does not express apoE, it got fragmented into the 25-kDa fragment that was 





clones and CRISPR control clones as discussed above to confirm APOE KD need to be 
performed to confirm the link between HtrA1 and apoE expression further. 
In conclusion, this study shows an optimized system to generate a DSB in the APOE gene of 
cells after lentiviral transduction using the gRNA1 sequence. However, the induction of the 
HDR repair pathway will need to be improved with any of the considerations discussed 
above. The use of the CRISPR/Cas9 system to generate an isogenic line with a different 
APOE genotype is still of high relevance, not only to study differences in apoE 
fragmentation but also in apoE function.  
4.4.1. Future directions 
In this study, the generation of CRISPR clones from SK-N-SH cells has been described. 
Besides further characterisation needs to be performed, they can be used to understand the 
link between apoE and HtrA1 expression by exogenous apoE addition of the various 
isoforms. Moreover, the optimization of the gRNA that generates a DSB in the APOE gene 
shown in this study can be used in other relevant cell types as iPSCs, a novel model to study 
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The discovery of induced pluripotent stem cells (iPSCs) has revolutionized the field of 
disease modelling. iPSCs were first generated from mouse fibroblasts (Takahashi and 
Yamanaka, 2006) and one year later from human fibroblasts (Takahashi et al., 2007). The 
utility of iPSCs relies on the possibility to study cells in a dish that have the genetic 
background of patients. In the study of neurodegenerative diseases such as AD, where the 
availability of living tissue is reduced, iPSCs open a new opportunity to understand the 
underlying mechanisms of the pathology, while recapitulating early stages of the disease in a 
dish. Moreover, iPSCs allow us to study how different cell types can contribute to the same 
pathology. 
iPSCs, by definition, are pluripotent stem cells. Pluripotency is defined as the ability to 
differentiate into any cell type from the three germ layers; the technology used to create 
iPSC does do not have the ethical issues associated with embryonic stem cell research, 
because they are reprogrammed from somatic cells. The initial source of cells to reprogram 
iPSCs were fibroblasts of donors, but more recent studies have shown that iPSCs can also be 
reprogrammed from other somatic cell sources including peripheral blood cells, urine cells or 
keratinocytes, amongst many others (Raab et al., 2014). 
The generation of iPSCs from fibroblasts involves the expression of pluripotent transcription 
factors in the somatic cells. In the initial study, Takahashi et al. delivered the transcription 
factors Oct3/4, Sox2, Klf4, and c-Myc into mouse fibroblasts via retroviral transduction to 
generate iPSCs (Takahashi et al., 2007). Since then, other techniques such as mRNA 
transfection have been used, and the addition of extra transcription factors such as Lin28 or 
Nanog, have been used to increase the efficiency of the reprogramming process.  
The selection and characterization of individual iPSC clones is essential, after which three 





Oct4 or Nanog, (ii) their ability to differentiate into cells from the three germ layers should 
be demonstrated and (iii) evidence that no chromosomal alteration has occurred during 
reprogramming must be established. Techniques such as in vivo teratoma assay have been 
used to confirm the pluripotency of stem cells (Nelakanti et al., 2015; Wesselschmidt, 2011); 
however, new techniques such as PluriTest or Scorecard have been recently developed 
(Müller et al., 2011; Tsankov et al., 2015). Whereas PluriTest is a bioinformatic technique 
that compares the iPSC samples to a database to confirm pluripotency, Scorecard analyses 
the RNA levels of the three germ layers to confirm the differentiation potential of your iPSC 
sample. 
After reprogramming, iPSCs maintain the genetic background of the patient. Whereas 
mutations in genes related to the processing of APP are the cause of AD in FAD patients, 
SAD cases cannot be related to any specific mutation. The generation of iPSC from FAD 
and SAD patients gives us an opportunity to study the molecular mechanisms involved in the 
known mutations of the disease and to understand better the trigger of the disease in the SAD 
cases.  
5.1.1. Aim of the study 
The aim of the study was to generate and characterize two iPSC lines from dermal 
fibroblasts derived from a FAD PSEN1 A246E patient and a non-demented family member 







5.2. Materials and methods 
5.2.1. APOE genotyping 
APOE genotyping of the AG06846 and AG06848 fibroblast samples was performed as 
described in Chapter 2. 
5.2.2. iPSC reprogramming 
Dermal fibroblast samples from AG06846 and AG06848 obtained from the Coriell Institute 
were reprogrammed into iPSCs using the StemMACSTM mRNA Reprogramming kit 
(Miltenyi Biotec, Germany). Prior to reprogramming, fibroblasts were adapted to PluritonTM 
Reprogramming Medium (Stemgent, USA) and plated in MatrigelTM. The three seeding 
densities recommended for slowly growing fibroblasts were chosen: 30000, 15000 and 7500 
cells/well in a 24-well plate. 
The media used was a combination of Pluriton Reprogramming Medium with Pluriton 
Supplement, B18R, a recombinant protein that increases cell viability during RNA 
transfection, 100 IU/ml Penicillin, and 100 µg/ml Streptomycin. The mRNA cocktail of the 
pluripotent transcription factors Oct4, Klf4, Sox2, c-Myc, Lin28 and Nanog, plus eGFP to 
track successful transfection, was mixed to obtain the following: 36 ng/µl Oct4, 12.7 ng/µl 
Klf4, 10.7 ng/µl Sox2, 13.8 ng/µl c-Myc, 8.8 ng/µl Lin28, 9.4 ng/µl Nanog and 8.6 ng/µl 
eGFP. The transfection complex was prepared by combining the mRNA cocktail with the 
Stem MACS transfection buffer and transfection reagent following the manufacturer’s 
instructions.  
mRNA transfections were performed every day for 11 days and full medium changes were 
performed every day 4 h after mRNA transfection to avoid toxicity in the cells. In case of 
high cell death, a full media change was also performed prior to mRNA transfection to help 





medium. iPSC colonies started to appear at day 19 and, once colonies were between 100 – 
200 µm diameter, they were manually transferred to Matrigel-coated plates in TeSR-E8 for 
isolation as individual clones. 
5.2.3. qRT-PCR 
The primers for qRT-PCR used in this chapter were NANOG and POU5F1, GAPDH and 
HPRT1 as described in Chapter 2 
5.2.4. Immunocytochemistry 
The antibodies for immunocytochemistry used in this chapter were anti-Oct4, anti-SSEA-4 
and anti-Tra-1-60 as described in Chapter 2. 
5.2.5. PluriTest 
RNA from the AG06846 and AG06848 selected iPSC clones was extracted using TriReagent 
(MRC Gene, USA) following the manufacturer’s protocol. Concentration and purity of the 
RNA samples were analysed using Nanodrop 2000C instrument. Three µg of total RNA 
were used to perform PluriTest based on the Illumina HT 12v4 gene expression microarray 
data (Müller et al., 2011). 
5.2.6. Three germ layer differentiation 
Direct differentiation into the three germ layers was performed in AG06846 clone 2 and 
AG06848 clone 2 iPSC cultures. The iPSCs were plated at 2500 cells/60 mm diameter 
Matrigel-coated tissue culture plate to ensure same colony size across the cultures. Full 
media changes were performed daily using TeSR-E8 for 8 days. 
To differentiate iPSCs into the ectoderm germ layer, TeSR-E8 was replaced by Ni medium 
(Appendix A3.2) supplemented with 1 µM LDN193189 from day 8 to day 10 of iPSC 





into a non-adherent tissue culture plate to generate floating embryoid bodies (EBs). Ni 
medium was supplemented with 2 µM SB431542 and 3 µM CHIR99021, and half volume 
media changes were performed every second day from day 10 until the samples were 
harvested in TriSURE at day 17. 
To differentiate iPSCs into the mesoderm germ layer, TeSR-E8 was replaced by mesoderm 
base medium (Appendix A3.2) supplemented with 100 ng/ml Activin A, 10 ng/ml FGF-2, 
100 ng/ml BMP4 and 100 ng/ml VEGF on day 8 of iPSC culture. On the next day and every 
second day thereafter, half volume media changes using same media without Activin A 
supplementation were performed until the samples were harvested in TriSURE at day 15. 
To differentiate iPSCs into the endoderm germ layer, the STEMdiffTM Definitive Endoderm 
kit (TeSR-E8 Optimized) (Stemcell Technologies) was used following the manufacturer’s 
instructions until the samples were harvested in TriSURE at day 14. 
mRNA extraction from TriSURE, DNAse I treatment and cDNA generation were performed 
as described in Chapter 2. cDNA from the three germ layers was mixed in 1:1:1 ratio to 
obtain 1 µg. Specific genes of the three germ layers were analysed by TaqManTM hPSC 
ScorecardTM kit (Thermo Fisher Scientific) following the manufacturer’s instructions on 
Thermocycler QuantStudio 5 (Thermo Fisher Scientific). Analysis of the results was 
performed using the online Thermo Fisher Cloud application. 
5.2.7. Karyotyping 
Karyotyping of the AG06846 and AG06848 selected iPSC clones was performed by Sullivan 







Sequencing of the PSEN1 gene for the region of interest was performed to detect the 
presence or absence of the A246E mutation using the AG06846 and AG06848 fibroblasts 
and selected iPSC clones as described in Chapter 2. 
5.2.9. Short Tandem Repeats profiling 
Short tandem repeats (STR) analysis of 18 locations was performed at the Garvan Molecular 
Genetics Institute (Australia) comparing the selected AG06846 and AG06848 clones with 
the respective fibroblasts to ensure 100% identity of the reprogrammed cells matched the 
parental fibroblasts. 
5.2.10. Human pluripotent stem cell registry 
The iPS clones AG06846.2 and AG06848.2 were registered in the human pluripotent stem 








Dermal fibroblasts from a 56 year old female FAD patient and a 75 year old female escapee 
from the same family (Nee et al., 1983) were obtained from the Coriell Institute (AG06848 
and AG06846, respectively). Genotyping of the APOE gene was performed by PCR using 
fibroblast genomic DNA. Analysis of the agarose gel indicated an APOE ε2/3 background of 
the AG06846 non-demented control and an APOE ε3/4 background of the AG06848 FAD 
patient (Figure 5.1). 
 
Figure 5.1. Confirmation of APOE ɛ2/3 genotype on AG06846 and APOE ɛ3/4 on AG06848 cell 
lines. Genomic DNA was amplified by PCR and agarose gel showed the APOE genotype of AG06846 
and AG06848 fibroblasts. “M” shows the 100 bp marker, the 785 and 1598 bp bands are a PCR 
positive control showing HLA amplification, and the presence or absence of bands at 173 bp 
determines the APOE genotype for each sample. 
 
Fibroblasts were successfully reprogrammed using the StemMACSTM mRNA 
Reprogramming kit with colonies appearing 5 to 7 days after the last transfection. Successful 
mRNA transfection was tracked by eGFP expression from day 2 and change in morphology 
from elongated fibroblasts to round iPSC colonies can also be observed in Figure 5.2. Each 
colony was manually picked up and transferred into a new plate to ensure expansion as an 







Figure 5.2. Successful reprogramming of AG06846 and AG06848 dermal fibroblasts into iPSCs. 
AG06846 and AG06848 fibroblasts were reprogrammed via mRNA transfection into iPSCs. 
Representative brightfield and fluorescence images of iPSCs reprogrammed from fibroblasts from A-
C. AG06846 and D-F. AG06848. A and D. Fibroblasts prior to reprogramming, B and C. Fibroblasts 
at day 2 of the reprogramming protocol where eGFP expression indicated successful mRNA 
transfection and C and F. iPSC colonies. Scale bar = 100 µm. 
 
Based on morphology and initial characterization (data not shown), clone 2 of each cell line 
was chosen and a full characterization was performed. 
Levels of mRNA expression of the pluripotency markers POU5F1 and NANOG were 
analysed by qRT-PCR in the selected iPSC clones and the parental fibroblasts. Relative 
expression of POU5F1 and NANOG was normalised to the housekeeper genes HPRT1 and 
GAPDH as shown in Figure 5.3. AG06846 clone 2 showed an increase in expression of 4518 
± 75 fold (p < 0.0001, t = 60) in POU5F1 and 82 ± 2 fold (p < 0.0001, t = 34) in NANOG, 





and 180 ± 7 fold (p < 0.0001, t = 25) increase in NANOG expression when compared to their 
respective parental fibroblasts. 
 
Figure 5.3. Selected iPSC clones showed higher mRNA expression of the pluripotency markers 
POU5F1 and NANOG than fibroblasts. mRNA expression of AG06846 and AG06848 fibroblasts 
and the selected iPSC clones was analysed by qRT-PCR. Relative expression of the pluripotency 
factors POU5F1 and NANOG normalised to the housekeeper genes GAPDH and HPRT1 and each 
iPSC clones compared to the parental fibroblasts. Data are derived from one experiment performed in 
triplicate. Individual data points are shown. Histogram bars represent mean values and error bars 
represent S.E.M. Graph shows *** p < 0.001, compared to each fibroblast line by two-tailed t-test. 
 
Protein expression of the pluripotency markers Oct4, SSEA4 and Tra-1-60 was determined 
via immunocytochemistry in the AG06846 clone 2 and AG06848 clone 2 iPSCs. Oct4, a 
pluripotency transcription factor located in the nucleus, overlaps with the nuclear markers 
RedDot 2 and Hoechst 33342 in AG06846 clone 2 and AG06848 iPSC, respectively (Figure 
5.4). However, SSEA4 and Tra-1-60 are proteins located in the cell membrane and they did 







Figure 5.4. AG06846 and AG06848 iPSC clone 2 expressed the pluripotency marker Oct4. 
Confocal images of the A-C. AG06846 iPSC clone 2 and D-F. AG06848 iPSC clone 2 A and D. 
Fluorescence image of the pluripotency marker Oct4. B and E. Fluorescence image of the nuclear 
marker RedDot2 and Hoechst 33342. C and F. Merged images. Scale bar = 50 µm. 
 
Figure 5.5. AG06846 and AG06848 iPSC clone 2 expressed the pluripotency marker SSEA4. 
Confocal images of the A-C. AG06846 iPSC clone 2 and D-F. AG06848 iPSC clone 2. A and D. 
Fluorescence image of the pluripotency marker SSEA4. B and E. Fluorescence image of the nuclear 






Figure 5.6. AG06846 and AG06848 iPSC clone 2 expressed the pluripotency marker Tra-1-60. 
Confocal images of the A-C. AG06846 iPSC clone 2 and D-F. AG06848 iPSC clone 2. A and D. 
Fluorescence image of the pluripotency marker Tra-1-60. B and E. Fluorescence image of the nuclear 
marker stain Hoechst 33342. C and F. Merged images. Scale bar = 50 µm. 
 
Quantitative analysis of pluripotency transcription factors by qPCR and qualitative analysis 
of pluripotency markers and transcription factors detected by immunocytochemistry are a 
good indicator of the pluripotency potential of the selected iPSC clones. However, to further 
confirm the pluripotency potential of the iPSCs, the bioinformatic assay PluriTest (Müller et 
al., 2011) was performed. PluriTest relates two parameters: Pluripotency Score and Novelty 
Score. The Pluripotency Score compares the samples to a database formed by a collection of 
human pluripotent stem cells and somatic cells. High values on the Pluripotency Score 
indicate similarity to the pluripotent stem cells from the database and not to the somatic 
cells. Figure 5.7A shows the PluriTest results where AG06846 clone 2 obtained a 
Pluripotency Score of 24.16 and AG06848 clone 2 obtained 18.64, consistent with 
pluripotency. The Novelty Score compares the samples with a stem cell model matrix; high 
levels on the Novelty Score indicate differences in the characteristics when compared to their 





clone 2 obtained a Novelty Score of 1.46 and AG06848 clone 2 obtained 1.47. When both 
scores were plotted together with the stem cell matrix background, where the empirical 
distribution of the pluripotent (red cloud) and non-pluripotent (blue cloud) in the reference 
data set is shown (Figure 5.7B), both selected iPSC clones fitted within the threshold that 
confirmed pluripotency.  
 
Figure 5.7. Pluripotency potential of AG06846 and AG06848 iPSC clone 2 was confirmed via 
PluriTest. mRNA from the iPSCs AG06846 and AG06848 clone 2 was analysed via PluriTest A. 
Results of the Novelty and Pluripotency Score of AG06846 clone 2 and AG06848 clone 2 iPSCs. B. 
PluriTest results plotted in a Stem Cell Matrix background showing the AG06846 clone 2 and 
AG06848 clone 2 iPSC samples fitting within the threshold that confirmed pluripotency.  
 
Confirmation of the differentiation potential of the selected iPSC clones of AG06846 and 
AG06848 was performed by direct differentiation of iPSCs into the three germ layers as 
shown in Figure 5.8A. TaqMan hPSC Scorecard was used to analyse a set of specific genes 
for each germ layer by mRNA expression by comparing the distributions with a pool of 
undifferentiated and 5 days differentiated samples of 13 PSC lines used as a reference set in 
the assay. As shown in Figure 5.8B, self-renewal genes were downregulated after the 
differentiation, while genes of the ectoderm layer such as MAP2 or PAX6, mesoderm layer 
such as HAND1 or HOPX, and endoderm layer such as LEFT1 or SOX17 were upregulated 





potential to differentiate into cell types belonging to the three germ layers. And further 







Figure 5.8. Differentiation potential of AG06846 and AG06848 iPSC clone 2 was assessed via 
Scorecard after direct three germ layer differentiation. iPSCs were differentiated directly into the 
three germ layers by growth factors and small molecule inhibitors. A. Schematic diagram showing the 
different protocols to obtain ectoderm, mesoderm and endoderm from iPSCs. B. Scorecard results 





Karyotyping was performed in the AG06846 clone 2 and the AG06848 clone 2 iPSCs to 
ensure that no gross changes in the chromosomes happened after reprogramming. Both 
selected iPSC clones showed standard G-banding metaphase with no abnormality detected in 
15 cells at 400 bands per haploid site (Figure 5.9). In addition, Short Tandem Repeat (STR) 
profiling at 18 specific locations was performed comparing the iPSC selected clone with its 
respective parental fibroblast confirming 100% identity match (Appendix A3.1).  
 
Figure 5.9. iPSC AG06846 and AG06848 clone 2 showed normal karyotype. Karyotyping of the 
iPSCs AG06846 and AG06848 clone 2 was performed. Representative standard G-banding metaphase 
karyotyping of the A. AG06846 iPSC clone 2 and B. AG06848 iPSC clone 2.  
 
Both fibroblast lines came from a family with a history of FAD, carrying the PSEN1 A246E 
mutation (Nee et al., 1983). To confirm the presence of the mutation in the AG06848 FAD 
patient and its absence in the AG06846 non-demented control, Sanger sequencing was 
performed in the region of interest of the PSEN1 gene. AG06846 showed the GCG sequence 
that codes for alanine in both alleles, coding for wild-type PSEN1; while AG06848 was 
heterozygous, carrying the mutated GAG that codes for glutamate in one allele, and therefore 
having the PSEN1 A246E mutation (Figure 5.10). Importantly, the presence or absence of 







Figure 5.10. AG06846 cell line contained wild-type PSEN1 gene whereas AG06848 cell line 
contained the A246E mutation. Genomic DNA of the AG06846 and AG06848 fibroblasts and the 
selected clones was amplified and sequenced for the region of interest within the PSEN1 gene. 
Electropherograms showed the PSEN1 gene sequence from the AG06846 and AG06848 fibroblasts 






The generation of iPSCs has been one of the great biomedical discoveries in the last decades. 
However, we must be cautious ensuring quality controls in their generation to have 
reproducible and comparable results. Here we have shown the generation and 
characterization of iPSC lines from two family members: one FAD patient with the PSEN1 
A246E mutation and one non-demented control with wild-type PSEN1. 
iPSCs can be reprogrammed from different sources of somatic cells such as blood cells, 
urine cells, or skin cells. In our case, we obtained the dermal fibroblasts lines AG06846 and 
AG06848 from the Coriell Institute to generate the iPSC lines. Since the generation of the 
first iPSC from humans in 2007 using retrovirus (Takahashi et al., 2007), three major ways 
of reprogramming are now available: RNA transfection, virus delivery or DNA episomes. 
We used mRNA transfection as a non-viral, non-integrative method of reprogramming.   
Once iPSC colonies appear in the culture after reprogramming, each of them were treated as 
a different clone due to potential differences such as partial reprogramming. However, some 
studies have accepted the heterogeneity of initial clones and shown that bulk-cultured iPSCs 
did not reveal significant differences with the clonal selected iPSCs after a few passages 
(Willmann et al., 2013). We performed initial characterization based on the expression of 
pluripotency markers via qPCR and immunocytochemistry to compare expression levels 
within each clone (data not shown), resulting in clone 2 of each cell line to be the chosen 
one. A previously published method to confirm pluripotency relied on the in vivo teratoma 
assay, where iPSCs were implanted into an immune-compromised mouse that developed a 
benign tumour containing cells differentiated into the three germ layers, confirming 
pluripotency (Nelakanti et al., 2015; Wesselschmidt, 2011). However, new methods to test 
pluripotency and three germ layer differentiation potential have been developed and these 
include PluriTest and Scorecard (Müller et al., 2011; Tsankov et al., 2015). In this study, the 





AG06846 clone 2 and the AG06848 clone 2. Results for both samples showed a low Novelty 
Score (1.46 for AG06846 cl. 2 and 1.47 for AG06848 cl. 2) and a relative high Pluripotency 
Score (24.16 for AG06846 cl. 2 and 18.64 for AG06848 cl. 2). The plotting of both as shown 
in Figure 5.7B showed how they fit within the threshold thereby confirming pluripotency. 
Differentiation into the three germ layers was analysed via Scorecard after direct 
differentiation towards ectoderm, mesoderm and endoderm layer. Results showed 
downregulation in genes involved in self-renewal and pluripotency, and the upregulation of 
specific genes selected for each of the three germ layers, confirming the differentiation 
potential of the cells.  
As a quality control for disease modelling, it is important to confirm that the specific 
mutations from the fibroblasts are still present or absent in the iPSCs after reprogramming. 
In this study, Sanger sequencing of the PSEN1 gene was performed to confirm the presence 
of the A246E mutation in the AG06848 fibroblasts and iPSC clone 2, and its absence in the 
AG06846 fibroblasts and iPSC clone 2 (Figure 5.10). Moreover, STR profiling was 
performed to ensure a 100% identity match of each iPSC clone to its respective parental 
fibroblast line. 
One of the factors that have been debated in the last few years regarding iPSC studies is the 
sample number to use for experiments. Each stem cell is considered a biological replicate; 
however, there is a trend to use three different clones as technical replicates from each 
biological replicate. Following that, the number of iPSC lines times by three clones of each 
cell line reaches numbers that are hard to access for some laboratories. Also, depending on 
the experiments, the amount of time and money spent to generate them takes many of those 
laboratories out of the field of stem cell research. Some studies in other diseases such as 
schizophrenia have discussed the trade-off between more iPSC lines or more clones from 
each line, resulting in more power the presence of biological replicates instead of multiple 





within iPSC clones when compared to iPSC from different individuals. As the genetic 
variation between individuals may hide some changes related with the specific diseases, it is 
important to have a high sample number with the appropriate controls. However, when 
comparing samples, the generation of isogenic controls would be the most appropriate 
control. Isogenic controls can be generated by genome-editing techniques including 
CRISPR/Cas9, TALENs or zinc fingers, in which a mutation in the gene of interest can be 
restored to the wild-type genotype, or vice versa, whereas the remainder of the genetic 
background remains identical.  In conclusion, we have reported the generation and 
characterisation of two valuable iPSC lines from a donor with a FAD mutation and a non-
demented control from the same family that, together with other iPSC lines derived from 
healthy individuals and AD patients can be used as a model to generate relevant cell types to 
help us understand the pathology of AD.  
5.4.1. Future directions 
In this study, the generation and characterization of two iPSC lines from fibroblasts has been 
described. However, ensuring proper culture techniques and specific protocols that mimic 
the developmental pathways is essential to differentiate iPSCs into relevant cell types. The 
use of multiple iPSC lines differentiated into a relevant cell type model to study AD will be 








Chapter 6:  
Generation of iPSC-derived basal 














The cholinergic system, characteristic for the use of the neurotransmitter ACh, is responsible 
for learning and memory. AD patients suffer neurodegeneration, and BFCNs have been 
shown to be the first type of neurons to degenerate (Mufson et al., 2008; Whitehouse et al., 
1982).  
The use of iPSCs has opened the possibility to generate relevant cell types that contain the 
genetic background of each patient, allowing to study AD from a different perspective. To 
ensure successful differentiation of BFCNs in vitro, a combination of growth factors and 
SMIs mimicking the signalling pathways that BFCNs undergo in vivo during development 
are important. Following that, few protocols to generate BFCNs have been already published 
obtaining a combination of adherent and floating cultures, and some of them including 
transfection and cell sorting purification (Bissonnette et al., 2011; Moreno et al., 2018; Ortiz-
Virumbrales et al., 2017) (Table 1.4). Differences in efficiency based on ChAT+ve cells have 
been shown in the published protocols. Characterisation of the BFCNs based on RNA and 
protein expression has been complemented in most cases with functional properties analysis 
(Table 1.4). 
The development of new analysis methods can generate deep characterisation of the BFCN 
cultures. Nanostring is a recently developed technology based on the quantification of RNA 
molecules based on molecular barcoding. This technology allows to analyse of a big set of 
genes from the same sample while only using a small amount of sample RNA. The 
normalisation of gene expression to 10 housekeeping genes, the selection of up to 100 genes 
and the internal quality control performed for each sample ensure the production of a robust 
data set. 
To use the BFCNs as a new model to understand the neurobiology of AD, a full 





relevant characteristics is essential. However, we also need to ensure that the pathological 
hallmarks of the disease such as Aβ expression, hyperphosphorylated tau or cytotoxicity can 
be quantified. The comparison between iPSC-derived BFCNs from AD patients and healthy 
controls in a dish opens the possibility to study the pathological features characteristic during 
early stages of disease development.  
6.1.1. Aim of the study 
The aim of the study was to generate and characterise a robust protocol to differentiate 
BFCNs from iPSCs and validate it by gene expression and basic functional characterization 






6.2. Materials and methods 
6.2.1. iPSC lines 
The cell lines used in this study are outlined in Table 6.1. iPSC culture was performed as 
described in Chapter 2.  
 
Table 6.1. Induced pluripotent cell lines details. HC, Healthy control; SAD, sporadic 
Alzheimer’s disease; FAD, familial Alzheimer’s disease. 
 
6.2.2. Generation of basal forebrain cholinergic neurons 
6.2.2.1. Embryoid body formation 
Following iPSC culture technique (described in Chapter 2), 2 days before passaging, TeSR-
E8 medium was changed to Neural induction (Ni) medium (0.4% (v/v) B27 supplement, 1% 
(v/v) N2 supplement, 1% (v/v) Non-essential amino acids and 1% (v/v) GlutaMAX in 
DMEM/F12) supplemented with 0.1 µM LDN193189, a BMP inhibitor. Medium was 
changed if necessary depending on the density of the cultures, ensuring that they did not 
become acidic as indicated by the yellow change in colour of phenol red. On the passaging 
day, 1x dispase was added until colonies were fully detached from the plate. Colonies were 
collected and rinsed twice with DMEM/F12 to remove dispase allowing them to settle by 
Name iPSC line Gender 
Age at 
collection 
Disease status APOE genotype 
HC1 1-4 M 57 Healthy control ɛ3/3 
HC2 MBE60-1 M 78 Healthy control ɛ3/3 
HC3 MBE68-1 F 65 Healthy control ɛ3/3 
SAD1 RB7-11 F 83 SAD ɛ4/4 
SAD2 8-5 M 83 SAD ɛ4/4 





gravity for 2 min at 22 °C. Supernatant was removed, and colonies were resuspended on Ni 
media supplemented with 0.1 µM LDN193189 and 10 µM of the TGF-β inhibitor 
SB431542, pipetting gently up a down to break down the colonies. Colonies were transferred 
into a low adherent non-tissue culture plate to form floating EBs. Full medium change with 
Ni media supplemented with 0.1 µM LDN193189 and 10 µM SB431542 was performed 
every second day. 
6.2.2.2. Neural rosette formation 
On day 5 of EB stage, EBs were collected and plated them down into Matrigel-coated tissue 
culture plates with Ni media supplemented with 10 ng/ml FGF-2 to form neural rosettes. A 
partial volume media change with Ni medium and 10 ng/ml FGF-2 was performed after 48 h 
and with 10 ng/ml FGF-2 and 50 ng/ml SHH after 96 h. Neural rosette formations were 
visible by day 7. 
6.2.2.3. Neurosphere formation 
On day 7 of neural rosette stage, neural rosettes were visible under the microscope. Cell 
media was removed, and cells were incubated with 1x dispase until the edges were loosened. 
Dispase was removed and cells were carefully rinsed 3 times with DMEM/F12 to ensure 
removal of cell debris. Neural expansion (Ne) medium (2% (v/v) B27 supplement, 1% (v/v) 
N2 supplement, 1% (v/v) Non-essential amino acids and 1% (v/v) GlutaMAX in 
DMEM/F12) supplemented with 100 ng/ml SHH was added and the selected neural rosettes 
were detached by aspirating them using a P1000. Floating neural rosettes were transferred 
into a low adherent non-tissue culture plate to form floating neurospheres. A half volume 
media change was performed every second day using NEM supplemented with 100 ng/ml 
SHH for the first 6 days; 100 ng/ml SHH and 100 ng/ml FGF-8 from day 6 until day 12; and 





6.2.2.4. Basal forebrain cholinergic neurons maturation 
On day 15 of neurosphere stage, neurospheres were washed twice with DMEM/F12 prior 
dissociation with 1x accutase (Innovative Cell Technologies, USA) for 20 min at 37 °C. 
Enzymatic dissociation was stopped using trypsin inhibitor (1x) (Sigma-Aldrich), diluted 
with DMEM/F12 and spun down at 300 x g for 5 min. Cells were manually counted and 
125000 cells/well were plated in Matrigel and collagen I-coated 24-well plate format. 
Neuron medium (1% (v/v) B27 supplement and 1% (v/v) GlutaMAX in Brainphys (Stemcell 
Technologies)) supplemented with 100 ng/ml of SHH, 100 ng/ml of FGF-8, 10 ng/ml of 
BMP9 and 100 ng/ml of NGF was used on days 1 and 3 of cholinergic maturation. On day 5, 
a half volume media change using neuron media supplemented with 5 ng/ml of BDNF and 
100 ng/ml of NGF in addition to 1 µM 5-Fluoro-2’-deoxyuridine (5FDU) to stop the 
proliferation of the non-neuronal cells was used. On day 7 full media changed was 
performed using Neuronal media supplemented with 5 ng/ml BDNF and 100 ng/ml NGF. A 
partial volume media change using Neuron medium with 5 ng/ml BDNF and 10 ng/ml NGF 
was performed every second day for a total of 4 weeks of neuronal maturation. 
6.2.3. Cell imaging and neurite length 
Brightfield pictures during the different stages of differentiation were captured using the 
Infinity 2 camera (Lumenera, Canada). Brightfield pictures of the neurons were also taken 
every week for the 4 weeks of neuronal maturation using the Incucyte Zoom. Analysis of 
neurite length was performed using the Incucyte Zoom analysis system as described in 
Chapter 2.   
6.2.4. Immunocytochemistry 
The antibodies used for immunocytochemistry were anti-ChAT, anti-β-III-tubulin, anti-p75, 






A custom CodeSet was designed to be used with the PlexSet technology of Nanostring 
(Nanostring, USA). The list with the specific genes of interest can be found in Appendix A4. 
mRNA from iPSC and BFCN samples was harvested in TriSURE and extracted following 
the manufacturer’s instructions. mRNA concentration of the samples was measured using 
Qubit 3.0 Fluorometer (Thermo Fisher Scientific). To determine the optimal amount of 
mRNA per sample needed to not saturate the Nanostring, a titration run was performed and 
analysed using the nSolver System (Nanostring). A total of 100 ng mRNA per sample were 
run in the nCounter SPRINT (Nanostring). To normalize the samples, a pool of all the 
samples (called reference sample) needed to be run for each Probe Set, and a total of 10 
housekeepers (AARS, ASB7, CCDC127, CNOT10, EID2, MTO1, RABEP2, SUPT7L, 
TADA2B, ZNF324B) was selected based on the literature and Nanostring recommendations. 
Normalization was performed using the nSolver System, data were further analysed using 
Excel and graphs were made on Prism7. Samples generated were analysed for each gene 
independently showing number of molecules counted by the nCounter SPRINT System after 
normalization with housekeepers. 
6.2.6. Whole-cell patch clamp 
Whole-cell patch-clamp was performed in the BFCNs after 4 weeks of maturation by Dzung 
Do-Ha to assess the neuronal functionality. All experiments were performed at 22-24 °C in 
artificial cerebral spinal fluid (aCSF, 135 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 
10 mM HEPES and 10 mM D-glucose; adjusted to pH 7.4 (with NaOH) and ~305 mOsm) 
and using intracellular solution (150 mM KCl, 2 mM MgCl2, 10 mM HEPES, 4 mM Mg-
ATP, 0.3 mM Na-GTP, 10 mM Na2PCr and 1 mM EGTA; adjusted to pH 7.4 (with KOH) 
and ~295 mOsm) Cells were visualised with an inverted Leica DM RB microscope and 
chosen based on neuronal morphology, which included large cell bodies and long extensions. 





borosilicate glass (with filament) (Harvard Apparatus) to a resistance of 5-7 MΩ. 
Electrophysiological signals were recorded at 10 Hz using Digidata 1550 and amplified 
using a MultiClamp 700B amplifier (Axon Instruments, Molecular Devices 
Electrophysiology). The acquired data were analysed using the pCLAMP10 software. 
Whole-cell patch clamp configuration was achieved after establishing a GΩ seal (> 1 GΩ). 
Cells with a series resistance (Rs) below 25 MΩ were used for further analysis. Membrane 
Capacitance (CM), Rs and resting membrane potential (RMP) were determined using the 
Membrane Test and pClamp10 analysis software. To determine firing properties of 
differentiated neurons, direct current was injected to hold the cell at -60 mV. In current 
clamp mode, step currents of 25 pA were injected form -50 pA until the cell fired or 500 pA. 
Synaptic events were recorded in voltage clamp mode by injecting direct current, holding the 
cell at -60 mV and performing a chart recording over 5 minutes. 
6.2.7. Amyloid β ELISA 
Aβ 40 and 42 enzyme-linked immunosorbent assay (ELISA) (Thermo Fisher Scientific) 
were performed using cell culture conditioned media following the manufacturer’s 
instructions. Microplate absorbance was read at 450 nm in a Spectramax Plus Plate Reader.  
6.2.8. Pierce LDH Cytotoxicity assay 
The lactate dehydrogenase (LDH) cytotoxicity assay was performed using the Pierce LDH 
Cytotoxicity assay kit (Thermo Fisher Scientific) in cell culture conditioned media following 
the manufacturer’s instructions. Microplate absorbance was read at 490 nm in a Spectramax 
Plus Plate Reader.   
6.2.9. Western blot 
The antibodies for western blot used in this chapter were anti-tau S214, anti-tau S404, anti-
tau13 and anti-GAPDH as described in Chapter 2. 10% (v/v) goat serum in TBS-T was used 






The generation of BFNCs from iPSCs involved a set of stages, both adherent and in 
suspension, with the addition of specific SMIs and growth factors to mimic the signals 
received during development. An overview of each stage of the protocol to generate BFCNs 
is represented in Figure 6.1. Incubation of iPSCs for 48 h prior to generation of embryoid 
bodies with Ni media supplemented with the BMP inhibitor LDN193189, was followed by 
the addition of LDN193189 and the TGF-β inhibitor SB431542 in EB stage, in order to 
promote the ectoderm fate of the iPSCs. This could be observed by the formation of neural 
rosette-like structures inside the EBs (Figure 6.1C) and the generation of neural rosettes 5 
days after plating the embryoid bodies into Matrigel-coated plates (Figure 6.1D). Addition of 
FGF-2 in this stage stimulated cholinergic differentiation, and the formation of neural 
rosettes ensured the selection of the cells mimicking the neural tube formation by visual 
screening (Figure 6.1D). The neural rosettes were manually selected to generate floating 
neurospheres, a structure that allowed the expansion of the neural progenitors (Figure 6.1E). 
SHH, a morphogen that induces ventralization of the neural tube, the region from where the 
BFCNs will develop (Li et al., 2009). In the late stage of neurospheres, the addition of FGF-
8 mimicked the telencephalon development, and BMP9 induced the cholinergic phenotype 
of the progenitors (Takahashi and Liu, 2006). As the last stage of the protocol, neurospheres 
were disaggregated and plated as single cells, allowing the neural progenitors to mature as 
BFCNs (Figure 6.1F). Specific growth factors such as BDNF, that stimulates cholinergic 
differentiation, and NGF, that promotes maturation, arborization and survival, were required 
to promote the BFCN fate and increase ChAT activity (Alderson et al., 1990; Auld et al., 
2001; Sofroniew et al., 2001). As neurons are terminally differentiated and have exited the 
cell cycle, the addition of 5-Fluoro-2’deoxyuridine (5FDU), inhibits the proliferative cells by 
inhibiting DNA biosynthesis (van Laar et al., 1998; Xia et al., 1999), and therefore can be 






Figure 6.1. Differentiation BFCNs from iPSCs. iPSCs were differentiated into BFCNs by the 
combination of small molecule inhibitors and specific growth factors mimicking the developmental 
signals. A. Schematic diagram showing the different stages of the differentiation in black arrows over 
time. Orange arrows showing the cell culture media used in each stage and blue arrows showing the 
small molecule inhibitors or growth factors used at each specific time points. B-F. Representative 
brightfield pictures of the last day at each stage: B. iPSC, C. embryoid bodies, D. neural rosettes, E. 
neurospheres and F. BFCNs. Black scale bars = 200 µm and white scale bars = 100 µm. 
Five iPSC cell lines (HC1, HC2, HC3, SAD1 and FAD1; Table 6.1) were differentiated into 
BFCNs. A first differentiation round was performed using HC1, HC2, SAD1 and FAD1, and 
a second one using HC2 and HC3. During the four weeks of maturation, brightfield images 
of the BFCN cultures were taken every week using an Incucyte Zoom and neurite outgrowth 
was measured over time (Figure 6.2A-D). After analysing 16 pictures per well and a range 
between 2 to 8 wells for each of the 6 differentiations performed, an increase in neurite 
outgrowth from 16.8 ± 2.1 mm/mm2 at week 1 to 43.6 ± 2.2 mm/mm2 at week 4 was 







Figure 6.2. BFCN showed increased neurite length during the 4 weeks of maturation. BFCNs 
were differentiated from iPSCs and matured for 4 weeks. A-D. Representative brightfield images 
taken using Incucyte Zoom during maturation: A. week 1, B. week 2, C. week 3 and D. week 4. E. 
Analysis of neurite length expressed in mm/mm2 over 4 weeks of BFCN maturation. Scale bars = 150 
µm. Data in E are derived from 16 pictures per well and a range between 2 to 8 wells for each of the 6 
BFCN differentiations. Individual data are shown, and error bars represent S.E.M. Graphs show ** p 
≤ 0.01, *** p ≤ 0.001, by one-way ANOVA with Tuckey’s post-hoc analysis. 
 
Immunocytochemistry of neuronal and specific cholinergic markers was performed at 4 
weeks of maturation in BFCN cultures. The cholinergic marker ChAT and the neuronal 
marker β-III-tubulin were identified in the BFCN cultures. Of the β-III-tubulin+ve cells, 87% 
were also ChAT+ve (Figure 6.3A-C). Immunocytochemistry against the ACh receptor p75NTR 
was also performed, with only a few cells identified as p75NTR+ve in the cultures (Figure 
6.3D-F). BFCN cultures were also positive for the dendritic marker microtubule-associated 
protein 2 (MAP2), but no astrocytes were detected after staining against the activated 






Figure 6.3. BFCNs were positive for neuronal markers. BFCN cultures were matured for 4 weeks 
and immunocytochemistry for general neuronal markers, specific cholinergic neuronal markers and 
astrocytic markers was performed. A-L. Representative confocal pictures of the BFCN cultures at 
week 4 of BFCN maturation with the nuclear marker Hoechst 33342 in blue. A. Cholinergic marker 
ChAT in green. B. Neuronal marker β-III-tubulin in red. C. Merged picture of A and B. D. 
Cholinergic marker p75NTR in green. E. Neuronal marker β-III-tubulin in red. F. Merged picture of 
D and E. G. Astrocyte marker GFAP in green. H. Dendritic marker MAP2 in red. I. Merged picture of 






The mRNA expression of the BFCN samples was analysed by Nanostring and compared to 
iPSC samples. Prior to analysis of the results, the nSolver System was used to perform 
internal quality control of the samples and normalisation to a sample reference used in the 
PlexSet. Moreover, normalisation to 10 housekeepers was performed. The housekeepers 
were chosen to cover different ranges of expression (highly expressed such as AARS or 
CCDC127 and lower expressed such as RABEP2 or ZNF324B). The expression of each 
housekeeper gene is shown in Appendix A4 and there was no significant difference in the 
overall housekeeper expression between iPSCs and BFCNs (Appendix A4).   
To characterise the BFCN cultures, sets of genes for different stages of development were 
analysed, and their expression compared to iPSC cultures. As expected, the pluripotency 
markers NANOG and POU5F1 were highly expressed in iPSCs, whereas no expression was 
detected in BFCN cultures (Figure 6.4A and B). The neuronal progenitor markers achaete-
scute homolog 1 (ASCL1), distal-less homeobox 1 and 2 (DLX1 and DLX2), empty-spiracles 
homeobox 1 (EMX1), PAX6 and SRY-box 1 (SOX1) were analysed (Figure 6.4C-H). EMX1 
did not show a significant difference in expression between BFCN and iPSC cultures (Figure 
6.4F). However, all the other neuronal progenitor markers were upregulated in BFCN 
cultures compared to iPSCs: DLX1 was upregulated by 58.6 ± 16.8 fold (p = 0.04, D = 1), 
DLX2 was upregulated by 68.4 ± 15.9 fold (p = 0.004, t =3.9), ASCL1 was upregulated by 
32.5 ± 3.6 fold (p < 0.001, t = 8), PAX6 was upregulated by 12.1 ± 3.1 fold (p = 0.04, D = 1), 
and SOX1 was upregulated by 60.5-fold ± 13.3 (p = 0.0028, t = 4.1). The specific BFCN 
progenitor markers analysed were FOXG1, ISL1, LHX8, and NKX2-1 (Figure 6.4I-L). While 
FOXG1, ISL1and NKX2-1 were upregulated by 78.7-fold ± 10.4 (p < 0.001, t = 6.5), 70.7-
fold ± 19.8 (p = 0.04, D = 1) and 8.7 ± 4.8 (p = 0.04, D = 1), respectively; LHX8did not show 
a significant difference between cultures. However, two of the samples (HC1 and HC3, 






Figure 6.4. Expression of pluripotency, neuronal progenitors and specific cholinergic progenitor 
markers in iPSC and BFCN cultures. iPSCs and BFCNs samples were analysed by nCounter 
(Nanostring) and, after normalisation of total amount of RNA molecules to the housekeeper genes, 
results are shown as fold change of BFCN cultures over iPSCs. Analysis of the pluripotency markers 
A. NANOG and B. POU5F1; the neuronal progenitor markers C. ASCL1, D. DLX1, E. DLX2, F. 
EMX1, G. PAX6; and H. SOX1; and the specific cholinergic progenitor makers I. FOXG1, J. ISL1, K. 
LHX8 and L. NKX2-1. Data are derived from 5 iPSC lines and 6 BFCN differentiated samples. 
Individual data are shown. Histogram bars represent mean values and error bars represent S.E.M. 
Graphs show * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, by two-tailed t-test except in D, G, J and L that 









General neuronal markers as Fos proto-oncogene (FOS), L1 cell adhesion molecule 
(L1CAM), MAP2, disc large MAGUK scaffold protein 4 (DLG4, commonly known as 
postsynaptic density protein 95 (PSD95)), synapsin I (SYN1) and β-III-tubulin (TUBB3) were 
also analysed in iPSC and BFCN cultures (Figure 6.5A-F). MAP2 and TUBB3, that had also 
been identified in the BFCN cultures by immunostaining (Figure 6.3E and H), were 
upregulated by 40 ± 1.4 fold (p < 0.001, t = 24.6) and 13.1 ± 1.12 fold (p = 0.004, D = 1), 
respectively. FOS and L1CAM were also upregulated in BFCN cultures by 6.5 ± 1.1 fold (p 
= 0.012, t = 4.6) and 25.6 ± 2.3 fold (p < 0.0001, t = 9.7), respectively. Moreover, the pre-
synaptic marker SYN1 and the post-synaptic marker PSD95 were upregulated by 12.4 ± 1 
fold (p < 0.001, t = 10.9) and 10 ± 1 (p = 0.004, D = 1), respectively. 
The specific basal forebrain cholinergic markers ACHE, CHAT, solute carrier family 5 
member 7, (SLC5A7, commonly known as CHT1), nerve growth factor receptor (NGFR), 
neurotrophic receptor tyrosine kinase 1 (NTRK1, also known as TRKA) and solute carrier 
family 18 member 3 (SLC18A3, commonly known as VACHT), were analysed (Figure 6.5G-
L). The cholinergic neuron markers related with transport and recycling of the 
neurotransmitter acetylcholine ACHE, CHAT and VACHT were upregulated in BFCN 
cultures when compared to iPSCs by 48.6 ± 5.1 fold (p < 0.001, t = 8.5), 9.6 ± 1.8 fold (p = 
0.0017, t = 4.4) and 3.6 ± 0.5 fold (p = 0.0008, t = 4.9), respectively. However, whereas 
there the CHT1 expression tended to an increase in the BFCN cultures, it did not reach 
significance due to high variation between samples in the BFCN cultures. Moreover, from 
the specific NGF receptors analysed, NTRK1 was upregulated by 3.8 ± 0.8 fold (p = 0.01, t = 
3.2) increase, while NGFR did not show a significant difference when BFCNs were 
compared to iPSCs. However, iPSCs showed high expression in NGFR and this gene was 
not further upregulated following differentiation into BFCNs (Appendix A4). These data 







Figure 6.5. Expression of neuronal and specific BFCN markers in iPSC and BFCN cultures. 
iPSCs and BFCNs samples were analysed by nCounter (Nanostring) and, after normalisation of total 
amount of RNA molecules to the housekeeper genes, results are shown as fold change of BFCN 
cultures over iPSCs. Analysis of the neuronal markers A. FOS, B. L1CAM, C. MAP2, D. DLG4 
(PSD95), E. SYN1 and F. TUBB3; and the specific BFCN markers G. ACHE, H. CHAT, I. SLC5A7 
(CHT1), J. NGFR, K. NTRK1 (TRKA) and L. SLC18A3 (VACHT). Data are derived from 5 iPSC 
lines and 6 BFCN differentiated samples. Individual data are shown. Histogram bars represent mean 
values and error bars represent S.E.M. Graphs show * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, by two-










To characterize the purity of the BFCN cultures, the astrocyte markers aldolase (ALDOC), 
solute carrier family 1 member 3 (SLC1A3, commonly known as glial high affinity glutamate 
transporter 1 (EAAT1)), nuclear factor I A (NFIA) and S100B calcium binding protein B 
(S100B) were analysed (Figure 6.6A-D). ALDOC, NFIA and S100B did not showed a 
significant difference when BFCN cultures were compared to iPSCs, whereas EAAT1 was 
downregulated by 1.8 ± 0.5 (p = 0.03, D = 0.83) consistent with the lack of GFAP staining in 
Figure 6.3G. However, there was one BFCN sample (HC2 BFCN3, Appendix A4) that 
showed higher expression for EAAT1 and NFIA, suggesting a less pure neuronal culture in 
that specific sample. 
Other general neuronal and neuronal sub-type specific markers, such as solute carrier family 
6 member 3 (SLC6A3, commonly known as dopamine transporter 1 (DAT1)), glutamate 
decarboxylase 2 (GAD2), glutamate ionotropic receptor AMPA type subunit 1 and 2 (GRIA1 
and GRIA2), glutamate ionotropic receptor NMDA type subunit 1 (GRIN1), synaptosome 
associated protein 91 (SNAP91) and tyrosine hydroxylase (TH) were also analysed (Figure 
6.6E-K). The glutamate decarboxylase GAD2 and the glutamate receptors GRIA1, GRIA2 
and GRIN1 were upregulated in BFCN when compared to iPSCs by 110.9 ± 30.2 fold (p = 
0.009, t = 3.3), 126.7 ± 14.9 fold (p < 0.001, t = 7.624), 514 ± 62 fold (p < 0.001, t = 7.5) and 
392.2 ± 40.2 fold (p < 0.001, t = 8.794), respectively. The synaptosome associated protein 
SNAP91 was also upregulated by 294 ± 37 fold (p < 0.001, t = 7.1) in BFCN cultures when 
compared to iPSCs. An upregulation by 281.6 ± 58.7 fold (p = 0.0019, t = 4.3) was also 
found in BFCNs cultures, whereas the dopaminergic associated transporter DAT1 was 
downregulated by 1.7 ± 0.2 fold (p = 0.03, D = 0.83) decrease when compared to iPSCs. 
Together the gene expression and immunocytochemistry data are consistent with the 






Figure 6.6. Expression of astrocyte and other neuronal markers. iPSCs and BFCNs samples were 
analysed by nCounter (Nanostring) and, after normalisation of total amount of RNA molecules to the 
housekeeper genes, results are shown as fold change of BFCN cultures over iPSCs. Analysis of the 
astrocyte markers A. ALDOC, B. SLC1A3 (EAAT1), C. NFIA and D. S100B; and the other neuronal 
markers E. SLC6A3 (DAT1), F. GAD2, G. GRIA1, H. GRIA2, I. GRIN1, J. SNAP91 and K. TH. Data 
are derived from 5 iPSC lines and 6 BFCN differentiated samples. Individual data are shown. 
Histogram bars represent mean values and error bars represent S.E.M. Graphs show ** p ≤ 0.01, by 











Whilst the expression of protein markers was useful to confirm cholinergic neuron gene 
expression, neurons are defined by their electrical properties. Consequently, we analysed the 
electrophysiological properties of the iPSC-derived BFCNs (performed by Dzung Do-Ha). 
The functional properties of the BFCN cultures were analysed by whole-cell patch clamp at 
week 4 of BFCN maturation. A total of 31 cells from 4 BFCN samples were patch-clamped, 
showing an average resting membrane potential of -31 ± 2 mV and cell capacitance of 22 ± 2 
pF (Figure 6.7A and B). Of the neurons analysed, 23% were able to fire action potentials 
when the membrane potential was held at -60 mV (Figure 6.7C), and 35% of the cells 







Figure 6.7. Electrophysiology data of BFCN cultures at week 4 of maturation. A. Resting 
membrane potential and B. Cell capacitance. C. Sample trace of a train of action potential when 
membrane potential was held at -60 mV. D. Sample trace of synaptic events. Data in A and B are 
derived from 4 BFCN differentiated samples. Individual data points representing individual cells are 
shown. Histogram bars represent mean values and error bars represent S.E.M. 
 
In order to assess the potential to use BFCNs as a model to study AD, APOE, clusterin 
(CLU), HTRA1, LRP1 and other genes related with AD as APP, BACE1, MAPT, nitric oxide 
synthase 1 (NOS1), PSEN1 and PSEN2 (Figure 6.8) were also analysed in iPSC and BFCN 
cultures. APOE was highly expressed in iPSC, showing a 25.2 ± 0.8 fold (p < 0.0001, t = 





fragmentation, and LRP1, the major apoE receptor, did not show significantly different 
expression in iPSC and BFCN cultures. However, there was again one BFCN sample (HC2 
BFCN3, Appendix A4) that showed higher expression in CLU and HTRA1. MAPT, gene 
coding tau protein, was upregulated by 170.2 ± 14.4 fold (p < 0.0001, t = 10.6) in BFCN 
when compared to iPSCs. APP, coding for the amyloid beta precursor protein, showed high 
expression in both iPSC and BFCN cultures (Appendix A4), but BFCNs were upregulated 
by 1.42 ± 0.04 fold (p = 0.0012, t = 4.7) when compared to iPSCs. BACE1, coding for β-
secretase, responsible for APP fragmentation, and PSEN2, coding one of the subunits of the 
γ-secretase complex, were upregulated by 5 ± 0.3 fold (p < 0.004, D = 1) and 1.6 ± 0.1 fold 
(p = 0.005, t = 3.7), respectively. However, PSEN1, another γ-secretase subunit, was 
downregulated by 1.3 ± 0.2 fold (p = 0.1, t = 1.799) in BFCN cultures compared to iPSCs. 
NOS1 did not show a significantly different expression between samples as there was high 
variability in the BFCN cultures, with some samples being upregulated (HC1, HC3, FAD1) 






Figure 6.8. Expression of APOE and Alzheimer’s disease related markers in iPSC and BFCN 
cultures. iPSCs and BFCNs samples were analysed by nCounter (Nanostring) and, after 
normalisation of total amount of RNA molecules to the housekeeper genes, results are shown as fold 
change of BFCN cultures over iPSCs. Analysis of APOE and genes related with APOE function A. 
APOE, B. CLU, C. HTRA1 and D. LRP1; and the Alzheimer’s disease related markers E. APP, F. 
BACE1, G. MAPT, H. NOS1, I. PSEN1 and J. PSEN2. Data are derived from 5 iPSC lines and 6 
BFCN differentiated samples. Individual data are shown. Histogram bars represent mean values and 
error bars represent S.E.M. Graphs show ** p ≤ 0.01, *** p ≤ 0.001, by two-tailed t-test except in B, 











One of the major hallmarks of AD is the formation of amyloid plaques, generated by the 
deposition of Aβ peptides, with AD patients showing a higher Aβ42/Aβ40 ratio than healthy 
individuals. No differences were found in APP expression levels or the enzymes responsible 
for its fragmentation within BFCN cultures of healthy controls and AD samples (Appendix 
A4). In order to detect the expression of Aβ peptides 40 and 42, conditioned media of the 
BFCN cultures at week 4 of maturation was analysed by ELISA (Figure 6.9A). 
Unfortunately, due to the small sample size, no statistical analysis could be performed; 
however, there was a trend of higher levels in the disease samples, especially in the FAD 
sample when compared to the healthy controls. Cytotoxicity in the BFCN cultures was 
analysed by lactate dehydrogenase (LDH) assay using the conditioned media of BFCNs at 
week 4. Again, due to the small sample size, significant results could not be detected in this 
study, but there was a trend showing intrinsic cytotoxicity in the AD samples when 
compared to the healthy controls (Figure 6.9B). Hyperphosphorylation of tau protein is 
another hallmark of AD, therefore we analysed 2 phosphorylation sites of tau, S214 and 
S404, and, even if the sample size was too small to apply statistical analysis, both SAD and 
FAD samples showed higher levels than HCs when normalised to tau 13 (Figure 6.9D and 
E). However, when tau 13 levels were normalised to GAPDH, both SAD and FAD samples 
did not show higher levels than HCs, but HC2 had the highest levels of all (Figure 6.9F). In 
overall, these data suggest that the BFCNs generated can be used to study the characteristic 
pathological hallmarks of AD, as the AD samples generated showed a higher expression of 






Figure 6.9. Expression of Amyloid β, tau and lactate dehydrogenase activity in BFCN cultures. 
Conditioned media of BFCN samples after 4 weeks of maturation were analysed. A. Amyloid β (Aβ) 
peptides were measured by ELISA and results are shown as Aβ42/Aβ40 ratio. B. LDH cytotoxicity 
assay was performed and results were normalized to total protein. C. Western blot for intracellular tau 
S214, S404, tau 13 and GAPDH. D. Quantification of the western blot for tau S214 normalised to tau 
13. E. Quantification of the western blot for tau S404 normalised to tau 13. F. Quantification of the 





triplicates for 6 BFCN samples. Data in B are derived from one experiment run in duplicates for 4 
BFCN samples. Data in D, E and F are derived from one experiment. Data in B, D, E and F are 
normalised to HC1 values. HC, Healthy Control; SAD, Sporadic Alzheimer’s Disease; FAD, Familial 
Alzheimer’s Disease. Individual samples are shown. Histogram bars represent mean values and error 







The generation of BFCNs from iPSCs can be an important model to understand the 
neurobiology of AD, as this neuronal population has been found to be drastically reduced in 
AD patients (Whitehouse et al., 1982). The work in this chapter establishes a reliable 
protocol to differentiate BFCNs cultures mimicking the in vivo signals required in 
development to generate BFCNs discussed above. The protocol relies on the use of small 
molecule inhibitors and growth factors avoiding transfection or cell sorting as other 
published protocols (Bissonnette et al., 2011; Moreno et al., 2018; Ortiz-Virumbrales et al., 
2017) to achieve a BFCN culture that expresses the characteristic markers of cholinergic 
neurons (Figure 1.3). 
The protocol and the results shown in this chapter are focused on BFCN differentiations 
using the SMIs LDN193189 and SB431542. These samples correspond with BFCN 2 and 3 
samples in Appendix A4. However, another differentiation without using SMIs was also 
performed and results can be found as BFCN 1 samples in Appendix A4. The addition of 
SMIs in the initial stages of differentiation was essential to improve the number of cells 
differentiated into a neuronal fate similar as other protocols published (Crompton et al., 
2013; Moreno et al., 2018; Ortiz-Virumbrales et al., 2017), as low yield or failure in the 
generation of neural rosettes was initially obtained. The neurons obtained with the protocol 
without the addition of SMIs showed similar levels for most of the markers analysed via 
Nanostring than the protocol with SMIs. However, there was one sample (SAD2 BFCN1, 
Appendix A4) that showed higher expression for most of the specific cholinergic markers 
analysed (ISL1, LHX8, NKX2-1, CHAT, CHT1, TRKA and VACHT). Differentiation of 
BFCNs with SMIs from that specific iPSC line will need to be generated in the future to 
understand better if the high expression levels of cholinergic markers are due to intrinsic 
factors of that specific cell line. Moreover, some GFAP+ve cells were found in the protocol 





addition of SMIs (Figure 6.3G-I), confirming the benefit of a purer neuronal culture after the 
use of SMIs in the protocol. 
An important step in this protocol is the addition of 5FDU, an inhibitor of DNA synthesis 
(van Laar et al., 1998; Xia et al., 1999). Its addition at day 5 in the BFCN stage of maturation 
stops the proliferation of other non-neuronal cells that could be in the culture, and therefore, 
it increases the purity of the neuronal culture. A highly pure neuronal culture in all the BFCN 
samples is essential to obtain reliable results. When samples are analysed by a highly 
sensitive technique as Nanostring where RNA molecules are counted, the effect of other cell 
types can have a big influence on the results generated. In this study, one of the samples 
(HC2 BFCN3) showed higher levels than other samples of the astrocytic markers EAAT1, 
NFIA and S100B, whereas was the BFCN sample with lower levels of the neuronal markers 
MAPT, PSD95, SYN1 or L1CAM. The other BFCN sample from the same iPSC line (HC2 
BFCN 2) showed levels of all the markers more comparable with the other BFCN samples. 
This is an indication that more differentiations from the same iPSC lines, together with more 
biological replicates, need to be performed to draw any conclusions in the study of AD. 
Whereas other protocols to generate iPSC-derived BFCNs have been published (Table 1.4), 
in this study we describe a protocol that mimics the signalling received during development 
that achieved a highly pure BFCN culture without relying on other techniques that require 
transfection and cell sorting (Bissonnette et al., 2011; Moreno et al., 2018; Ortiz-
Virumbrales et al., 2017). Moreover, we ensure a reliable characterization of the BFCNs 
based on the PlexSet technology of the nCounter SPRINT System (Nanostring), where a 
high number of genes can be analysed from a relatively low amount of sample mRNA. We 
showed the gene expression of markers from different stages of differentiation as a relative 
expression of the BFCN cultures normalised to iPSCs in Figures 6.4, 6.5 and 6.6. Moreover, 





in Appendix A4. This gene expression analysis shows a broader characterisation of the 
BFCNs generated with this protocol when compared to the previously published (Table 1.4). 
Developmental genes showed higher expression levels in BFCN compared to iPSCs (Figure 
6.4), except EMX1, a transcription factor related with the development of the cerebral cortex 
and not with the forebrain region (Gulisano et al., 1996; Yoshida et al., 1997), that showed 
no significantly different expression in BFCNs when compared to iPSCs. ASCL1, a key gene 
expressed in neural progenitor cells that promotes the cell cycle exit (Castro et al., 2011; 
Ross et al., 2003), and DLX1 and DLX2, regulated by ASCL1 in the forebrain (Poitras et al., 
2007) showed increased expression in BFCN cultures when compared to iPSCs. SOX1 and 
PAX6, another two important transcription factors for the development of neuroectodermal 
commitment, specific cholinergic progenitor markers such as FOXG1 and ISL1, required for 
forebrain cholinergic fate (Cho et al., 2014; Manuel et al., 2010), and NKX2-1, that 
determines the medial ganglion eminence fate, showed higher expression in BFCN cultures 
when compared to iPSCs. However, LHX8, also implicated in the cholinergic fate, did not 
show a significant difference in BFCN and iPSC cultures, even if two of the BFCN samples 
showed high expression (Figure 6.4K). Overall, the expression of neuronal developmental 
markers and specific BFCN developmental markers indicates the expected fate towards 
BFCN neurons of the cells in culture. 
All the general neuronal markers analysed showed a significant increase in BFCN cultures 
when compared to iPSCs (Figure 6.5A-F): TUBB3 expression, the dendritic marker MAP2, 
the neuronal activity marker FOS, the neuronal cell adhesion molecule L1CAM and the pre-
synaptic and post-synaptic markers SYN1 and DLG4 (PSD95). However, to ensure that 
specific BFCNs were generated in culture, the specific BFCN markers related with the 
synthesis and transport of Ach (described in Figure 1.3B) were analysed (Figure 6.5G-L). 
ACHE, CHAT, VACHT and the high affinity NGF receptor NTRK1 (TRKA) were 





significant difference between BFCN and iPSC cultures. However, previous studies have 
shown that NGFR plays a role in pluripotency  (Tomellini et al., 2014), explaining the 
similar expression between BFCN and iPSC cultures. Moreover, double 
immunocytochemistry of ChAT and β-III-tubulin showed an efficiency of 87% ChAT+ve 
neurons (Figure 6.3C) indicating the cholinergic fate of the cultures. 
Astrocytic markers were analysed to understand the purity of the BFCN cultures. None of 
the astrocytic markers ALDOC, NFIA and S100B showed a significant difference whereas 
SLC1A3 (EAAT1) showed a downregulation in the BFCN culture expression when 
compared to the iPSC cultures (Figure 6.6A-D). Immunocytochemistry did not show any 
GFAP+ve staining in the cultures analysed (Figure 6.3G), whereas the protocol without SMIs 
did (Appendix A5), indicating that the current protocol generates a purer culture of BFCNs. 
Analysis of the functional properties of the BFCNs was determined by whole cell patch 
clamp, with neurons showing synaptic events and action potentials when the membrane 
potential was held at -60 mV (Figure 6.7C and D). However, the average of -30 mV taken 
together with the high expression of some developmental markers show the immaturity of 
the neurons. Recent publications have shown resting membrane potential values in iPSC of -
40 mV (Ortiz-Virumbrales et al., 2017; Yue et al., 2015). An increase in the maturation time 
over the current 4 weeks of the protocol or the presence of other cell types such as astrocytes 
in culture might be needed to generate fully mature neurons in culture (Hu et al., 2016). 
ApoE is mainly expressed in the brain by astrocytes, but microglia and neurons contribute to 
the expression under certain circumstances such as excitotoxic stress (Boschert et al., 1999; 
Elshourbagy et al., 1985; Lin et al., 1986). The purity of our cultures can also be confirmed 
by the low expression of APOE in the BFCN cultures, whereas it was highly expressed in 
iPSCs (Figure 6.8A). Moreover, HTRA1 expression was not significantly different in BFCNs 
when compared to iPSCs (Figure 6.8C), whereas AD related genes such as APP, BACE1, or 





levels of Aβ 40 and 42. Even though more cell lines will need to be used in order to perform 
statistical analysis of the Aβ42/Aβ40 ratio (Figure 6.9A), higher expression in AD samples 
has been previously shown (Duan et al., 2014; Ortiz-Virumbrales et al., 2017). Another 
pathological feature of AD is the presence of NFTs, composed by hyperphosphorylated tau. 
MAPT, the gene coding for protein tau, was also found upregulated in BFCN cultures 
(Figure 6.8G), and when specific phosphorylated epitopes of tau such as tau S214 or tau 404, 
we found an upregulation in the AD BFCNs when compared to the controls (Figure 6.9D 
and E). Even if more BFCN samples need to be analysed to perform statistical analysis, this 
is the first protocol reporting higher levels of phosphorylated tau in BFCN cultures.  
Here we have described the generation of a new protocol to differentiate BFCNs from iPSCs 
without the need for transfection or a cell sorter system as was done in previous protocols 
(Bissonnette et al., 2011; Moreno et al., 2018; Ortiz-Virumbrales et al., 2017). Further 
characterization showed a highly pure culture that expressed cholinergic markers 
independently of the disease background. This new protocol can be used as a model to study 
the neurobiology of AD as the pure BFCNs show expression of Aβ and tau, the two major 
hallmarks of the disease and to identify early changes in the neurodegeneration of AD. 
6.4.1. Future directions 
In this study, the generation of a robust protocol to generate BFCNs has been described. 
However, BFCN differentiation of more cell lines from healthy controls and both SAD and 
FAD patients should be performed to generate statistically significant results to unravel the 










Chapter 7: Discussion: 
Research significance, future directions 






7.1. Research significance 
AD is a devastating neurodegenerative disease characterised by cognitive decline and 
impaired memory and thinking that affects more than 50 million people worldwide. Since 
AD was discovered in 1907 by Alois Alzheimer, the number of publications in the AD field 
has been increasing over time. Regarding the enormous efforts made to understand the 
pathological mechanisms of the disease, there are still lots of questions that remain to be 
answered. Different models such as post mortem human brain samples, animal models or 
relevant cell lines have been used to study the disease from different approaches. The lack of 
success understanding the trigger of the disease and how to stop it implies that more research 
needs to be done; therefore, new approaches of established models and new models of study 
are important to understand the neurobiology of AD.  
7.1.1. New models to study apoE fragmentation 
The presence of the ɛ4 allele is the major genetic risk factor of AD (Corder et al., 1993; 
Saunders et al., 1993) and apoE is proteolytically cleaved in the brain in an isoform-
dependent manner (Elliott et al., 2011). However, there is controversy in the literature 
regarding the enzyme responsible for the apoE fragmentation and the specific function of the 
apoE fragments. In this study we used the established SK-N-SH neuroblastoma cell line to 
understand the role that HtrA1 plays in apoE fragmentation. When SK-N-SH cells were 
treated with ATRA, they differentiated into the S- and the N-type. The expression of apoE 
and the production of apoE fragments increases over time with ATRA treatment (Muñoz et 
al., 2018c). We propose that apoE is mainly expressed by the S-type cells (Figure 7.1), based 
on the lack of apoE expression in SH-SY5Y cells, the neuroblastic subclone of SK-N-SH. 
The increase in apoE fragmentation, specifically of the 25-kDa N-terminal fragment, is 
generated by the serine protease HtrA1. This enzyme is a membrane protein, and we propose 
that it is expressed mainly by the N-type cells in SK-N-SH, based on the fragmentation of r-





down with siRNA in the SK-N-SH cells, the proliferation of the S-type is inhibited and 
APOE levels are reduced. Furthermore, the 25-kDa fragment increases neuritogenesis in the 
N-type cells. 
 
Figure 7.1. Proposed model of apoE fragmentation through HtrA1 and the role of the apoE 25-
kDa fragment. SK-N-SH (APOE ɛ3/3) cells were differentiated with ATRA in culture, which 
generated a mixed population of substrate-adherent cells (S-type) and neuroblastic cells (N-type). The 
proposed model based on our results indicates that the S-type cells produce apoE, whereas HtrA1 is 
mainly expressed by the N-type. HtrA1 is responsible for the fragmentation of apoE generating 
specifically the 25-kDa N-terminal fragment of apoE (apoE 25). ApoE 25 acts promotes an increase in 
neurite outgrowth. 
 
It was attempted to use the SK-N-SH cells to generate an isogenic APOE ɛ4/4 cell line using 
the CRISPR/Cas9 system but, unfortunately, this change in genotype was not successful. 
However, the generation of APOE KD clones was achieved and, when treated with ATRA in 
culture, they differentiated into cells morphologically similar to the SH-SY5Y cells, a 
neuroblastic subclone of SK-N-SH cells. The generated APOE KD clones were used to study 
apoE fragmentation and were compared with SH-SY5Y. The SH-SY5Y cells were shown to 





25-kDa fragment over time, but when r-apoE 25 was added, there was no further degradation 
in culture. However, the APOE KD clones generated showed a reduction in HTRA1 
expression when there was a reduction in APOE expression. Under normal condition, 
neurons do no express apoE, however, some studies have shown that apoE expression is 
upregulated upon excitotoxic stress induced by kainic acid (Boschert et al., 1999; Xu et al., 
2006). Moreover, astrocytes and astrocytic cytokines such as interleukin-1β have been 
shown to activate apoE expression in neurons, mediated through the Erk pathway (Harris et 
al., 2004b; Liu et al., 2011) As represented in Figure 7.2, one hypothesis is that, under 
normal circumstances, neuronal cells (as modelled by the N-type in the SK-N-SH cells) 
show low or no levels of HtrA1. However, when apoE is present, there is an upregulation in 
HtrA1 expression, and therefore in apoE 25. It has been shown that apoE plays a role in 
neuroprotection (Harris et al., 2004b; Pedersen et al., 2000), and it still needs to be 
determined if apoE 25 has a different role under stress conditions. Further studies are 
required to understand the link between HtrA1 and apoE expression and the lack of 
neuroprotection when apoE levels are reduced or absent, and the APOE KD clones generated 







Figure 7.2. Proposed model to compare the use of SH-SY5Y cells and the APOE KD clones 
generated in this study. SH-SY5Y and the APOE KD clones differentiate into the N-type cell after 
ATRA treatment. Under normal circumstances, SH-SH5Y cells do not express apoE, but we propose 
that they upregulate apoE under certain stress conditions. The increase in apoE upregulates HtrA1, 
generating the apoE 25-kDa N-terminal fragment, that might play a role like apoE in neuroprotection. 
The lack of apoE in the APOE KD clones will not upregulate HtrA1 and it will lack such 
neuroprotection. 
 
The exogenous addition of r-apoE3 in SH-SY5Y promoted the generation of the 25-kDa N-
terminal fragment, whereas r-apoE 25 was not further degraded in culture. The ɛ4 allele of 
the APOE gene is the major genetic risk factor of AD (Corder et al., 1993; Saunders et al., 
1993); therefore, it is of high relevance understand the differences in the fragmentation 
process between isoforms. As shown in Figure 7.3, we hypothesize that when apoE is 
exogenously added to neurons in culture they upregulate HtrA1, therefore increasing the 
apoE 25-kDa fragment. Whereas apoE 25 from an apoE3 background promoted 
neuritogenesis, it is unknown the exact function of apoE 25 of apoE2 or apoE4 background. 
Moreover, it has been shown that HtrA1 is more selective in the cleavage of apoE4 when 
compared to apoE3, but the 25-kDa fragment of apoE4 is also unstable and it is further 





study can be used as a model to study the apoE fragmentation by exogenous addition of 
apoE2, apoE3 and apoE4 in culture. 
 
Figure 7.3. Proposed future studies investigating differences in apoE fragmentation using the 
APOE KD clones generated in this study. APOE KD clones are differentiated into the N-type cell 
after ATRA treatment. We propose that the exogenous addition of apoE3 in culture upregulates 
HtrA1, increasing the apoE 25-kDa fragment and promoting neuritogenesis. However, the addition of 
apoE4 might have the same role, but the specific function of the apoE 25-kDa fragment of apoE4 is 
unknown. 
The use of iPSCs with different APOE genotypes, including the least studied apoE2, 
provides new opportunities to understand the differences in the apoE fragmentation and the 
function of specific fragments such as apoE 25. In this study we showed that iPSCs express 
high levels of APOE and HTRA1 (Figure 7.4). The role that apoE and HtrA1 might play in 
pluripotency remains unknown and, moreover, the presence of apoE fragments such as apoE 
25 needs to be confirmed in iPSCs. The iPSC-derived BFCNs showed no expression of 
APOE and low levels of HTRA1 expression. As neurons express apoE under certain 
circumstances such as excitotoxic stress as a repair condition (Boschert et al., 1999; Xu et 
al., 2006), the use of stressors such as kainic acid to trigger endogenous apoE release in 





when compared to apoE3 (Figure 7.4), and to understand the possible differences in apoE 
release that could affect the neuropathology of AD. Moreover, the generation of apoE 25 
from different isoforms will help us understand differences in the neuritogenic function or 
other unknown functions. 
 
Figure 7.4. Proposed future studies to use iPSCs and iPSC-derived cells to study apoE 
fragmentation. iPSCs showed high expression of APOE and HTRA1, whereas BFCNs showed 
HTRA1 expression but low levels of APOE. We hypothesise that the exposure of BFCNs to an 
excitatory stressor such as kainic acid will upregulate apoE expression, and therefore, HtrA1 
expression. ApoE, that plays a role in neuroprotection, will also be fragmented into apoE 25, 
increasing neuritogenesis. The difference in the apoE4 background in BFCNs will results in lack of 
neuroprotection by apoE4, and a lack in neuritogenesis from the apoE 25 fragment. 
 
7.1.2. A new model to study the neurobiology of AD 
Although APOE ɛ4 is the major genetic risk factor of AD, other unknown genetic factors 
might play an important role in the pathology of AD. iPSCs are stem cells that contain all the 
genetic background from affected individuals and can also reproduce cellular phenotypes of 
the disease. iPSCs can be differentiated into any cell type from the three germ layers, 
including BFCNs, that are the first subtype of neurons to degenerate in AD (Mufson et al., 
2008; Whitehouse et al., 1982). In this study we show the generation of BFCNs by using a 





maturation, without the use of transfection methods or cell sorters as previously published 
(Bissonnette et al., 2011; Moreno et al., 2018; Ortiz-Virumbrales et al., 2017). The gene 
expression profile of the BFCNs was characterised for specific developmental and mature 
cholinergic markers. In addition, the BFCNs generated were characterised for functional 
analysis by whole-cell patch clamp. Moreover, we showed that the BFCNs generated can be 
used to study the pathological hallmarks of AD measured by Aβ42/Aβ40 ratio, tau 
phosphorylation or cytotoxicity. This new model should therefore provide further benefits to 
AD research in the future. 
AD has mostly been studied in the late stages to understand the pathology of the disease. 
However, aging in a dish remains a limitation (as reviewed in Mertens et al., (2018)), even if 
some studies have been already shown different approaches that may be used to model late-
onset diseases. Manipulation of telomerases (Vera et al., 2016) or treatment with progerin 
(Miller et al., 2013) have induced the aging phenotype in iPSC-derived neurons modelling 
Parkinson’s disease (PD). Like PD, AD is a neurodegenerative disease where deposition of 
amyloid plaques or NFTs stars decades before the cognitive symptoms appear. iPSC-derived 
BFCNs can help us understand the early underlying pathological mechanisms that occur in 
the early stages of the disease. The use of three healthy controls and two AD iPSC lines in 
this study are a promising starting point that showed trends for the neuropathological 
hallmarks of AD; these will need to be followed up with more cell lines to identify disease 





7.2. Future directions 
ApoE is produced in the brain predominantly by astrocytes and microglia. Numerous 
protocols differentiating astrocytes from iPSCs have been published (as reviewed in Engel et 
al., (2016)), and various protocols to differentiate microglia have also recently been 
published (Abud et al., 2017; Douvaras et al., 2017; Muffat et al., 2016). The differentiation 
of iPSCs into these cell types will help understanding differences in basal apoE release 
coming from different cell types and/or apoE backgrounds that could influence the 
neuropathology of AD. Moreover, a recent study has detected HtrA1 as a marker of 
forebrain astrocytes with an important role in development and injury response (Chen et al., 
2018). HtrA1 has also been shown to play a role in regulation of microglia in response to 
inflammation (Liao et al., 2013). Further understanding the link between apoE and HtrA1 
and the role that HtrA1 plays in apoE fragmentation in each of the different cell types and 
apoE isoforms will help to understand the role of apoE in AD. 
The use of CRISPR/Cas9 technology to generate isogenic controls in the study of AD has 
increased in the last years. The isogenic control lines are especially important as, while 
changing one specific gene, the rest of the genetic background remains intact. In this study 
we completed the first steps to use CRISPR/Cas9 to change the APOE genotype in the SK-
N-SH neuroblastoma cell line. Whereas we optimised the gRNA that generates a DSB in the 
APOE gene that could be used to generate an APOE KD in an iPSC model, more 
optimisation is still required to achieve a change in the genotype, as previously discussed. 
However, the generation of isogenic controls in iPSC lines from AD patients have been 
achieved recently. Whereas iPSC-derived BFCNs from a FAD patient with a PSEN2 N141I 
mutation showed an increase in the Aβ42/40 ratio and an electrophysiological deficit, the 
correction to wild-type PSEN2 by CRISPR/Cas9 restored the electrophysiological deficit and 
normalised the Aβ42/40 levels (Ortiz-Virumbrales et al., 2017). Moreover, another study 





APOE ɛ3/3 background (Lin et al., 2018). After differentiation of the iPSCs into astrocytes, 
microglia and neurons, they showed that the APOE ɛ4/4 neurons had generated more Aβ 
levels than the APOE ɛ3/3, and the APOE ɛ4/4 microglia and astrocytes were impaired in the 
Aβ clearance. Moreover, APOE ɛ4/4 astrocytes showed lower apoE levels and cholesterol 
accumulation (Lin et al., 2018). Clearly, the use of APOE isogenic iPSC controls will be a 
useful model to study further the role of apoE in AD. 
The iPSC field is moving towards the generation of 3D organoids (as reviewed in Gabriel 
and Gopalakrishnan, (2017); Lee et al., (2017)). Organoids are aiming to generate “mini 
brains” in a dish and, despite its potential, limitations on the control of the cell types formed 
or lack of a vascular system still need to be addressed. However, the rapid advance in the 
field has shown the development of innate microglia in the organoids (Ormel et al., 2018) or 
the generation of specific brain regions such as forebrain (Krefft et al., 2018). In the future, 
the generation of more sophisticated brain organoid models that reproduce the AD 
phenotype (Raja et al., 2016) can be used for drug screening and thereby help in the 





7.3. Final conclusions 
This research aimed to generate new models to study the neurobiology of AD in vitro. The 
use of well-established models such as the SK-N-SH neuroblastoma cell line and new 
models such as iPSCs are important to understand the underlying mechanisms of the disease 
that remain unknown.  
In summary, this research provided: 
- A cell-based model to show that the serine protease HtrA1 is responsible for the 
fragmentation of the apoE 25-kDa N-terminal fragment of apoE in a physiologically 
relevant model. 
- The first demonstration of the neurogenic function of the apoE 25-kDa N-terminal 
fragment. 
- The generation of an APOE KD model of the SK-N-SH neuroblastoma cell line 
using CRISPR/Cas9 technology. 
- The generation of two iPSC lines derived from an AD patient bearing the PSEN1 
A246E mutation and a non-demented family member with wild-type PSEN1. 
- The generation and characterization of iPSC-derived BFCNs to study the 
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A1. Apolipoprotein E 
A1.1. APOE gene sequence 
Sequence of the APOE ε3 allele is as followed, the cDNA sequence is underlined, the 
nucleotide highlighted in orange will change into a C for APOE ε4 allele and the nucleotide 
highlighted in blue will change in T for APOE ε2 allele. 
 





















































































A1.2. ApoE amino acid sequence 









Highlighted in blue is the signal peptide, in black is the N-terminal domain, in orange is the 
hinge region and in green is the C-terminal domain. The amino acids highlighted in red 
correspond to the amino acid that changes into R for the apoE ε4 isoform and the amino acid 




















A2. CRISPR  
A2.1. Guide RNA sequences 
Target ID Gene Sequence (5’ - 3’) 
gRNA1 APOE CTCGCCGCGGTACTGCACCAGG 
gRNA2 APOE CTGGCAGTGTACCAGGCCGGGG 
gRNA3 APOE CGCGGCCCTGTTCCACCAGGGG 
 
A2.2. Location of gRNA within exon 4 of APOE gene 
The target region of the three CRISPR gRNAs are highlighted in the following sequence 
covering the exon 4 of the APOE ε3 allele. gRNA1 is highlighted in orange, gRNA2 is 























A2.3. ssODN sequences 












A2.4. Location of ssODN sequences within exon 4 of APOE gene 
The target regions of the two donor DNA sequences are highlighted in the following 
sequence representing the exon 4 of the APOE ε3 allele. The ssODN1 sequence is underlined 




























A2.5. Off-target sites of gRNA1. 
Table A5. Predicted off-target sites of gRNA1 generated in silico from the online platform Benchling (Hsu et al., 2013). 
Sequence PAM Score Gene Chromosome Strand Position Mismatches On-target 
CACGGCGCTGCTGCACCAGG CGG 1.432 ENSG00000127419 chr4  1 951971 4 FALSE 
GGAGGCGGTGCTGCACCAGG GAG 1.412  chr1 -1 4712786 4 FALSE 
CGACGCGGTGCTCCACCAGG TAG 1.085 ENSG00000087903 chr19  1 5997129 3 FALSE 
AGCCGCGGCACAGCACCAGG CGG 0.966  chr19  1 1975531 3 FALSE 
CTCCTCTGTCCTGCACCAGG TGG 0.961  chr9  1 91636587 4 FALSE 
CGCCCTGGGACTGCACCAGG TGG 0.925  chr22 -1 29871667 3 FALSE 
CCCCTCGGCCCTGCACCAGG AGG 0.875 ENSG00000125510 chr20 -1 62730399 4 FALSE 
TGTCGCGGTGCCGCACCAGG TAG 0.776 ENSG00000105613 chr19 -1 12969357 4 FALSE 
CGACACGGTTCAGCACCAGG TGG 0.720  chr6 -1 68068796 4 FALSE 







A2.6. Electropherograms of the region of interest of the APOE gene 
The CRISPR clones were sequenced for the region of interest of the APOE gene. 
Electropherograms of the clones used in the study ae shown. Arrows indicate the direction of 
the primer, asterisks show the nucleotide that determines the APOE ɛ3/3 background and the 
red triangle indicates the predicted cut site of the Cas9 nuclease. All clones were generated 
using gRNA1 except clone 3 that was generated using gRNA3. 
- Clone 1 
 
- Clone 2 
 
- Clone 3 
 






- CRISPR Control 1 
 
-  CRISPR Control 2 
 
- CRISPR Control 3 
 
- CRISPR Control 3 
 








- Clone 6 
 







A3. Induced pluripotent stem cells 
A3.1. Media composition  
- Neural induction (Ni) medium 
DMEM/F12 (1:1) (Life Technologies) 
0.4% B27 Supplement 1x (Life Technologies) 
1% N2 Supplement 1x (Life Technologies) 
1% MEM – Non-essential aminoacids (Life Technologies) 
1% GlutaMAX 1x (Life Technologies) 
- Neural expansion (Ne) medium 
DMEM/F12 (1:1) (Life Technologies) 
2% B27 Supplement 1x (Life Technologies) 
1% N2 Supplement 1x (Life Technologies) 
1% MEM – Non-essential amino acids solution (Life Technologies) 
1% GlutaMAX 1x (Life Technologies) 
-  Neuron medium 
Brainphys (Stemcell Technologies) 
1% B27 Supplement 1x (Life Technologies) 











- Mesoderm base medium 
DMEM/F12 (1:1) (Life Technologies) 
0.5% FBS (Interpath) 
1% GlutaMAX 1x (Life Technologies) 
1% MEM Non-essential amino acids solution (Life Technologies) 
55 µM 2-mercaptoethanol (Thermo Fisher Scientific) 
45 µM Ascorbic acid (Sigma-Aldrich) 
- Growth factors and small molecules inhibitors 
Activin A (Miltenyi Biotec) 
BDNF: Brain Derived Neurotrophic Factor (Miltenyi Biotec)  
BMP4: Bone Morphogenetic Protein 4 (Miltenyi Biotec) 
BMP9: Bone Morphogenetic Protein 9 (Peprotech, USA) 
CHIR99021 (Focus Bioscience) 
FGF-2: Fibroblast Growth Factor 2 (Global Stem, USA) 
FGF-8: Fibroblast Growth Factor 8 (Stemcell Technologies)  
LDN193189 (Stemcell Technologies) 
NGF: Nerve Growth Factor (Peprotech) 
SB431542 (Stemcell Technologies) 
SHH: Sonic Hedgehog (Stemcell Technologies) 

















A4. Nanostring analysis 
List of genes that were analysed on the nCounter SPRINT (Nanostring), the accession number and the position of the probes used for each gene, and the 
category they belong to can be found in Table A6. 
Table A6. List of genes analysed in Nanostring for iPSC and BFCN cultures. 
Gene name Approved name Accession Position Category 
AARS Alanyl-tRNA synthetase NM_001605.2 836-935 Housekeeper 
ACHE Acetylcholinesterase NM_000665.3 1058-1157 BFCN 
ALDOC Aldolase, fructose-bisphosphate C NM_005165.2 261-360 Astrocytes 
APOE Apolipoprotein E NM_000041.2 97-196 APOE 
APP Amyloid beta precursor protein NM_000484.3 1726-1825 AD 
ASB7 Ankyrin repeat and SOCS box containing 7 NM_024708.3 1281-1380 Housekeeper 
ASCL1 Achaete-scute homolog 1 NM_004316.3 1651-1750 Neuronal progenitor 
BACE1 Beta-secretase 1 NM_012104.3 2401-2500 AD 
CCDC127 Coiled-coil domain-containing 127 NM_145265.2 295-394 Housekeeper 
CHAT Choline O-acetyltransferase NM_020549.4 1106-1205 BFCN 





Name Approved name Accession Position Category 
CLU Clusterin NM_001831.3 1364-1463 APOE 
CNOT10 CCR4-NOT transcription complex subunit 10 NM_001256741.1 1963-2062 Housekeeper 
SLC6A3 (DAT1) Solute carrier family 6 member 3 (dopamine transporter 1) NM_001044.3 1549-1648 Neuronal 
DLX1 Distal-less homeobox 1 NM_001038493.1 1336-1435 Neuronal progenitor 
DLX2 Distal-less homeobox 2 NM_004405.3 591-690 Neuronal progenitor 
SLC1A3 (EAAT1) Solute carrier family 1 member 3 (glial high affinity glutamate transporter 1) NM_004172.4 559-658 Astrocytes 
EID2 EP3000-interacting inhibitor of differentiation 2 NM_153232.3 566-665 Housekeeper 
EMX1 Empty-spiracles homeobox 1 NM_004097.2 1747-1846 Neuronal progenitor 
FOS Fos proto-oncogene NM_005252.2 1476-1575 Neuronal 
FOXG1 Forkhead box protein G1 NM_005249.3 1401-1500 BFCN progenitor 
GAD2 Glutamate decarboxylase 2 NM_000818.2 1246-1345 Neuronal 
GRIA1 Glutamate ionotropic receptor AMPA type subunit 1 NM_000827.3 2841-2940 Neuronal 
GRIA2 Glutamate ionotropic receptor AMPA type subunit 2 NM_001083620.1 866-965 Neuronal 
GRIN1 Glutamate ionotropic receptor NMDA type subunit 1 NM_000832.5 1291-1390 Neuronal 
HTRA1 HtrA serine peptidase 1 NM_002775.4 1186-1285 APOE 





Name Approved name Accession Position Category 
L1CAM L1 cell adhesion molecule NM_024003.2 3241-3340 Neuronal 
LHX8 LIM homeobox 8 NM_001001933.1 1301-1400 BFCN progenitor 
LRP1 LDL receptor related protein 1 NM_002332.2 4241-4340 APOE 
MAP2 Microtubule associated protein 2 NM_031845.2 5171-5270 Neuronal 
MAPT Microtubule associated protein tau NM_016834.3 1206-1305 AD 
MTO1 Mitochondrial tRNA translation optimization 1 NM_133645.2 1466-1565 Housekeeper 
NANOG Nanog homeobox NM_024865.2 1101-1200 Pluripotency 
NFIA Nuclear factor I A NM_001134673.2 1086-1185 Astrocytes 
NGFR Nerve growth factor receptor NM_002507.3 2731-2830 BFCN 
NKX2-1 NK2 homeobox 1 NM_003317.3 2012-2111 BFCN progenitor 
NOS1 Nitric oxide synthase 1 NM_000620.4 2213-2312 AD 
NTRK1 (TRKA) Neurotrophic receptor tyrosine kinase 1 NM_001012331.1 1366-1465 BFCN 
PAX6 Paired box 6 NM_000280.3 1174-1273 Neuronal progenitor 
POUF51 POU class 5 homeobox 1 NM_002701.4 1226-1325 Pluripotency 
DLG4 (PSD95) Disc large MAGUK scaffold protein 4 (post-synaptic density protein 95) NM_001365.3 2461-2560 Neuronal 





Name Approved name Accession Position Category 
PSEN2 Presenilin 2 NM_000447.2 916-1015 AD 
RABEP2 Rabaptin, RAB GTPase-binding effector protein 2 NM_024816.2 1783-1882 Housekeeper 
S100B S100 calcium binding protein B NM_006272.2 305-404 Astrocytes 
SNAP91 Synaptosome associated protein 91 NM_001242794.1 1043-1142 Neuronal 
SOX1 SRY-box 1 NM_005986.2 1496-1595 Neuronal progenitor 
SUPT7L SPT7 like, STAGA complex gamma subunit NM_014860.2 1171-1270 Housekeeper 
SYN1 Synapsin I NM_006950.3 566-665 Neuronal 
TADA2B Transcriptional adaptor 2B NM_152293.2 1589-1688 Housekeeper 
TH Tyrosine hydroxylase NM_000360.3 1307-1406 Neuronal 
TUBB3 Tubulin beta 3 class III NM_006086.2 1538-1637 Neuronal 
SL18A3 (VACHT) Solute carrier family 18 member A3 (vesicular acetylcholine transporter) NM_003055.2 1651-1750 BFCN 







Results for each individual sample analysed from the Nanostring organized in the categories 
fromTable A6. iPSC samples are in orange and BFCN samples are in blue; healthy control 
samples are open symbols and Alzheimer’s disease samples are closed symbols; BFCN 1 







- Pluripotency markers 
 















- Cholinergic progenitor markers 
 







- BFCN markers 
 

























- APOE related markers 
 






A5. Immunocytochemistry in BFCNs without SMIs 
 
 
